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Oral squamous cell carcinoma (SCC) is a lethal, deforming disease of global 
significance and rising incidence. In 2011, 6,767 new cases and 2,056 deaths 
occurred in the UK. Cancers are preceded by oral potentially malignant disorders 
(PMD), recognizable mucosal diseases harbouring significantly increased risk of 
carcinoma. These manifestations offer clinicians a ‘therapeutic window’ to intervene 
during carcinogenesis, although contemporary practice remains unable to predict 
individual lesion behaviour or quantify risk for malignant transformation. No clear 
management guidelines exist and available scientific literature is unable to answer 
the fundamental question whether intervention prevents cancer. 
This MD thesis includes 7 published papers on oral pre-cancer and 4 observational 
studies from a specialist PMD service coordinated by the author in Newcastle upon 
Tyne in Northern England. 
PMD management involves a complex interaction between patients, clinicians’ 
views on diagnosis and treatment and histopathological assessment of mucosal 
biopsy specimens. Uncertainty regarding the ‘potentially malignant state’ remains a 
pernicious influence throughout.  
Newcastle PMD patients were profiled as predominantly male, with a median age of 
60yrs, and regular users of both tobacco and alcohol. Most presented with single-
site disease, primarily leukoplakia on the floor of mouth and ventro-lateral tongue, 
with over 80% exhibiting epithelial dysplasia on histopathological examination. 
Approximately 70% underwent interventional therapy using CO2 laser surgery.  
840 laser treatments were performed between 1996 and 2015 and the efficacy of 
laser intervention was examined by reviewing clinico-pathological details and clinical 
outcome for 590 PMD patients followed for a mean of 7.3yrs. Histopathology 
required ‘up-grading’ in 36% following definitive examination of laser excision 
specimens. 74.2% of patients were disease free, primarily younger patients with 
‘low-grade’ dysplasia, 9% exhibited persistent disease and were older with gingival 
lesions often proliferative verrucous leukoplakia (PVL). In 12%, unexpected SCC 
was identified on excision, whilst 4.8% transformed to malignancy.  
Interventional laser surgery facilitates definitive diagnosis and efficacious treatment, 
allows early diagnosis and treatment of SCC, identifies patients at risk of 
progressive disease and defines clinical outcome categories. Evidence is lacking, 
however, that intervention halts the progress of carcinogenesis.    
Multi-centre, prospective, randomized, controlled trials are needed to confirm the 
efficacy of interventional surgery, to characterise PMD natural history and to 
disseminate research findings. It is hoped that the clinical work presented in this MD 
thesis will inform and encourage further research into PMD and lead to a reduction 














 Chapter One 
 
















1.1 Oral Squamous Cell Carcinoma 
 
Oral cancer, principally squamous cell carcinoma (SCC) arising from the 
mucosal lining of the mouth, presents clinically as non-healing erosive or 
ulcerative lesions which progress to irregular, raised, invasive and ultimately 
painful tumour growths. Established oral carcinoma, which is one of the 
commonest head and neck malignancies, is a lethal and deforming disease 
due to local invasion, oral and facial destruction, metastasis to cervical lymph 
nodes and widespread blood-borne tumour dissemination particularly 
affecting the lungs and the liver (Mehanna et al 2010a & 2010b). The clinical 
severity of the disease, and its significant systemic nature, is well-illustrated 
in Figure 1.1.  
Worldwide, oral cancer is estimated to be the 6th most common cancer with 
5-year survival rates around 50% and a prognosis significantly compromised 
by advanced disease and late presentation, which are common features in 
contemporary clinical practice (Conway et al 2008, Warnakulasuriya 2009). 
In the UK 6,767 new cases of oral cancer were diagnosed in 2011, with 
2,056 deaths reported (National Cancer Intelligence Network 2014). There 
has been a significant rise in incidence, particularly affecting young and 
female patients, and researchers predict an ‘epidemic’ of mouth cancer will 
occur during the 21st Century (Warnakulasuriya 2009 & 2010, Kalavrezos & 
Bhandari 2010).  
Whilst the number of patients suffering uncontrolled oral cancer disease at 
primary sites in the head and neck has fallen over the last 30 years, due to 
improved management techniques, primarily combining treatment modalities 
of surgery and chemo-radiotherapy, many will die as a result of metastatic 
disease and up to a quarter of patients experience multiple cancer 
development in the upper aerodigestive tract either synchronously or 







Figure 1.1: Oral Squamous Cell Carcinoma showing (A) invasive, ulcerated lesion arising 
on the posterior tongue and retromolar region with associated leukoplakia of the faucial 
pillars, (B) CT scan confirming metastatic tumour deposits affecting both submandibular and 
upper deep cervical lymph nodes, and (C) chest radiography illustrating extensive 











The presentation of multiple lesions in an individual patient is a manifestation 
of widespread epithelial instability, which is a hallmark of head and neck 
squamous cell carcinoma, classically referred to as ‘field change’ 
cancerization (Dakubo et al 2007). This was the term first introduced by 
Slaughter et al (1953) who proposed that oral cancers develop in multifocal 
areas of ‘pre-cancer change’. The risk of multiple, primary cancer 
development is probably highest in younger patients and those continually 
exposed to carcinogenic influence (Warnakulasuriya 2009, Hamadah et al 
2010). 
Aetiological factors responsible for malignant transformation of oral 
squamous epithelium most commonly involve the excessive consumption of 
tobacco products and alcohol misuse (Anantharaman et al 2011, Lee et al 
2013). Globally, 25% of oral cancers have been attributed to tobacco use, 
either by smoking or chewing habits, and an association that is dose-
dependent increasing markedly for smoking durations greater than 20 years, 
daily cigarette consumption in excess of 20 and enhanced addiction to 
tobacco (Petti 2009, Lee et al 2013). 
Around 7 to 19% of oral cancer cases have been linked with regular alcohol 
consumption which also seems to increase risk in a dose-dependent 
manner, such that individuals consuming 4 to 5 drinks daily show a 2 to 3 
times higher risk than non-drinkers (Marron et al 2012). Whilst there is no 
doubt that oral cancer risk increases further amongst alcohol drinkers who 
also smoke, uncertainty remains regarding the true significance of alcohol 
use in people who have never smoked (Petti 2009, Hashibe et al 2007). 
A further complication is that many people who smoke and drink do not 
develop cancer whilst other studies have observed that, equally, many oral 
cancer patients have never been overexposed to tobacco or alcohol, so it is 
likely that other risk factors are involved (Macfarlane et al 2010). Genetic 
predisposition to DNA mutation in oral epithelium, poor diet and nutrition, 
ageing, an impaired immune response, low socioeconomic status, short 
stature, manual occupations, poor oral health and infections have all been 





obtuse and is still evolving (Zain 2001, Conway et al 2008 & 2010, Lagiou et 
al 2009a & 2009b, Donadini et al 2010, Johnson et al 2010, Warnakulasuriya 
2010, Edefonti et al 2011, Chuang et al 2012, Ahrens 2014, Leoncini et al 
2014). Petti (2009), for example, reported that 10 to 15% of oral cancer 
cases may be attributed to diets low in fresh fruit and vegetable intake, but 
again the specific interaction between putative anti-carcinogenic properties of 
the diet versus heavy smoking and alcohol drinking remains unclear.  
daSilva et al (2011) also emphasized the close interrelationships that exist 
between the principal aetiological agents of oral cancer: lifestyle habits 
(tobacco exposure and alcohol consumption), dietary factors, occupation, 
socioeconomic status, exposure to external agents and genetic susceptibility.  
Although a significant role for human papillomavirus (HPV) infection 
(especially subtype 16) has been suggested during oral carcinogenesis, this 
seems uniquely associated with a rise in oropharyngeal, tonsil and tongue 
base cancer affecting younger patients and often presenting with extensive 
cervical lymph node metastases and a postulated sexually transmitted 
aetiology. Thus, HPV associated head and neck cancer probably represents 
a distinct disease entity and the role of HPV in classic, tobacco-related intra-
oral cancer still remains obscure (Mehanna et al 2010a & b, Syrjanen et al 















1.2 Oral Carcinogenesis and Epithelial Dysplasia  
 
A ‘progression model’ proposed for oral carcinogenesis suggests that, 
following genetic mutation and irreversible genotypic damage, various 
phenotypic epithelial tissue disorganisation and dysmaturation changes 
occur which, if allowed to progress, ultimately lead to invasive carcinoma 
(Califano et al 1996, Donadini et al 2010, Castagnola et al 2011, Thomson 
2012b). Such disorganised features preceding cancer are identifiable at the 
microscopic level and are collectively described as epithelial dysplasia; these 
are listed in Table 1.1 (Speight 2007, Sloan 2012), and illustrated in Figure 
1.2.  
Oral epithelial dysplasia is thus an expression of a tissue maturation and 
cellular proliferation disorder (Warnakulasuriya 2001), and is an important 
histopathological entity that delineates morphological changes affecting both 
individual epithelial cells (which take on a more ‘primitive’ appearance) and 
the overall integrity of epithelial structure (which loses normal maturation and 
stratification) in lesions at risk of malignancy. In clinical practice, an 
assessment of the degree of dysplastic change in tissue is made following 
incision biopsy and microscopic classification into mild, moderate or severe 
categories, according to the tissue thickness occupied by the atypical 
epithelium (Speight 2007, Martorell-Calatayud et al 2009); Figure 1.2. As 
epithelial proliferative units and oral keratinocyte stem cell activity are 
postulated to lie within the basal and supra-basal layers, it is not surprising 
that the initial changes of mild dysplasia are first recognised within the basal 
third of the oral epithelium, ultimately progressing through the higher 
epithelial layers as severity increases (Warnakulasuriya 2001, Sloan 2012, 
Thomson 2012b). Carcinoma-in-Situ (CiS) is regarded as the most severe 
form of epithelial dysplasia and is characterised by full-thickness cytological 
and architectural disturbance (Speight 2007).   
The more severe the dysplasia, the higher the risk of malignant change, 
although there is a strong subjective element in dysplasia grading and both 





accuracy of diagnosis (Warnakulasuriya 2001, Speight 2007, Sloan 2012, 
Balasundaram et al 2013, Rastogi et al 2013, Shirani et al 2014). 
   
TABLE 1.1: HISTOPATHOLOGICAL FEATURES OF DYSPLASIA IN ORAL 
POTENTIALLY MALIGNANT DISORDERS 
 
CYTOLOGY                          
 
Variation in Nuclear Size (Anisonucleosis) 
Variation in Nuclear Shape (Pleomorphism)  
Variation in Cell Size (Anisocytosis) 
Variation in Cell Shape (Pleomorphism) 
Increased Nuclear to Cytoplasmic Ratio 
Increased Nuclear Size  
  Atypical Mitotic Figures 
  Increased Number & Size of Nucleoli 




Irregular Epithelial Stratification 
Loss of Polarity of Basal Cells 
Drop-shaped Rete Ridges 
Increased Number of Mitotic Figures 
Abnormally Superficial Mitoses 
Premature Keratinisation in Single Cells (Dyskeratosis) 
Keratin Pearls within Rete Ridges 
 
 
Tilakaratne et al (2011) specifically criticised the subjective nature of 
contemporary dysplasia grading, raising concerns regarding disease 
definition and terminology, and noted the lack of agreement between 
pathologists about the relative importance of individual histological features 
and the overall lack of reproducibility and poor predictive ability of current 
grading systems. Interestingly, however, these authors were not able to 
significantly improve objective diagnostic ability by attempting computational 
analyses and ranking of histopathological features. Dost et al (2014) have 
also criticised current dysplasia grading systems siting their imprecision, low 






Figure 1.2: Histopathological Features of Oral Potentially Malignant Disorders as 
observed under light microscopy of haematoxylin & eosin-stained tissue sections 
demonstrating (A) mild dysplasia, with cellular changes predominant in the basal third of the 
epithelium x400 (B) moderate, with extension of epithelial disorganisation to the middle third 
x200 (C) severely dysplastic change spreading to involve more than two-thirds of the 
epithelium x200 and (D) proliferative verrucous leukoplakia, a recurrent multi-focal lesion, 
illustrating folds of verrucous hyperplasia and marked lymphocytic infiltration beneath the 

























The use of epithelial dysplasia assessment to predict malignant 
transformation remains problematic because both the overall grading system 
and the individual features to be characterised are poorly defined 
(Tilakaratne et al 2011). As a result, a binary dysplasia classification, 
distinguishing between lesions at ‘low’ or ‘high risk’ of cancer progression 
has been proposed to try to improve objectivity but, despite appealing to 
clinicians attempting to rationalize treatment intervention, it has not yet found 
routine application in clinical practice (Kujan et al 2006).   
An additional, important observation regarding PMD diagnosis is the 
realization that even in the absence of epithelial dysplasia some oral 
mucosal lesions may still transform to cancer (Martorell-Calatayud et al 
2009). This has been noted, in particular, for isolated mucosal lesions 
exhibiting lichenoid inflammatory features (Krutchkoff & Eisenberg 1985, 
Goodson et al 2010b, Patil et al 2014). In addition early-stage proliferative 
verrucous leukoplakia, an aggressive multi-focal potentially malignant 
disorder,  with a known high risk of malignancy, shares a number of 
histopathological features similar to lichenoid mucositis such as 
hyperkeratosis, sub-epithelial lymphocytic infiltration, basal cell degeneration, 
and apoptosis, often without the classic features of dysplasia, rendering the 
diagnostic process complex (Speight 2007, Issrani et al 2013); Figure 1.2D. 
Oral epithelial dysplasia, however, remains the ‘reference’ investigation in 
oral potentially malignant disorder management and is one of the few 
clinically applicable predictors of risk for malignant transformation (Reibel 
2003, Tilakaratne et al 2011). Similarly, as the association between oral 
malignancy and the presence of dysplasia remains significant (Schaaij-
Visser et al 2010), early intervention to remove pre-cancerous dysplastic 
tissue appears a logical treatment approach. Dost et al (2014) recently 
proposed definitive treatment for all oral mucosal lesions exhibiting 
dysplasia, irrespective of severity. It is indeed this specific concept that forms 







1.3 Oral Potentially Malignant Disorders  
It has been recognized for many years that a spectrum of distinct oral 
mucosal abnormalities, now termed potentially malignant disorders (PMD) 
and which accompany dysplastic pre-invasive cancer change, may be 
identified clinically and characterized, albeit somewhat non-specifically, 
during oral examination. There is, therefore, an opportunity for both early 
diagnosis and therapeutic intervention during this clinically identifiable ‘oral 
pre-cancer window’ (Thomson 2012a, Mortazavi et al 2014). 
Potentially malignant disorders are defined as recognizable oral mucosal 
diseases which share a significantly increased risk of squamous carcinoma 
development compared with apparently normal mucosa. The term 
encompasses both localized lesions and more generalized conditions and, 
whilst emphasizing that not all will inevitably transform into cancer, also 
recognizes the widespread, often multi-focal nature of such disease within 
the entire upper aerodigestive tract (Hamadah et al 2010, Carnelio et al 
2011, Thomson 2012b & 2012e).  
 
The list of mucosal diseases considered potentially malignant includes 
classically described entities such as leukoplakia, erythroplakia, 
erythroleukoplakia and more recently recognised disorders such as 
progressive, multi-focal proliferative verrucous leukoplakia (Figure 1.3), as 
well as widespread conditions such as immunodeficiency, oral submucous 
fibrosis, chronic hyperplastic candidosis, and perhaps more controversially 
oral lichenoid lesions (van der Waal 2009a&b, Thomson & Goodson 2012, 










TABLE 1.2: CLINICAL PRESENTATION OF ORAL POTENTIALLY MALIGNANT 
DISORDERS 
 





Proliferative Verrucous Leukoplakia 
 
   
 
MORE WIDESPREAD CONDITIONS 
 
Immunosuppression 
  Oral Submucous Fibrosis 
  Lichen Planus and Lichenoid Lesions   
  Sideropenic Dysphagia 
 Discoid Lupus Erythematosus 




Estimates of the prevalence of oral potentially malignant disorders suggest 
an overall figure of between 2 to 3%, with the vast majority appearing 
clinically as leukoplakias, and usually presenting on the floor of the mouth, 
ventro-lateral tongue and buccal mucosa. Whilst previously seen as a 
disorder of older, male patients, increasing evidence suggests that a much 
younger population is now at risk (Petti 2003, Napier & Speight 2008).  
The concept that these disorders represent a recognizable potentially 
malignant state has arisen following a number of salient clinico-pathological 
observations including the observed transformation of precursor lesions into 
invasive cancers during patient follow up, the recognition that leukoplakic or 
erythroplakic lesions often co-exist with oral squamous cell carcinoma (as 
seen in Figure 1.1A) and the realization that numerous histopathological and 
biomolecular tissue changes are common to both cancers and their 






Figure 1.3: Clinical Appearance of Oral Potentially Malignant Disorders illustrating (A) 
leukoplakia, the most common clinical presentation, arising on the ventral tongue and floor 
of mouth, (B) erythroplakia of the anterior floor of mouth, which is a rarer lesion but 
statistically more likely to exhibit invasive carcinoma,  (C) erythroleukoplakia, often referred 
to as ‘speckled leukoplakia’, distributed in this example unilaterally on the floor of the mouth 
and (D) proliferative verrucous leucoplakia, a progressive, multi-focal, fissured and exophytic 


















The identification of a potentially malignant disorder in an individual patient 
does not mean, however, that inevitable malignant transformation will take 
place. Many oral lesions do not progress over time, whilst others may resolve 
or regress spontaneously and it remains impossible in clinical practice to 
reliably predict the behaviour of any individual lesion or patient. Nonetheless, 
affected patients remain at increased risk of squamous carcinoma 
development (Warnakulasuriya 2009).  
Attempts have been made to stratify ‘high’ and ‘low’ risk factors for potentially 
malignant disease development (Diajil et al 2010), but the ability to quantify 
risk for individual patients remains frustratingly elusive in contemporary 
practice. By synthesizing data from a number of publications summarizing 
risk factor research, however, a ‘high risk’ profile for oral carcinogenesis may 
be postulated: such patients are likely to misuse tobacco and alcohol 
(Hamadah et al 2007, Macfarlane et al 2010, Anantharaman et al 2011), 
exhibiting a strong addiction to smoking (Lee et al 2013) and persistent high 
alcohol consumption (Goodson et al 2010, Marron et al 2012), together with 
a diet low in fruit and vegetables (Hamadah et al 2010, Chuang et al 2012), 
and with poor oral hygiene and irregular dental care (Ahrens et al 2014). 
Most commonly, the patient will be a male of shorter-stature, low 
socioeconomic status and low educational attainment (Leoncini et al 2014, 
Conway et al 2014), experiencing periods of material deprivation or long-





occupations such as bricklaying and painting (Richiardi et al 2012). In 
contrast, patients’ age (Macfarlane et al 2010), general medical status 
(Macfarlane et al 2012) and human papillomavirus exposure (Anantharaman 
et al 2013) have all been shown to be less helpful in predicting disease 
status and risk. 
 
1.4 Screening, Prevention and Intervention 
In order to improve patient survival and reduce the morbidity following oral 
cancer diagnosis, it seems logical for oral clinicians to utilize the ‘oral pre-
cancer window’ to identify potentially malignant change at the earliest 
possible stage and to intervene to halt the disease process (Thomson 
2012f). In addition to the professional uncertainties surrounding diagnosis 
and management of potentially malignant disease there is also, 
unfortunately, considerable public ignorance regarding oral cancer and the 
patient population most ‘at risk’ is known to rarely attend for oral examination 
or regular dental care (Scott et al 2009).  
General population screening programmes for oral cancer have been 
recognized to be fundamentally flawed as health care interventions for 
similar reasons. However, a more pragmatic approach may be to specifically 
identify and then target individual patient groups deemed to be at ‘high risk’ 
of developing cancer. Thus, focused oral cancer screening, specific health 
care information and treatment interventions should all target the ‘at risk’ 
populations (Williams & Bethea 2011); this is an important practical 
application of the treatment intervention discussed later in this thesis. 
The ultimate and fundamental clinical management goal must, of course, be 
the prevention of cancer and all 3 classic tiers of preventive medicine are 
intrinsically linked throughout the process of diagnosis and management. 
Primary prevention, to entirely avoid disease development, concentrates on 
eliminating the principal risks factors of disease and promoting protective 
behaviour within a community or population; this clearly includes eliminating 





improving diet and nutrition. Secondary prevention, to detect premalignant or 
early malignant disease at a stage when intervention leads to either cure or 
significantly reduced morbidity and mortality, requires an effective 
interventional management strategy. Tertiary preventive strategies attempt to 
reduce the risk of disease recurrence and minimize disease-related 
complications, and require appropriate clinical service provision for ‘at risk’ 
patients (Thomson 2012c).  
An interesting but alternative viewpoint was proposed by Esserman et al 
(2013) who emphasized potential danger in over-diagnosis and over-
treatment of ‘indolent lesions of epithelial origin’, defined as clinically 
recognizable lesions never likely to proceed to invasive or metastatic cancer. 
Whilst this may have validity in general screening programmes, for some 
breast or prostate intraepithelial neoplasms for example, the reality remains 
that oral squamous carcinoma is a particularly lethal and progressive disease 
and far too many patients present with advanced, locally invasive, and 
ultimately incurable metastasizing disease. 
Previously available scientific literature has struggled to resolve the 
fundamental question whether early diagnosis and treatment of oral 
potentially malignant disorders will actually prevent the development of 
invasive cancer.  It is not, however, an unreasonable hypothesis and as such 
has provided the direct stimulus and catalyst for the clinical research work 












1.5 Current Problems in Diagnosis and Management  
There are many problems in contemporary clinical practice associated with 
both diagnosis and interventional management for potentially malignant 
disease, and these are summarized in Table 1.3 (Thomson 2012c). 
 
TABLE 1.3: PROBLEMS ASSOCIATED WITH  DIAGNOSIS AND  MANAGEMENT   
OF   POTENTIALLY  MALIGNANT  DISORDERS 
 
DIAGNOSTIC DILEMMAS                          
 
Confused terminology 
Non-specific diagnoses  
Lack of diagnostic consistency 
Clinical behaviour of lesions unpredictable 
Disease progression variable 
Poorly defined clinical outcomes  
  Unpredictable risk of malignancy 
   
 
CLINICAL MANAGEMENT ISSUES 
 
Treatment aims are unclear 
  No agreed treatment protocols 
  No relevant randomised controlled trials   
  Clinical outcome data vary 
 Medical management is unsuccessful 
 
 
The lack of relevant clinical trials in oral potentially malignant disorder 
management has posed a significant challenge in rationalizing contemporary 
clinical practice. High-quality randomised trials are, of course, important in 
ensuring effective comparison of treatment methods by limiting bias and 
confounding influences and remain fundamental to establishing meaningful 
systematic review evidence (Pandis 2013).  
In clinical practice, the condition of ‘potential malignancy’ is a difficult concept 
to define so it is unsurprising that proposed treatment interventions appear 





clinical trials reported in the literature have concentrated on medical 
therapies and suffer from small patient numbers and short study durations 
which question the ultimate significance of their results (Lodi et al 2006, Lodi 
& Porter 2008). It is also unhelpful that none of the studies have ever 
demonstrated long-term lesion resolution, reduction in disease incidence or 
prevention of malignant transformation (Ribeiro et al 2010). 
Despite the theoretical advantage of a chemopreventive strategy, no 
successful medical intervention has been established for potentially 
malignant disease management (Boyle 2001, Boyle 2004, 
Papadimitrakopoulou et al 2008, Ribeiro et al 2010, Mandal et al 2014, 
Dionne et al 2014). Mehanna et al (2009) and Dost et al (2014) have both 
concluded that effective treatment is likely to be based upon surgical excision 
of identifiable precursor lesions and thereby the eradication of visible 
manifestations of dysplastic mucosal fields. Balasundaram et al (2013) noted 
that, whilst there is little controversy in the literature regarding the need for 
intervention in severely dysplastic lesions (which probably possess the 
greatest risk of malignancy) opinion remains divided over the use of clinical 
observation versus treatment for lesions exhibiting mild to moderate 
dysplasia.  
Brennan et al (2007) stated, somewhat unhelpfully perhaps, that due to a 
lack of randomized controlled trials, no evidence-based recommendations 
could be provided for either surgical or non-surgical treatment interventions 
for oral dysplastic lesions. In the absence of evidence-based treatment 
protocols or meaningful randomized controlled patient intervention trials, 
therefore, the longitudinal patient cohort study and clinical outcome data 
presented as an integral part of this MD thesis offer a unique opportunity to 
study a coordinated diagnostic and interventional management strategy for 








1.6 Objectives of Potentially Malignant Disorder Treatment 
 
Marley et al (1996, 1998) first highlighted the significant variation in 
management protocols for potentially malignant oral lesions that existed in 
the UK between different clinicians, and these observations have been 
confirmed by Kanatas et al (2011) and Kumar et al (2013) who note that 
there is still limited consensus on appropriate treatment. Arduino et al (2013) 
summarized the difficulties inherent in early diagnosis, detection and 
management of potentially malignant disorders, particularly emphasizing the 
lack of agreed pathological and diagnostic predictors and the need for long 
term patient studies to improve understanding of the natural history of these 
lesions.   
Limited understanding of the progress of potentially malignant disease and a 
lack of meaningful, randomized controlled clinical trials thus pose significant 
challenges in rationalizing contemporary clinical practice resulting in a variety 
of proposed treatments essentially based upon clinicians’ preferences and 
experience. In addition, the objectives of treatment intervention are poorly 
defined and rarely discussed in the literature, although most authors agree 
that prevention of malignancy is the main priority (Thomson 2012c). 
It is, however, possible and highly pertinent to define a number of salient 
management goals in treating oral potentially malignant disease (Thomson 












TABLE 1.4: MANAGEMENT GOALS IN TREATING ORAL 
POTENTIALLY MALIGNANT DISORDERS 
 
Accurate and definitive diagnosis 
Early recognition of malignancy  
Removal of dysplastic mucosa 
          Prevention of recurrent or further dysplastic lesions 
Prevention of malignant transformation 
           Minimal patient morbidity 
 
1.6.1 Accurate and Definitive Diagnosis. Accurate diagnosis is fundamental, 
but incision biopsies are unlikely to be representative of the true nature of 
oral dysplastic lesions, particularly large and widespread disorders 
(Lumerman et al 1995, Cox et al 1999, Goodson et al 2011). Pentenero et al 
(2003) noted an ‘under-diagnosis ratio’ of 23.9% following incision biopsy of 
46 potentially malignant lesions, whilst Holmstrup et al (2007) similarly 
commented that premalignant lesion biopsies were not always reliable, 
noting that 35 out of 101 excised premalignant lesions demonstrated more 
severe histopathological diagnoses compared with initial incision biopsy. Lee 
et al (2007) also observed ‘under-diagnosis’ in 29.5% of cases following 
comparison of incision biopsies with resection specimen analysis in 200 
lesions. It is thus increasingly recognised that complete excision and 
histological examination of the entire clinical lesion is necessary to establish 
accurate dysplasia grading and definitive diagnosis (van der Waal 2009a, 
Thomson 2014). 
In a series of Newcastle patient cohort studies, we have previously shown 
that excision biopsy following laser surgical treatment allowed more definitive 
histopathological diagnoses compared to initial incision biopsies which 
required ‘up-grading’ in 14 to 28% of cases due to increased dysplasia 





Thomson 2009, Goodson & Thomson 2011). van der Waal (2009a) 
effectively summarized these data by stating that incision biopsy provides 
only a ‘provisional’ dysplasia diagnosis and that surgical excision of 
potentially malignant lesions in their entirety should be deemed mandatory 
for definitive diagnosis and grading. Balasundaram et al (2013) recently 
concurred that all potentially malignant disorders, regardless of clinical 
appearance or incision biopsy diagnosis, should be treated by whole lesion 
surgical removal.  
 
1.6.2 Early Recognition of Malignancy. Formal surgical excision of potentially 
malignant lesions may facilitate early recognition of cancer.  Einhorn & 
Wersall (1967) were among the first authors to highlight the importance that 
surgical removal of mucosal lesions might have in identifying early cancer 
undetected by incision biopsy, whilst Chiesa et al (1986) found unexpected 
malignancy in 6 out of 59 (10.2%) cases of excised potentially malignant 
lesions. Holmstrup et al (2007) noted that 7% of surgically excised 
premalignant lesions harboured a carcinoma, although there was a long time 
interval (mean 10.4 months) between initial incision biopsy and lesion 
removal in this retrospective study. Lee et al (2007) reported that 24 out of 
200 patients (12%) who had undergone single-site biopsy demonstrated a 
malignancy upon whole precancer lesion excision, but that this fell to only a 
2.4% unexpected carcinoma rate when multiple incision biopsies were taken 
from a lesion pre-operatively.   
We found pre-existing ‘unexpected’ carcinomas in 15 out of a consecutive 
series of 169 potentially malignant disorder patients (9%), who were all 
treated for lesions diagnosed as exhibiting dysplasia only on incision biopsy. 
The true efficacy of interventional treatment was confirmed by the 
observations that all laser surgery excisions were carried out within 6 weeks 
of initial biopsy, the fact that none of the patients required additional post-
laser treatment for their excised carcinomas and that all patients remained 





Ho et al (2013) recently reported early detection of 23 squamous carcinomas 
by long-term monitoring of 91 oral epithelial dysplasia patients in a specialist 
clinic, although there was no standardized treatment intervention for this 
retrospective study and 19 cases were only diagnosed when biopsy was 
prompted by clinically apparent malignant change.   
 
1.6.3 Removal of Dysplastic Mucosa. Oral potentially malignant disorders 
are, by definition, mucosal conditions and do not require the aggressive 
treatment necessary for removal or destruction of invasive cancer. It seems 
self-evident, therefore, to intervene early and remove dysplastic mucosa at a 
‘pre-invasive’ stage. Surgical treatment has become increasingly 
recommended by a number of workers (van der Waal 2009, Mehanna et al 
2009, Dost et al 2014), whilst others question whether surgical excision can 
reduce the risk of PMD recurrence or malignant transformation (Lodi & Porter 
2008). 
Surgical intervention for oral mucosal lesions may be carried out by 
conventional scalpel excision, cutting diathermy or photodynamic therapy but 
the efficacy of dysplastic tissue removal by CO2 laser surgery has been 
confirmed in 2 patient cohort studies in which dysplasia-free or small residual 
foci of mild dysplasia only were seen in three quarters of treated cases 
(Hamadah & Thomson 2009, Diajil et al 2013). Whilst the precise techniques 
of laser excision will be described later in this thesis it is also noteworthy that, 
due to the standard practice of laser ablating oral cavity margins for 2 to 
3mm beyond the excision margin during the final stage of treatment, no 
significant association has been seen between residual dysplasia in 
resection margins and clinical outcome (Thomson 2014). 
Thermal cytological artefacts, including superficial vacuolation, detachment 
and shredding of keratin, basal cell degeneration and pseudodysplastic 
epithelial changes, have all been reported following CO2 laser excision 
biopsies (Seoane et al 2010), but these do not appear to adversely affect 





1.6.4 Prevention of Recurrent or Further Dysplastic Lesions. We have 
previously defined a range of specific clinical outcomes following potentially 
malignant disorder treatment including: clinical resolution (disease free 
status), persistent, recurrent or further PMD disease, malignant (same site) 
transformation and oral cancer development (at new sites); Thomson 
(2012d, 2014). Many authors now concur that consistency amongst defined 
diagnosis and treatment outcome categories is essential to inform future 
studies and ensure improved understanding of the natural history of oral 
potentially malignant disorders (Napier & Speight 2008, van der Waal 
2009a). 
Table 1.5 tabulates outcome data for 4 Newcastle cohort studies; whilst 
follow-up periods ranged from 4 to 10 years post-treatment, percentage 
outcomes for the categories remain remarkably similar between studies. 
Mean outcome data show that 68% of patients are disease free, 14% 
develop recurrent disease, 13% further disease, 2% undergo malignant 
transformation and 3% develop cancers at new oral sites.  
It is difficult to find meaningful data with which to compare these studies as 
many of the papers in the literature are anecdotal, observational and 
retrospective in nature with no defined patient cohorts, heterogeneous 
lesions, and uncoordinated management and follow-up regimes. An 
important, consistent observation, however, is that the incidence of recurrent 
or further disease increases with the length of patient follow up, and that non-
homogeneous leukoplakias, larger lesions, more severe dysplasias and floor 
of mouth and ventral tongue sites appear to be at greatest risk (Diajil et al 
2013).  
Smoking and alcohol remain persistent risk factors in patients following laser 
surgery and risk the development of further lesions. It is important to note, 
however, that we have also found high rates of further PMD disease in non-
smokers and non-alcohol drinkers, which emphasizes the complexity of risk 
assessment and the probable importance of genetic predisposition and 
‘other’ risk factors in precancer disease (Hamadah & Thomson 2009, Diajil et 





TABLE 1.5: CLINICAL OUTCOME DATA FOR INTERVENTIONAL LASER 
SURGERY (NEWCASTLE COHORT STUDIES) 
 Thomson & Wylie 
        (2002) 
 
     Stocker et al 
          (2005) 
       Hamadah     
     & Thomson 
         (2009) 
          Diajil et al 




         76             67          64             62 
Recurrent Disease 
(%) 
           6           15           18             18 
Further Disease (%) 
 
         12           14          14             14 
Malignant 
Transformation (%) 
          4             0            0               5 
OSCC Development 
(%) 
          2             4             4                2 
No. of Patients 
 
Study Period (Years) 
        57 
 
          4 
        199 
 
            7 
          78 
 
          10 
           100 
 
             10 
 
 
1.6.5 Prevention of Malignant Transformation. The risk of malignant 
transformation for oral potentially malignant disorders remains unpredictable 
and highly variable; Arduino et al (2013) reviewed 25 papers published 
between 1967 and 2011 and quoted an overall range for transformation of 
leukoplakia varying from 0.13 to 36.4%. van der Waal (2009) noted that, 
probably due to an inherently severe level of pre-existing dysplasia, the vast 
majority of erythroplakias will undergo malignant transformation although the 
paucity of documented case series precluded estimation of transformation 
rates. High rates of transformation, varying between 70 to 100%, have also 
been quoted for proliferative verrucous leukoplakias which, albeit 
controversially, are recognized as distinct, high risk multiple-site oral lesions 





It is a fundamental hypothesis of this thesis, and probably the most 
significant reason for actively treating potentially malignant disease, that 
surgical excision of dysplastic lesions should reduce the risk of malignant 
transformation. Lumerman et al (1995) observed a 6% rate of malignant 
transformation in patients who had lesions excised, compared with 15% in 
those who received no treatment. Schepman et al (1998), on the other hand, 
compared the incidence of oral carcinoma in both treated and untreated 
leukoplakia patients and observed little difference in malignant 
transformation risk. 
Lodi & Porter (2008) have postulated that the natural history of potentially 
malignant lesions may be independent of treatment intervention, and that 
there may be a ‘subgroup’ of lesions inevitably destined for cancer 
development, irrespective of treatment intervention, although this does seem 
a rather negative perspective. 
Whilst recognizing the inconsistent and unpredictable ‘natural history’ of 
potentially malignant disorders, Napier & Speight (2008) highlighted a 
particular increased risk of malignancy in older patients, females, non-
smokers, dysplastic lesions arising on the tongue, floor of mouth and 
retromolar/soft palate complex, lesions of large size, those appearing non-
homogeneous in nature and those of long duration. They concluded that 
accurately predicting which patients or lesions will develop carcinoma 
remains impossible in contemporary clinical practice.  
Mehanna et al (2009) reviewed 14 un-related, non-randomized studies 
reporting on 992 potentially malignant disorder patients and quoted an 
overall malignant transformation rate of around 12%. Whilst mild to 
moderately dysplastic lesions showed a 10.3% transformation rate, this 
increased to 24.1% for severe dysplasia. Patients whose lesions were not 
excised exhibited a much higher transformation rate of 14.6% compared with 
only 5.4% for patients whose lesions were removed. Perhaps of most 
significance, however, was the 25% transformation rate observed in a UK 





term patient follow up there appeared to be no coordinated treatment or 
interventional protocol in place.  
Newcastle patient cohort studies of interventional laser surgery for dysplastic 
lesions have shown much lower malignant transformation rates, of between 
2 to 5% depending on whether same site or new site cancer formation was 
examined, and certainly support the hypothesis that appropriate intervention 
reduces the risk of cancer development (Thomson & Wylie 2002, Hamadah 
& Thomson 2009, Diajil et al 2013). It is pertinent, in contrasting these low 
transformation rates with those in the literature, to emphasize that the 
Newcastle patients in these studies were treated for significant dysplastic 
disease, whereby 32 to 55% of lesions exhibited severe dysplasia or 
carcinoma-in-situ in initial incision biopsies (Thomson 2014).   
Surgical excision of dysplastic lesions appears to decrease the risk of same 
site malignant transformation (Arnaoutakis et al 2013), but does not eliminate 
the risk of new site oral cancer development (Kumar et al 2013, Dost et al 
2014). The clinical consequence is the realization that continued patient 
surveillance, regular clinic monitoring and risk factor profiling remain 
pertinent for all potentially malignant disorder cases following treatment 
(Thomson 2012d&e).  
 
1.6.6 Minimal Patient Morbidity. For interventional treatment to become the 
management of choice for potentially malignant disorders, it is important that 
post-operative morbidity is low. Fortunately, significant complications 
following CO2 laser treatment appear to be rare and, whilst some patients 
report post-operative pain, submandibular salivary gland swelling following 
floor of mouth procedures and lingual nerve dysaesthesia after tongue 
surgery, these are all usually transient and self-limiting and only rarely 
require additional treatment (Thomson & Wylie 2002, Goodson et al 2012).  A 
small number of patients experience more severe or longer lasting 
complications but these are usually cases who have undergone more 
extensive surgery or who have continued to smoke heavily and consume 





In general, the use of CO2 laser surgery is well tolerated and accepted by 
patients, aids haemostasis, promotes excellent healing and produces 
minimal scarring with little functional deficit or patient morbidity. A particular 
advantage is the ability to repeat excisions or ablations at the same site 
without compromising oral healing or function (Thomson 2012c).  
Ho et al (2013) recently reinforced the value of intervention in potentially 
malignant disorders to facilitate detection of oral carcinomas at an early 
stage, thus enabling curative treatment with simple and minor surgical 
interventions. Increasingly, the use of trans-oral laser microsurgery is being 
applied more widely in head and neck surgery to reduce morbidity, whilst 
maintaining efficacy, of tumour resection procedures (Werner et al 2002, 
Thomson & Goodson 2015).  
  
1.7 Interventional Laser Surgery 
 
Interventional laser therapies have evolved following demonstrable failure of 
observational or medical therapies and the limitations of conventional 
surgery in treating oral cavity potentially malignant disease. Laser is an 
acronym for ‘light amplification by stimulated emission of radiation’ and the 
laser device emits a monochromatic, coherent wave of light energy delivered 
to target tissue via fibre-optic systems or a series of articulated arms and 
mirrors. A photo-thermal reaction occurs when laser light interacts with 
tissue; between 60 to 1000C coagulation facilitates localised haemostasis or 
tissue necrosis, whilst at 1000C and above vapourisation allows the surgeon 
to incise tissue, and to either resect or ablate lesions (Thomson 2012c).  
The carbon dioxide (CO2) surgical laser has been used extensively in the 
treatment of oral mucosal lesions. Sealed CO2 gas is the active medium 
generating laser light in the mid-infrared range at 10,600nm; as this is near 
the spectroscopic absorption peak for water, all oral soft tissues successfully 






Figure 1.4 summarizes the surgical excision of a buccally-sited potentially 
malignant mucosal lesion using the CO2 laser; a hand-held delivery device, 
with a laser spot size of 1mm diameter, is used. A helium-neon aiming beam 
facilitates guidance to the target and an evacuation system removes smoke 
and debris from the surgical site.  
Single pulse laser mode is used to outline resection margins, which are 
situated at least 5mm outside the apparent clinical margins of the target 
lesion. Although it is recognised that excision margin placement is based 
upon subjective judgement by the operating surgeon, we have not found 
adjunctive visual examination techniques to helpfully influence the intra-
operative siting of resection margins or to significantly improve the 
achievement of disease-free resection margins (Thomson et al 2010, 
Goodson & Thomson 2014). Pulse marks are connected using the laser in a 
continuous mode, deepening the incision to approximately 5mm in the sub-
mucosal plane; Figure 1.4B.  
Depth of excision is influenced by anatomical site, less when involving thin 
floor of mouth tissue or resections overlying alveolar bone, and by the extent 
of known dysplasia; severe dysplastic lesions are resected at a deeper level 
due to the risk of foci of micro-invasive or early invasive squamous cell 
carcinoma co-existing. The whole specimen is then resected by undercutting 
at a constant depth, as illustrated in Figure 1.4C, which demonstrates the 
buccinator muscle lying immediately beneath the excision specimen. 
Following excision, the surgical bed and all peripheral margins are 
vapourised using a defocused laser beam to eliminate residual disease, 
facilitate haemostasis and to effectively extend the treatment field beyond the 
surgical excision zone; Figure 1.4D. 
The excision specimen is sutured at one or two points to aid later tissue 
orientation, Figure 1.4E, and is then placed in formal saline solution prior to 







Figure 1.4: Interventional Laser Surgery Excision showing (A) erythroleukoplakic buccal 
mucosal lesion which demonstrated severe dysplasia on incision biopsy, (B) resection 
margins as marked out by CO2 laser, (C) dysplastic mucosal lesion resected by laser at a 
constant sub-mucosal level, (D) appearance following post-excision laser vapourisation of 
lesion margins and base to eliminate residual mucosal disease and facilitate haemostasis, 

























Clinically, there is little in the way of immediate post-operative pain, swelling 
or discomfort and patients are allowed to take clear fluids straight away, 
followed 2 hours later by a gradually increasing soft diet. Excised areas heal 
well by secondary intention, with a fibrinous cream coloured coagulum 
forming over the wound within the first few days followed by re-
epithelialization from surrounding wound edges usually complete within 4 to 
6 weeks; these features are illustrated in Figure 1.5 A and B. Due to the 
effects of laser vapourisation, a lack of mechanical trauma during surgery 
and the absence of wound suturing, scarring is usually minimal and excellent 
aesthetic and functional results ensue (Thomson 2012c); Figure 1.5 C. 
Whilst excision techniques are preferred, there is a limited role for ablation 
therapy in which surface mucosa only is destroyed, to a varying depth 
selected by the surgeon and dependent upon the pathological lesion treated, 
using a defocused laser beam. Whilst ablation is not the treatment of choice, 
because tissue is not excised for histopathological examination and the most 
abnormal basal epithelium may be left in situ, such techniques do have a 
small role particularly in treating non-dysplastic or mildly dysplastic lesions 
on tightly bound down alveolar or gingival tissue where excision can result in 
slow or non-healing mucosa with painful areas of denuded and ultimately de-
vitalised alveolar bone (Thomson 2012c). Figure 1.6 illustrates laser ablation 
destruction of a small patch of mildly dysplastic proliferative verrucous 












Figure 1.5: Healing Following Interventional Laser Surgery Excision showing (A) 
immediate post-surgical appearance following excision of a dysplastic lateral tongue lesion 
and vapourisation of all surgical margins (see also Figure 4.1B), (B) 2 weeks post-laser with 
creamy fibrinous exudate and pink, healthy granulation tissue, and (C) healing at 2 months 











Figure 1.6: Interventional Laser Surgery Ablation (Gingiva) showing (A) the pre- and (B) 
the post-ablation appearance of posterior maxillary gingiva, following superficial destruction 













The technique of interventional CO2 laser surgery as a treatment modality 
offers precise precancerous lesion excision, surgery administrable under 
general or local anaesthesia, full histopathological assessment of tissue 
specimens, minimal post-operative morbidity and, importantly, facilitates a 
coordinated and structured patient follow up and surveillance strategy to 
ensure early recognition of recurrent or further dysplastic disease or the 
development of cancer (Thomson & Wylie 2002, Goodson et al 2012, 
Thomson 2014).  
There remains, however, a lack of evidence-based treatment protocols and 
meaningful randomized trials in potentially malignant disorder management. 
In a small, comparative cohort study we assessed the results of surgical 
intervention in 78 PMD patients deemed at ‘high risk’ of malignant 
transformation with observational management in 39 ‘low risk’ cases and 
demonstrated that, whilst 64% of laser treated patients were disease free 3-
years post-intervention, 77% of observed lesions persisted (Thomson et al 
2009). Clearly limited in significance by its non-randomization, the study 
nonetheless supports the efficacy of laser as a treatment intervention.   
Although a readily available, effective and low morbidity interventional 
treatment, specific evidence is lacking to support the role of CO2 laser 
surgery role in reducing the risk of malignant transformation. Similarly, only 
limited data are available in the literature to determine overall length of 
individual patient follow up or the optimal time intervals between clinic 
appointments to monitor patients safely post-treatment. Many of these issues 











1.8 Oral Oncology in the North-East of England 
 
The Department of Health in England emphasised the importance of early 
detection of malignant disease in their Cancer Reform Strategy (2007), and 
this seems especially pertinent for oral squamous cell carcinoma. The 
incidence of oral cancer has risen steadily in the UK, especially over the last 
decade, and a particularly strong association has been seen with social 
inequality and material deprivation (Greenwood et al 2003). In a similar study 
from India, low socioeconomic status was linked to increased tobacco usage, 
enhanced alcohol consumption, poor fruit and vegetable intake, and a 
resultant increased risk of potentially malignant oral disease (Hashibe et al 
2003). 
The general health of people living in Newcastle upon Tyne is worse than 
average for many of the parameters reported in England, with reduced life 
expectancy, high levels of adult smoking and smoking-related deaths, and 
significant rates of alcohol-related hospital admission being particularly 
pertinent to the themes explored in this thesis (Public Health England 2015). 
Unsurprisingly, a North-South divide in oral cancer incidence exists, 
especially for males, with the highest rates within England seen in the North. 
Figure 1.7 illustrates this with data from 2006-08 confirming a standardised 
rate for oral cavity cancer of 4.06 per 100,000 for North-East England, only 
exceeded by that within North-West England (4.23) and Scotland (4.71); 
National Cancer Intelligence Network (2014). 
O’ Hanlon et al (1997) previously reported an average annual number of new 
mouth cancer cases in North-East England of 47 males and 20 females, with 
26 deaths in males and 11 in females each year; incidence and mortality 
were both confirmed to be greater in the North than in the rest of England 
and Wales.    
With a regional North East population of approximately 2.6 million and a city 
population of around 280,000 (Office for National Statistics 2012), the 





Trust serve a large patient base distributed over a wide geographical area. 
Review of patient referral data for the Northern Head and Neck Cancer Unit 
at Freeman Hospital in Newcastle show that approximately 200 new head 
and neck malignancies are diagnosed each year, with around 45 oral 
cancers requiring treatment (McKie et al 2008). More recently, the Newcastle 
unit was characterised as undertaking a ‘high’ annual workload for major 
head and neck cancer surgery (Price et al 2014).  
Figure 1.7:  Oral Cancer Incidence in North-East England illustrating a standardised rate 
of 4.06 per 100,000 (orange labelling) for 2006-08; data and illustrations obtained from the 








It is interesting to note, however, that no data exist to document the 
incidence or prevalence of oral potentially malignant disorders in the North-
East of England. Therefore, the best currently available information is based 
upon clinical records. The Newcastle potentially malignant disorder clinic was 
established in 1996 by this author, and is currently run on a weekly basis in 
the out-patient department of the Maxillofacial Unit at the Royal Victoria 
Infirmary. Approximately 1200 patient attendances occur annually comprising 
both new patient referrals of suspicious oral mucosal lesions, from both 
primary health care practitioners or from specialist colleagues in secondary 
care, and longer-term follow-up of previously diagnosed and treated cases 
(Thomson & Wylie 2002, Thomson 2012c). A specific objective of this thesis, 
therefore, will be to use anonymised clinic data to more fully characterise the 
presentation and management of oral potentially malignant disorder patients 

















1.9 Overall Aims and Hypotheses of the Thesis 
The overall aim of the research work presented in this thesis is, in the 
absence of any formal, national oral potentially malignant disease statistics 
or a robust evidence-base, to profile patient demography and detail clinico-
pathological data from patient cohorts presenting to a specialist, potentially 
malignant disorder service in a large university teaching hospital in 
Newcastle upon Tyne in North-East England, and to determine clinical 
outcomes for those patients treated primarily by interventional CO2 laser 
surgery and to thereby attempt an assessment of the effectiveness of this 
treatment protocol and its influence on the progress of oral carcinogenesis. 
 
A number of hypotheses will be tested: 
1. Assessment of standard clinico-pathological features cannot predict 
disease progression or clinical outcome for oral potentially malignant 
disorders, 
 
2. Incision biopsy techniques are insufficient for definitive 
histopathological diagnosis, which requires whole lesion excision for 
microscopic examination, 
 
3. Interventional laser surgery is an effective tool for definitive diagnosis 
and effective treatment of potentially malignant lesions and, 
 
4. Active intervention during the progress of ‘pre-malignancy’ halts the 
















 Perspectives on Oral Potentially 















2.1. Introduction and Overview of Presented Publications 
 
The diagnosis and management of oral potentially malignant disease 
involves a complex interaction between presenting patients and their 
information and management needs, clinicians’ views on disease recognition 
and treatment, and histopathological assessment and diagnosis of mucosal 
biopsy specimens. Uncertainty regarding the concept of the ‘potentially 
malignant state’ remains a difficult and pernicious influence throughout this 
process. This chapter will explore all of these issues which, taken together, 
are a fundamental influence on clinical management strategies for patients 
with such disorders. 
Three recent, pertinent publications and four relevant research papers 
dealing with contemporaneous aspects of each of these potentially malignant 
disorder management issues are presented in support of this MD thesis, and 
are now included in the chapter (where appropriate, in chronological order of 
publication) within each of the following 4 themes:  
 
1. The Clinicians’ Perspective (Publication 2.2)  
2. The Patients’ Perspective (Publications 2.3a, 2.3b and 2.3c) 
3. The Pathology Perspective (Publication 2.4) 
4. The Clinical Management Perspective (Publications 2.5a and 2.5b)  
 
Each publication is preceded by a summary page detailing the background to 
the paper, the key message, overall paper significance and relevance to the 







 2.2 The Clinicians’ Perspective 
 
Thomson PJ, McCaul JA, Ridout F, Hutchison IL. To treat...or not to treat? 
Clinicians’ views on the management of oral potentially malignant disorders. 
British Journal of Oral & Maxillofacial Surgery 2015 53 : 1027-1031 
 
Background: Current PMD management requires clinical recognition of suspicious 
mucosal lesions and incision biopsy to facilitate histopathological assessment of 
dysplasia, followed by excision of ‘high risk’ lesions and long-term patient 
surveillance to monitor for further disease. In the absence of treatment consensus, 
the aim of this study was to determine contemporaneous clinicians’ views on 
available clinical management strategies. 
Key Message: 251 UK clinicians participated in a web-link questionnaire 
demonstrating some agreement on how to manage individual PMD lesions and on 
treatment decisions for 3 different clinical scenarios. Whilst most favoured excision 
of severely dysplastic lesions and observation of mild dysplasia, clinicians’ greatest 
equipoise in decision making was seen in patients with moderate dysplasia.  
Paper Significance: This is a contemporaneous review of a substantive number of 
UK clinicians’ views on diagnosis and management techniques for oral potentially 
malignant disease. In addition, this is the first paper to try to elicit clinician support 
and involvement in a proposed, prospective randomised clinical trial to investigate 
treatment efficacy.  
Thesis Relevance: The approach to PMD clinical management presented and 
analysed later in this MD thesis evolved through a lack of universally agreed 
treatment protocols. Clinicians’ views on PMD diagnosis and treatment, however, 
remain fundamental, not only to determine current practice in UK management 
strategies but also to ensure relevance, pragmatism and effective recruitment to 












2.3. The Patients’ Perspective 
 
2.3a Green RA, Exley C, Thomson PJ, Steele JG.  Understanding patient 
views and experience of oral pre-cancer.  Journal of Dental Research 2010  
89B: 2571  
https://iadr.confex.com/iadr/2010barce/webprogram/Paper132749.html 
 
Background: Whilst many studies have examined quality of life issues related to 
oral cancer diagnosis and treatment, there is little in the literature regarding 
potentially malignant disease. Qualitative interviews were carried out with 16 North-
East oral potentially malignant disorder patients to explore their views and treatment 
experiences. 
Key Message: Patients varied significantly in their conception and misconception of 
their disease and its cause. The impact of the diagnosis on their lives and unmet 
information needs were consistent patient concerns. The individual clinician-patient 
relationship was deemed important, with patients particularly emphasizing the 
importance of ‘expert’ knowledge and consistency during their clinical management.   
Paper Significance: This is an innovative study which has provided a unique 
insight into the potentially malignant disease treatment pathway from the patients’ 
perspective. This research paper has been cited in the literature and continues to 
inform specialist practice. 
Thesis Relevance: Challenges exist for clinicians throughout the process of 
diagnosis and management of oral potentially malignant disease, including the use 
of terminology, conveying information, recognising and then meeting patients’ 
additional needs, encouraging behavioural change and rationalizing treatment 
decisions. These issues are pertinent when determining and reviewing clinical 














2.3b Green RA, Thomson PJ, Exley C, Steele JG.  Understanding the 
transition from primary to secondary care: experiences of patients with oral 
pre-cancer.  British Journal of Oral & Maxillofacial Surgery  2011  49 Suppl. 1 
: S60  doi:10.1016/j.bjoms.2011.03.105 
 
Background: In a development of the study reported in paper 2.3a, data from 28 
qualitative interviews with North-East England potentially malignant disorder 
patients were reviewed to characterise patients’ experience of their individual 
progression through local healthcare systems, from initial primary care contact 
through to attendance at secondary care, specialist hospital services.   
Key Message: Patients’ accounts of their health care journey provided new and 
invaluable insights into the oral pre-cancer patient’s journey. Timely referral to 
appropriate specialist care reduces patient uncertainty and helps allay feelings of 
‘powerlessness’ during the health care journey.  
Paper Significance: This is the first paper to directly elicit potentially malignant 
disorder patients’ experiences of their management as they proceed from primary to 
secondary healthcare services.  
Thesis Relevance: In developing a formal review of treatment intervention for oral 
potentially malignant disease, this paper offers an invaluable, additional perspective 


















2.3c Green RA, Exley C, Steele JG, Thomson PJ.   Patients understanding 
of the unknown: oral pre-cancer.  Journal of Dental Research   2014 93B: 
1515    
https://iadr.confex.com/iadr/14iags/webprogram/Paper188348.html 
 
Background: Following on from papers 2.3a and 2.3b, data from 28 qualitative 
interviews with North-East England oral potentially malignant disorder patients were 
analysed to specifically map individual patient health care journeys.   
Key Message: Patients experienced significant uncertainty at a number of stages 
during their diagnosis, treatment and clinic follow-up. For many, such uncertainty 
was seen as a negative experience which impacted on both their working and social 
lives. 
Paper Significance: This is the first paper to demonstrate the significance of 
uncertainty and its resultant impact upon patients’ overall experiences of oral 
potentially malignant disease. 
Thesis Relevance: From a patient perspective, the uncertainty inherent in a 
potentially malignant condition leads to a deleterious impact on many aspects of 
their lives. Opportunities exist throughout the patient journey at diagnosis, during 
interventional treatment and follow-up to ensure clarity and consistency in 
explanation and use of terminology. Recognising the significance of uncertainty in 
contemporary PMD management is important during review of study data presented 














2.4. The Pathology Perspective 
 
Goodson ML, Sloan P, Robinson CM, Cocks K, Thomson PJ. Oral precursor 
lesions and malignant transformation – who, where, what and when?  British 
Journal of Oral & Maxillofacial Surgery 2015 53 : 831-835 
 
 
Background: Histopathological assessment and dysplasia grading of mucosal 
biopsies remains fundamental to assess malignant transformation risk in clinically 
recognisable oral potentially malignant lesions. The aim of this study was to 
evaluate the relevance of histopathological diagnoses of previously identified 
precursor lesions upon subsequent malignant transformation.   
Key Message: By retrospectively reviewing 1,248 SCCs diagnosed in Oral & 
Maxillofacial Surgery Units in North-East England between 1996 and 2009, 58 
previously biopsied same-site precursor lesions were identified. The single most 
common histopathological finding in 19 cases was lichenoid inflammation with no 
discernible dysplastic features. 
Paper Significance: This study highlights limitations of incision biopsy diagnosis 
and dysplasia grading as predictive tools and supports the view that squamous 
carcinoma may arise in the absence of recognizable oral epithelial dysplasia. The 
paper also re-affirms the importance of clinical vigilance and active surveillance in 
the management of all clinically suspicious oral lesions irrespective of histological 
findings. 
Thesis Relevance: Whilst the importance of effective communication between 
diagnostic pathologists and oral clinicians cannot be over-estimated in PMD 
management, dysplasia grading must be considered limited both as a diagnostic 
tool and as a predictor of clinical outcome. These particular issues will be explored 











2.5. The Clinical Management Perspective 
 
2.5a Thomson PJ, Diajil AR, Goodson ML.  Rationalizing risk assessment in 
oral potentially disorder management.  International Dental Journal 2015 65 
Suppl. 2 : 51 
 
 
Background: This recently presented paper reports the results of a 300 publication 
literature review in an attempt to stratify known aetiological factors involved in oral 
carcinogenesis into ‘high’ and ‘low’ risk categories. 
Key Message: Despite the absence of reliable predictive tools or biomarkers, 
integrating risk profiling to existing diagnostic and clinic protocols may prove a 
pragmatic tool to discriminate between ‘high’ and ‘low’ risk PMD patients. 
Paper Significance: This is the first paper to delineate a ‘high’ risk PMD patient 
profile based upon the analysis of both lifestyle and medical and family histories. 
Thesis Relevance: Whilst interventional surgical management appears a readily 
available, effective, low morbidity treatment, in the future we will need to definitively 
classify potentially malignant disorder patients into ‘high’ and ‘low risk’ categories 
and develop individually tailored treatment protocols. These issues will be further 



























2.5b Thomson PJ. Managing oral potentially malignant disorders: A question of 
risk.   Faculty Dental Journal  2015  6 : 186-191 
 
 
Background: Recognising the significance of risk profiling outlined in paper 2.5a, 
this opinion paper expands upon the important concept of risk as it relates to initial 
diagnosis and subsequently throughout the overall management of oral potentially 
malignant disorders. 
Key Message: An oral disease process characterised as ‘potentially malignant’, 
neither entirely benign nor frankly malignant, is a difficult concept for both clinicians 
and their affected patients.  
Paper Significance: Whilst contemporary clinical practice struggles to predict 
individual PMD lesion behaviour, quantify risk for malignant transformation or 
objectively plan treatment intervention, recognising and addressing the uncertainty 
and unpredictability inherent in potentially malignant disease offers a strategy to 
objectify treatment protocols. 
Thesis Relevance: It remains difficult in contemporary practice to quantify the risk 
of malignant transformation and predict clinical outcome. Further work in this thesis 
will examine treatment outcomes and cancer development in patient cohorts to try 
to improve understanding of the natural history of PMD disease and aid the 
development of objective and predictive diagnoses for future interventional 














2.6.1. Introduction. The principal dilemma facing clinicians upon new patient 
presentation with an oral potentially malignant disorder (PMD) is to establish 
a definitive histopathological diagnosis and to confirm the optimal 
management strategy for that individual patient (Thomson 2014, Field et al 
2015). As Field et al (2015) have pertinently observed, ‘clinicians have a duty 
of care to patients to offer advice and management’. This is difficult, of 
course, when the evidence base for treatment guidelines is weak and 
knowledge limited by lack of relevant clinical trial data. Fundamentally, 
however, it remains important to attempt to identify individual patients and 
mucosal lesions at risk from the most progressive types of potentially 
malignant disease and, ultimately, those with the greatest likelihood of 
malignant transformation. 
 
2.6.2. The Clinicians’ Perspective. In Publication 2.2 we specifically sought 
contemporaneous views on individual clinico-pathological scenarios in order 
to ascertain clinicians’ perspectives on management techniques for 
potentially malignant lesions. Questionnaire responses were received from 
251 UK clinicians, making this one of the largest reported clinician surveys 
on PMD disease ever published. 
Whilst most participating clinicians favoured excision of ‘high-risk’ severely 
dysplastic lesions and observation of ‘low-risk’ lesions, opinion was more 
divided for those disorders graded as moderately dysplastic, reflecting the 
prognostic uncertainty of ‘mid-grade’ dysplastic change. Although it is 
encouraging that a degree of consensus regarding management is apparent, 
the majority of responding clinicians were practising surgeons and therefore 
probably more likely to recommend intervention. The results also reflect an 
assumption, which may well be misplaced, that it is possible to reliably 
characterise some mucosal lesions as exhibiting ‘low-risk’ disease; this issue 





Clinicians’ views have been sought before, of course, initially in two papers 
by Marley et al (1996, 1998) who clearly highlighted a significant lack of 
agreement in PMD treatment decisions from 141 UK Oral and Maxillofacial 
Surgeons, whose management protocols included elimination of potential 
sources of mucosal trauma, prescription of anti-fungal agents, surgical 
excision, laser ablation and even radiotherapy treatment. Epstein et al (2007) 
similarly elicited a varying range of treatment responses including surgery, 
laser and cryotherapy, from 65 US Oral Medicine clinicians. More recently, 
Kanatas et al (2011) elicited the opinions of 199 UK surgeons regarding 
assessment, biopsy and follow-up of PMD lesions and found wide-ranging 
views and practice, with little in the way of consensus.  
There are signs, however, that there may now be a move towards greater 
agreement supporting surgical intervention as the preferred treatment option 
for oral potentially malignant lesions, with increasing reports in the literature 
confirming efficacy of disease resolution and possible reduction in malignant 
transformation risk (Mehanna et al 2009, Thomson 2014). The evidence 
base supporting these concepts remains limited, however, and the important 
principles governing the interventional management of potentially malignant 
disease will be examined in detail later in this thesis. 
 
2.6.3. The Patients’ Perspective. The issues introduced in publications 2.3a, 
2.3b and 2.3c, documenting patients’ views and experience, are increasingly 
recognised as important, if not mandatory, issues in modern healthcare 
provision and research. It is interesting that, despite the inherent 
uncertainties that plague PMD diagnosis, treatment and follow-up, and 
particularly the lack of consensus-based clinical guidelines, patients clearly 
value and support ‘expert’ knowledge and opinion, especially when 
combined with a degree of consistency of approach to their individual 
management. These have always been core components of our Newcastle 
treatment philosophy and indeed are facilitated by the provision of dedicated 





Green (2013) observed that patients’ understanding of potentially malignant 
disease can be highly variable, however, and may be significantly influenced 
by the quality of communication with their clinicians and by the use of 
terminology. Whilst ‘lay’ terms are often favoured by clinicians in attempting 
to explain the concept and nature of pre-cancer disease, patients may well 
prefer and subsequently require more precise definitions and terminology in 
order to access supplemental information, especially via internet sources. It 
seems clear, therefore, that more attention is required to meet patients’ 
information needs and to improve their overall understanding of potentially 
malignant disease. Green (2013) concluded that patients must be fully 
engaged in all aspects of their treatment decisions and necessary health-
related behaviour changes for PMD management to become truly effective. 
Ford & Farah (2013) recently emphasised the importance of exploring both 
the individual experience and the support needs of patients with oral 
potentially malignant disorders. van der Waal (2014) commented that 
clinicians may experience real difficulties in conveying PMD diagnoses and 
prognoses to patients, observing that whilst some patients will be able to 
balance uncertainties regarding treatment efficacy and morbidity, others will 
experience confusion and concern surrounding clinicians’ inability to either 
predict or prevent malignant transformation. These latter observations, which 
have been experienced by the author in his own clinical practice and are 
explored in some detail in publication 2.5b, certainly support the research 
findings reported in publication 2.3c.     
Assessment of patients’ quality of life is also now regarded as an integral 
component of evaluating disease outcome, especially for chronic disease 
states and malignant conditions, including oral cancer (Tadakamadla et al 
2015). In attempting a recent systematic literature review, however, 
Tadakamadla et al (2015) found a paucity of data regarding quality of life 
studies for patients with oral potentially malignant disease, despite the known 
significant effects such disorders inevitably have on oro-facial function, 





It is interesting in publication 2.3b that ‘timely’ referral from primary care to 
specialist services was found to be important to patients to help reduce 
anxiety and ensure appropriate patient engagement. We have previously 
examined the PMD management pathway for 100 Newcastle patients once 
entering specialist care and confirmed that efficient treatment times 
contribute to an overall successful management strategy (Diajil et al 2014). It 
remains difficult, however, to influence individual patients’ initial presentation 
to primary care services or their subsequent referral times into specialist 
care. These issues will be explored in more detail later in the thesis.   
The patient experiential studies reported in this thesis, particularly those 
highlighting patients’ understanding of their disease, clearly demonstrate the 
numerous influences that may adversely affect patients during their PMD 
treatment journey and emphasise that these factors will require further study 
and greater attention in future clinical research work.    
 
2.6.4. The Pathology Perspective. The role of the pathologist in PMD 
management has been described as firstly, to exclude benign disease 
processes and then secondly, to determine the presence and degree of 
epithelial dysplasia thus estimating the risk of cancer development (Speight 
& Torres-Rendon 2011). Publication 2.4 reports upon a retrospective 
histopathological study in which details of known oral mucosal precursor 
lesions, those that specifically preceded same-site invasive carcinoma 
development, were identified from laboratory databases and then 
characterised in detail. It is significant that in this study only 25 out of the 58 
precursor lesions (43%) were actually shown to be dysplastic in nature, but 
of especial interest was the high number of non-dysplastic lichenoid lesions 
that progressed to carcinoma, the latter developing clinically into aggressive, 
advanced-stage malignancies. 
The potential for malignant change to occur in oral lichenoid lesions has 
been recognised, but remained controversial, for many years. There is little 
doubt that red and white oral mucosal lesions, clinically resembling lichenoid 





progress rapidly to invasive carcinoma (Lovas et al 1989, Thomson & 
Goodson 2012a), and indeed such a clinical presentation was illustrated in 
Figure 1.4A. It is also well recognised that both dysplasia and lichenoid 
inflammation can co-exist in oral lesions, and this certainly adds to the on-
going uncertainty and debate surrounding the malignant potential of lichenoid 
lesions (van der Meij et al 2007, Patil et al 2014). 
Regardless of clinical appearance, the histological finding of dysplasia within 
oral lichenoid disorders is probably the most salient diagnostic factor and 
such lesions should be regarded as ‘high-risk’ potentially malignant disease 
(Thomson & Goodson 2012a). It may well be that intense inflammatory cell 
infiltration of the immediate sub-epithelial tissue represents an enhanced 
immune response to antigenically disturbed dysplastic epithelium. 
Notwithstanding the above, it is important to emphasise that despite 
consensus review and re-grading of biopsy specimens by experienced oral 
pathologists in Publication 2.4, 19 oral precursor lesions were confirmed to 
have exhibited hyperkeratosis and lichenoid inflammation only on 
histopathological diagnosis, with no evidence of pre-existing dysplasia.    
In terms of its clinical relevance, therefore, Publication 2.4 clearly supports 
long term follow-up in specialist clinics for patients with clinically suspicious 
oral mucosal lesions, irrespective of histopathological diagnosis. This theme 
has been developed and reported on recently by a number of authors and 
will be discussed in more detail later in this thesis (Mehanna et al 2009, van 
der Waal 2014). 
Of especial pertinence for the histopathological examination of PMD lesions, 
and thus an important feature of many of the subsequent studies to be 
discussed in this thesis, is the confirmation of substantial agreement 
between oral pathology specialists in Newcastle regarding biopsy diagnoses 
and grading of epithelial dysplasia. Substantive inter-observer agreement 
was seen (kappa = 0.642), as was agreement between original archival and 
study re-grading diagnoses (kappa = 0.825). Mullin et al (2015) recently 





especially specialist views, during the management of head and neck 
disease. 
 
2.6.5. The Clinical Management Perspective. The concept of risk, as applied 
to the rational management of potentially malignant disease and discussed in 
Publications 2.5a and 2.5b, is both crucial in nature and fundamental to 
successful intervention and yet remains persistently obscure and highly 
variable in contemporary clinical practice. Risk stratification for malignant 
transformation relies on currently available clinical and histopathological 
assessments of suspicious oral mucosal lesions, but is frustratingly limited in 
practice by its highly subjective nature (Thomson 2014, Field et al 2015). 
The dilemmas facing clinicians planning PMD treatment have already been 
discussed and summarized in Chapter 1. The inability to predict the 
individual behaviour of oral mucosal lesions and the difficulty in quantifying 
malignant transformation risk combine to render objective patient treatment 
planning extremely difficult. Whilst the clinical recognition of an oral mucosal 
abnormality may be relatively straightforward, the precise diagnosis ascribed 
to an individual PMD patient can be demanding, requiring detailed 
coordination of specific clinical and pathological data together with an 
attempt to distinguish ‘high risk’ from ‘low risk’ cases (Thomson 2012c). 
Whilst many of these themes will be examined and discussed in more detail 
in the next chapters of this thesis, it is clear that the ability to integrate risk 
profiling into existing diagnostic, treatment and clinic surveillance protocols 
would provide an invaluable pragmatic tool to contemporary clinical 
management strategies.    
 
2.6.6. Conclusions. Throughout the publications presented in this chapter is 
the central theme of a fundamental lack of understanding of the natural 
history of oral potentially malignant disease, which affects both clinicians and 
their patients; this was observed and emphasised by Napier & Speight 





the work presented in the next 3 chapters of this thesis will attempt, using 
observational and longitudinal cohort studies of PMD patient populations 
from North-East England, to delineate a better understanding of the clinical 
presentation, efficacy of interventional treatment and significance of long 




























 CLINICAL STUDY 1  
  
Demography of Newcastle Potentially 















There are very few meaningful studies in the literature that address the 
specific epidemiology of oral potentially malignant disorders, so it remains 
difficult to report accurate incidence or prevalence data. Napier & Speight 
(2008) suggested a global prevalence rate of 1 to 5% for all potentially 
malignant disease, whilst Petti (2003) estimated a figure of between 1.5 and 
2.6% for oral leukoplakia, the commonest potentially malignant lesion. 
Epidemiological studies such as these are often flawed, however, due to 
inconsistent diagnostic methodology, non-representative study populations 
and lack of confirmatory histopathological data (Thomson 2012a). This is 
compounded by the realization that no data exist at all to document either 
national or regional UK statistics. 
The Newcastle Potentially Malignant Disorder (PMD) clinic was first 
established in 1996 by this author, initially in conjunction with the regional 
Oral and Maxillofacial Oncology service at Newcastle General Hospital and 
then from 2010 onwards as a specific, weekly clinic in the new out-patient 
Maxillofacial Unit at the Royal Victoria Infirmary (RVI). We have previously 
noted approximately 1200 patient attendances each year, which comprised 
new patient referrals of suspicious oral mucosal lesions, both from primary 
health care practitioners and specialist colleagues in secondary care, and 
longer-term follow-up of previously diagnosed and treated cases (Thomson & 
Wylie 2002, Thomson 2012c). Assuming a Newcastle upon Tyne population 
of around 280,000, an annual prevalence estimate of 0.43% may be made. 
This, however, is a rather crude calculation which does not discriminate 
between new patient presentations, review cases, or patient treatment 








3.2 Aim of the Study  
 
The aim of this simple, cross-sectional study, therefore, was to determine a 
more detailed demographic profile of a defined cohort of oral potentially 
malignant disorder patients attending for diagnosis and treatment at the 
specialist Newcastle upon Tyne Hospitals NHS Foundation Trust potentially 
malignant disorder clinical service during a 4 week period in 2015. In this 
manner, a comprehensive descriptive record of patient numbers, age, sex, 
oral lesions and interventional PMD management occurring in North-East 




3.3.1. Caldicott Approval.  Applying appropriate principles to creation of new, 
demographic and clinico-pathological oriented databases, formal Caldicott 
approval was obtained from the Joint Newcastle University / Newcastle upon 
Tyne Hospitals NHS Foundation Trust to collect anonymized data from 
medical records, operating logs and pathology reports from PMD patients 
treated by the author and attending specialist Oral and Maxillofacial services 
at the Royal Victoria Infirmary (Appendix I). Individual patient consent was 
not sought for data collection, because no patient identifiable material was 
used and no individual treatment, clinical intervention or clinical outcome was 
influenced by database construction and analysis.  
 
3.3.2. Patient Demography. During 4 consecutive weeks in 2015, 
commencing Monday 12 January and finishing Friday 6 February, 
anonymized demographic and clinico-pathological details were recorded 
prospectively for consecutive patients attending clinics or undergoing surgery 
for oral potentially malignant disorders. Each patient was assigned a study 





and alcohol habits, reason for hospital attendance (new presentation, review 
patient or surgical treatment), clinical appearance (leukoplakia, 
erythroleukoplakia or erythroplakia) and anatomical site of oral mucosal 
lesions, whether single-site or multiple-lesion disease presentation, 
histopathology diagnoses, together with details of the treatment modality 
patients underwent (clinical observation, medical treatment or CO2 laser 
surgery intervention).  
 
3.3.3. Histopathology Diagnosis. All biopsy procedures on PMD patients 
were carried out, as deemed appropriate by well-defined existing 
management protocols (Thomson & Wylie 2002), in Oral and Maxillofacial 
Surgery clinics under the direction of the author and formalin-fixed tissue 
specimens subsequently assessed via standardized histopathology 
examination by experienced oral pathologists at the Royal Victoria Infirmary 
working to agreed diagnostic criteria (Sloan 2012). Using the World Health 
Organization (WHO) classification, specimens were graded into mild, 
moderate or severe dysplasia categories, carcinoma-in-situ (CiS) or 
squamous cell carcinoma (SCC); Gale et al (2005). In addition, the presence 
of hyperkeratosis, lichenoid inflammation (LI), or the diagnoses of 
proliferative verrucous leukoplakia (PVL) or chronic hyperplastic candidosis 




A total of 75 patients attended the Newcastle PMD service during the 4 week 
period. Detailed clinico-pathological data for this study group are listed in 
Appendix II. If patients presented with multiple lesions or had undergone 
more than 1 biopsy procedure, a single ‘most significant’ histopathological 
diagnosis was determined by the author from a review of the relevant clinical 






In terms of ethnicity, 74 patients (98%) were white European and 1 was 
Asian. The patient population included 46 males (with an age range of 41 to 
83 years, and a mean of 60.9 years) and 29 females (age range from 29 to 
85 years, with a mean of 58.1 years). The cohort varied between 13 to 26 
patients per week and overall comprised 20 new referrals, 51 review patients 
and 4 surgical cases, as shown in Figure 3.1 and Table 3.1.  
 
Figure 3.1:  PMD Patient Attendances plotting the number of patients seen each week 
during the period 12 January to 6 February 2015 (w/c week commencing). 





TABLE 3.1: REASON FOR PATIENT ATTENDANCE AT PMD SERVICE 
 
_____________________________________________________________ 
Patient Activity                                No. of Patients                           % 
_____________________________________________________________ 
New Patients                                             20                                       27 
                 Review Patients                                         51                                       68 
Patients Undergoing Surgery                      4                                         5   
_____________________________________________________________ 


















Although data relating to the numbers of cigarettes smoked per day or units 
of alcohol consumed per week were not fully completed for every patient in 
this study, the majority reported they currently smoked cigarettes or were 
recent ex-smokers (67%), as shown in Table 3.2, and all patients confirmed 
either regular or occasional alcohol consumption.    
 
 
TABLE 3.2: SMOKING HABITS OF PMD PATIENTS 
_____________________________________________________________ 
Current Tobacco Use                 No. of Patients                                  %           
_____________________________________________________________ 
                  Smoker                                                 38                                            51 
 Ex-Smoker                                            12                                           16 
 Non-Smoker                                          25                                           33 
_____________________________________________________________ 




Table 3.3 shows that 84% of patients presented with oral leukoplakia, whilst 
erythroleukoplakia and erythroplakia were much less common; 11% and 5% 
respectively. Fifty patients (67%) presented with single-site disease and 25 
(33%) exhibited multiple PMD lesions at distinct or bilateral anatomical sites; 
in 20 cases (27%) 2 sites were involved, whilst in a further 5 patients (7%) 3 
sites were affected (full details are listed in Appendix II).  
 
In total, 100 oral lesions were seen in the 75 patients and Table 3.4 lists the 
numbers at each anatomical site, together with the distribution of single and 
multiple lesion presentations. Overall, the floor of mouth and ventro-lateral 
tongue comprised the most commonly affected region (46%), with buccal 
mucosa next most common (14%). Multiple lesion disease appeared to 








TABLE 3.3: CLINICAL APPEARANCE OF PMD LESIONS 
____________________________________________________________ 
Clinical Appearance                  No. of Patients                                 %                         
____________________________________________________________ 
Leukoplakia                                           63                                           84 
Erythroleukoplakia                                  8                                           11 
Erythroplakia                                           4                                            5          
____________________________________________________________ 





TABLE 3.4: ANATOMICAL SITE DISTRIBUTION OF PMD LESIONS 
___________________________________________________________________ 
      Anatomical Site             Total Lesions         Single Lesions        Multiple Lesions                                                                                        
___________________________________________________________________ 
           Floor of Mouth                          21                                13                               8 
           Ventral Tongue                        11                                  9                                2 
           Lateral Tongue                         14                                11                               3 
           Tongue Dorsum                         2                                  2                                0 
           Buccal Mucosa                         14                                 4                               10 
           Labial Commissure                     5                                 3                                2 
           Labial Mucosa                            2                                 1                                1 
           Palate                                         9                                 7                                2 
           Fauces                                        2                                 1                               1 
           Retromolar Region                      2                                 0                               2 
           Gingiva                                        8                                 2                               6 
           Alveolus                                    10                                 2                               8    
________________________________________________________________ 







Following lesion biopsy, histopathological diagnoses were available for 74 
patients (1 patient failed to return for biopsy investigation), and these are 
listed in Table 3.5. Although a total of 100 mucosal lesions were identified 
(Table 3.4), not all were biopsied and therefore a single, most significant, 
histopathology diagnosis was identified by the author and assigned to each 
patient. Whilst a wide range of diagnoses were recorded, the presence of 
epithelial dysplasia or carcinoma-in-situ was identified in the majority of 
cases (53 or 71%). In 17 cases a diagnosis of PVL, most commonly with the 
additional presence of dysplasia, was made. 
 
TABLE 3.5: HISTOPATHOLOGY DIAGNOSES FOR PMD PATIENTS 
_________________________________________________________________________ 
Histopathology Diagnosis                                    No. of Patients                     % 
_________________________________________________________________________ 
Unknown                                                                                  1                               1.3 
Hyperkeratosis                                                                         4                               5.3 
Hyperkeratosis + Lichenoid Inflammation (LI)                          8                             10.7 
Chronic Hyperplastic Candidosis                                             5                               6.7 
Proliferative Verrucous Leukoplakia (PVL)                              2                                2.7 
Mild Dysplasia                                                                        20                             26.7 
Mild Dysplasia + LI                                                                   2                               2.7 
Mild Dysplasia + PVL                                                             12                             16.0                
Moderate Dysplasia                                                                10                            13.3 
Moderate Dysplasia + LI                                                           3                             4.0                                                               
Moderate Dysplasia + PVL                                                       3                             4.0         
Severe Dysplasia                                                                      2                             2.7              
Carcinoma-in-Situ                                                                     1                             1.3             
Squamous Cell Carcinoma (SCC)                                            2                             2.7  
 _________________________________________________________________________ 







Review of clinical management showed that the majority of patients, 52 
(69%), had been treated by interventional laser surgery, 20 were managed 
by clinical observation alone and 2 were treated medically (systemic anti-
fungal treatment for chronic hyperplastic candidosis); 1 patient failed to 
return following initial consultation (Table 3.6). During the 4-week study 
period, 4 patients attended theatre for laser treatment, primarily to excise 
dysplastic leukoplakia arising on the tongue (the latter data are summarized 
by study numbers 59 to 62 in Appendix II). 
 
 
TABLE 3.6: PMD PATIENT MANAGEMENT 
_____________________________________________________________ 
Management                                      No. of Patients                         %        
_____________________________________________________________ 
Interventional Laser Surgery                       52                                      69 
Clinical Observation                                    20                                      27 
                 Medical Treatment                                        2                                       2.7 
                 Did Not Re-Attend                                         1                                       1.3 
_____________________________________________________________ 




3.5 Discussion  
 
3.5.1. Patient Numbers and Demographics. Seventy-five Newcastle PMD 
patients (55 review or treatment cases, and 20 new referrals) were identified 
during the 4-week study period; extrapolated over 12 months, this amounts 
to around 900 clinical cases, and is similar to un-published audit data 
obtained for the Maxillofacial Oncology / Dysplasia service during 4 weeks in 
January 2008 in which 97 cases, 17 new and 80 follow-up patients were 
identified (Ball 2008; Appendix III). These patient figures appear reasonably 





the majority of UK Oral and Maxillofacial Surgeons saw less than 50 PMD 
patients per year and also more recently Kanatas et al (2011), in a 
questionnaire-based study of 199 UK surgeons, who reported even lower 
patient figures: only 38% of responding clinicians saw more than 30 new 
PMD patients per year, whilst a further 38% estimated they reviewed less 
than 30 in their clinics. In addition, the majority of clinicians (59%) did not 
provide designated, specialist clinics so the potential to concentrate expertise 
in diagnosis and management of their PMD patient cohorts must inevitably 
be reduced. 
 
Overall, the patient group in this study appeared fairly representative of the 
Newcastle upon Tyne population, which has a self-reported ethnicity of 95% 
white British/Other and a median age of 41 years (Office for National 
Statistics 2012). Male patients, with a mean age of 60.9 years, accounted for 
61% of the study group. Unfortunately, there are very few comparable data 
sets in the literature to compare these results, although Napier and Speight 
(2008) previously observed oral leukoplakia to be most common in males 
between the fourth and seventh decades of life. In an earlier UK study, Jaber 
et al (2003) reviewed 630 patients with dysplastic PMD lesions attending 
specialist Oral Medicine clinics in Southern England (Bristol and London) 
between 1972 and 1996 and found that 56% were male, with a mean age of 
55 years. Warnakulasuriya et al (2011) reported on 1,357 PMD patients seen 
in Oral Medicine clinics at Guy’s Hospital in London over a 10-year period in 
the 1990’s, noting that the majority (61%) were female and that 70% were 
over 47-years of age; this cohort, however, comprised primarily patients with 
oral lichen planus and, as only 15% of oral lesions exhibited epithelial 
dysplasia, these data may not be wholly relevant or indeed comparable to 
the MD study group.   
 
Worldwide, data is more difficult to interpret owing to significant variation in 
risk factor behaviour and disease presentation. In Brazil, Pulino et al (2011) 
analyzed biopsy results from 252 patients with suspicious oral lesions 
attending specialist clinics at the University of Sao Paulo over a 7-year 





57.8 years, again with male predominance. Villa & Gohel (2014) identified 
only 27 PMD patients out of a total of 3,142 (0.9%) attending specialist 
diagnostic clinics at Boston University’s School of Dental Medicine during an 
8-month review, but similarly noted that males and current smokers were 
most likely to exhibit potentially malignant disease. 
  
3.5.2. Clinico-Pathological Features. 63 patients in this study (84%) 
presented with oral leukoplakia, with floor of mouth and ventro-lateral tongue 
sites most commonly affected (46%); Jaber et al (2003) reported similar 
findings with around 42% of lesions arising on ventro-lateral tongue and floor 
of mouth sites, although only 50% presented as leukoplakia. In this study, 
both the labial commissure/buccal mucosal region and the 
palate/fauces/retromolar complex accounted for 19% of PMD cases, with 
gingiva and alveolar mucosa providing a further 18%; these sites accounted 
for 22%, 12% and 10%, respectively, of oral lesions reported by Jaber et al 
(2003). Napier & Speight (2008) usefully observed that PMD site is highly 
dependent upon both ethnicity and tobacco habit, with labial 
commissure/buccal mucosa particularly affected in South-East Asian patients 
using oral tobacco products and floor of mouth/ventral tongue sites more 
common in European populations smoking cigarettes.  
 
Twenty-five patients (33%) presented with multiple-lesion disease, with the 
buccal mucosa, floor of mouth, and gingiva/alveolar mucosa most frequently 
involved (32 out of 45 lesions, or 71%); Appendix II and Table 3.4. We have 
previously shown multiple lesion disease to particularly affect buccal mucosa 
and floor of mouth sites (27 out of 54 lesions, or 50%) in a North-East 
population of 96 PMD patients (Hamadah et al 2010). There were no specific 
age, sex or tobacco use influences on disease presentation in either this or 
our earlier study (Hamadah et al 2010) but, as previously noted, 
comprehensive details relating to the amount of tobacco consumed were not 
available for all patients in this study.  
 
A wide range of histopathological diagnoses were recorded for the 75 study 





exhibited some degree of dysplasia on biopsy: 34 mild (64%), 16 moderate 
(30%) and 3 severe dysplasia or carcinoma-in-situ (6%); Jaber et al (2003) 
noted 47%, 29% and 24%, respectively, for these categories. Many of the 
lesions in this study exhibited, sometimes in combination with dysplasia, the 
varying presence of lichenoid inflammation (5) or proliferative verrucous 
leukoplakia (15). These later histological categories have, of course, become 
more pertinent in histopathology diagnoses in recent years, as previously 
discussed. In 2 cases (2.7%), squamous cell carcinoma was identified 
unexpectedly following laser excision of dysplastic lesions. We have 
previously reported a 9% incidence of unexpected carcinoma in laser 
excision specimens (Goodson & Thomson 2011) and such early diagnosis 
and treatment of invasive cancer provides strong evidence to support 
interventional treatment protocols (Dost et al 2014).  
 
3.5.3. Patient Management. Having previously documented the interventional 
laser surgery protocol practiced in Newcastle (Thomson & Wylie 2002, 
Thomson 2012c), it is unsurprising that 52 study patients (69%) were treated 
by CO2 laser: 48 attended for post-operative follow-up during the study 
period, with 4 actively undergoing surgery; Appendix II.  Whilst no universal 
consensus on treatment exists, complete excision of ‘high risk’ lesions is 
recommended and most authorities now advise that surgical excision or 
ablation of identifiable lesions is likely to be more effective than observation, 
both for treating PMD disease and preventing progression to malignancy 
(Arnaoutakis et al 2013, Kumar et al 2013). The difficulty remains in defining 
precisely which oral mucosal lesions are ‘high risk’, and this is an important 
issue which will be further addressed in this thesis. 
 
3.5.4. Limitations of the Study. Cross-sectional studies are, of course, 
disadvantaged by their ‘snap-shot’ nature and the potential for prevalence-
incidence bias, although there does appear reasonable consistency through 
recent years when the data are compared with that from our 2008 study 
(Appendix III). A further limitation of this particular data set is the recognition 
that ‘other’ Newcastle PMD patients may have presented to alternate clinical 





Surgery and other Dental or Oral Medicine clinics. It remains our experience, 
however, that over time the majority of Newcastle patients diagnosed with a 
potentially malignant disorder are referred during their ‘treatment journey’ to 
the specialist PMD service for advice and treatment (Green 2013).  
 
 
3.6 Conclusions  
 
The data collected in this study helps gain insight into the contemporaneous 
presentation and treatment of PMD disease in Newcastle upon Tyne, yet it 
remains a small ‘snap-shot’ of that activity. It is also disappointing for a 
specialist clinic service that comprehensive details of the amounts of tobacco 
and alcohol consumed were not recorded for every PMD patient at each 
clinic or treatment visit. Nonetheless, this study adds detailed information to 
our current knowledge base and may well help in the planning of future 
clinical service provision. It seems clear, however, that analyses of patient 
presentation, diagnosis and treatment over a longer time period is necessary 
to provide further and more detailed data regarding PMD disease in North-
East England. Clinical Studies 2 and 4 reported later in this thesis will 
therefore utilize a retrospective cohort approach to delineate disease activity 





















 CLINICAL STUDIES 2 & 3  
 

















Whilst there are no evidence-based guidelines or agreed treatment protocols 
for the management of oral potentially malignant disease, most authorities 
now agree that initial incision biopsy to identify dysplasia should be followed 
by whole lesion excision for definitive histopathological diagnosis and optimal 
treatment intervention (van der Waal 2009a, Dost et al 2014). Whilst a 
variety of surgical procedures have been proposed over the years, including 
scalpel excision, electro-surgery, cryotherapy, and photodynamic therapy, 
use of the CO2 laser has become increasingly recommended due to the 
numerous reported side-effects and limitations of the other, afore-mentioned 
techniques (Ishii et al 2003, Mogedas-Vegara et al 2015).  
The use of laser surgery as a treatment intervention for mucosal disease and 
the removal of oral soft tissue lesions has thus become an increasingly 
advocated procedure in the literature since first introduced into clinical 
practice in the 1970’s (Tuffin & Carruth 1980, Frame 1984 & 1985, Frame et 
al 1984, Roodenburg et al 1991).  
We have previously published a detailed management protocol for laser 
excision of oral dysplastic lesions, and also introduced and reviewed the 
indications and practical applications of this technique in Sections 1.6 and 
1.7 of this thesis (Thomson & Wylie 2002, Thomson 2012c, Thomson 2014). 
Importantly, following a provisional diagnostic process and patient education 
regarding elimination of risk factor behaviours, interventional laser surgery 
facilitates precise precancerous lesion excision, minimally invasive surgery 
under general or local anaesthesia, full histopathological assessment of 
tissue specimens, reduced post-operative morbidity and coordinates patient 
follow up and surveillance strategies (Thomson 2014). Figure 4.1 illustrates 








Figure 4.1:  Interventional Laser Surgery showing (A) CO2 laser in use in the operating 
theatre for oral potentially malignant lesion treatment under general anaesthesia, and (B) 













Ishii et al (2003) listed the significant, pragmatic advantages of laser surgery 
as a PMD treatment modality emphasising: improved haemorrhage control 
and excellent visibility intra-operatively, accurate excision due to reduced 
wound contractility during surgery, analgesia consequent upon sealing of 
local nerve endings, minimal damage to adjacent tissue thus reducing the 
post-surgical acute inflammatory response, reduction in scarring and 
contraction leading to excellent soft tissue mobility, minimal oral dysfunction 
and the ability to carry out repeated procedures. In contrast, quoted 
disadvantages of laser including slower re-epithelialization of oral wounds, 
occasional surface granuloma formation during healing (as demonstrated in 
Figure 4.2), and the technical intra-operative and associated laser safety 
requirements appear quite minimal in nature.   
Figure 4.2:  Post-Laser Surgery Appearance illustrating granulation tissue arising on the 
lateral surface of the tongue, often caused by irritation from the adjacent dentition during re-
epithelialization. Whilst this resolves spontaneously over time, rapid subsequent healing is 
facilitated by a minor secondary procedure to excise the exuberant tissue. 
 
Although Figure 4.1 illustrates the use of CO2 laser surgery under general 
anaesthesia (GA), it is also practical to provide laser treatment under local 
anaesthesia (LA), especially for ablation procedures or the excision of 
smaller or more anteriorly-sited mucosal lesions, although in practice 
patients primarily undergo excision surgery to treat potentially malignant 
lesions and all are treated in the theatre environment to ensure optimal 
operating conditions and appropriate laser safety precautions (Thomson & 






This chapter will report on the results of 2 complementary clinical studies 
carried out to characterise the use of interventional CO2 laser surgery to treat 
oral potentially malignant disorders in Newcastle upon Tyne between 1996 
and 2015.  
 
 
4.2 Clinical Study 2 – A Retrospective Review of Interventional 
CO2 Laser Surgery in Newcastle 1996 – 2014 
 
4.2.1. Aims. The specific aim of this retrospective study was to review the 
use of interventional laser surgery in the management of oral potentially 
malignant disorder patients by one surgeon using a standardised treatment 
protocol, as originally described by Thomson & Wylie (2002), over a 19-year 
period.  
 
4.2.2. Method. A retrospective audit of Newcastle Oral and Maxillofacial 
theatre operating lists was undertaken to determine anonymized treatment 
details for patients attending for laser treatment of PMD disease between 
August 1996, when the author commenced clinical practice in Newcastle, 
and December 2014 (inclusive). All lesions underwent incision biopsy 
assessment prior to laser intervention, and both laser excisions and ablations 
were carried out, as deemed appropriate, by the same operator (PJT) 
working to standardised protocols with consistent diagnostic and treatment 
decisions (Thomson & Wylie 2002). It was not the intention of this study to 
document the demographics of treated patients, nor to record the clinico-
pathological diagnoses for individual oral mucosal lesions or long-term 
clinical outcome and follow-up data which will all be detailed and analysed in 







4.2.3. Results. In total, 773 CO2 laser operations were carried out on 590 
patients during the 19-year period, with a clear trend for increasing numbers 
of treatments to be performed through the years, as illustrated in Figure 4.3.   
Figure 4.3:  Number of Interventional Laser Surgery Operations carried out between 
1996 and 2014, demonstrating a trend for increasing numbers of treatments to be performed 




Whilst the majority of patients, 513 (87%) required only 1 laser surgery 
intervention, 77 (13%) required multiple treatments most frequently 2 or 3 
sequential procedures over time; these latter data are listed in Table 4.1 and 
graphically represented in Figure 4.4.  
Laser excision (removing the entire visible mucosal lesion) was the preferred 
technique in 650 cases (84%), but as can be seen from Figure 4.5 a trend for 
increasing numbers of ablation procedures (superficial lesion destruction) 
was evident as the years progressed, with 123 (16%) ablations carried out in 
total. Figure 4.6 also reveals a similar trend for increasing use of LA for laser 
surgery, although most operations were still performed under GA (608 cases 
or 79%); only 2 cases were operated under local anaesthesia and 



































TABLE 4.1: NUMBER OF LASER PROCEDURES PER STUDY YEAR 
__________________________________________________________ 
                                        No. Of Laser Procedures 
Year of Presentation           1                 2                3              4                5             >5                                                                                        
_______________________________________________________________________ 
                    1996                        0                0                1              0                0               1 
                    1997                        5                1                1              0                0               0 
                    1998                      13                2                1              0                0               0 
                    1999                      22                2                1              0                0               0 
                    2000                      35                1                0              1                1               1 
                    2001                      21                1                2              0                0               0 
                    2002                      12                3                0              1                0               0                                                  
                    2003                      24                2                2              1                0               0    
                    2004                      30                1                1              0                0               0 
                    2005                      13                0                0              0                0               0                                              
                    2006                      17                3                0              0                0               0  
                    2007                      22                2                2              0                0               0    
                    2008                      31                5                1              0                1               0 
                    2009                      35                2                2              1                0               0 
                    2010                      36                5                1              0                0               0 
                    2011                      50                8                4              0                0               0 
                    2012                      50                2                1              0                0               0 
                    2013                      64                8                0              0                0               0 
                    2014            33                1                0              0                0               0                                                                                                            
_______________________________________________________________________ 












Figure 4.4:  Numbers of Patients Undergoing More Than 1 Laser Surgery Operation. 
Whilst the number of procedures ranged from 2 to >5 (colour legend), most patients (69/77) 





Figure 4.5:  Number of CO2 Laser Excision and Ablation Procedures carried out each 
































































Figure 4.6:  Type of Anaesthesia Used for CO2 Laser Surgery each year between 1996 
and 2014 (total number of procedures = 773); GA General Anaesthesia, LA Local 





(a) Interventional Laser Surgery. This study provides one of the largest 
interventional laser surgery data sets presented in the current literature; 
Jerjes et al (2012a), for example in one of the very few similar CO2 laser 
studies in the contemporary literature, reported on only 123 laser procedures 
carried out on 77 patients during a 6-year study period at the Head and Neck 
Unit at University College Hospital in London. 
It is clear from reviewing Figure 4.2 that the use of CO2 laser surgery 
increased during the study period, peaking at 89 operative interventions in 
2013. This undoubtedly reflects a steady increase in patient throughput 
through the Newcastle PMD service and probably an increasing trend to offer 
intervention to patients, although it remains unclear whether this reflects any 
rise in PMD disease incidence in the North-East over this time period.  
The majority of patients (513) required only 1 laser treatment, although 77 















































commonly only 2 or 3 were required (in 69 patients); Table 4.1. In their study, 
Jerjes et al (2012a) observed that 62 out of 77 treated PMD patients required 
only one round of laser treatment, whilst a further 15 cases required up to 5 
episodes of laser treatment during follow-up. Whilst the details of individual 
patient histories were not examined in this section of the MD study, the most 
common reasons for repeat laser treatment were recurrence of oral lesions 
(same site) or appearance of further lesions (new site) over time. We have 
previously summarized clinical outcome for cohorts of laser-treated 
Newcastle patients, demonstrating recurrent PMD disease in 6 to 18% of 
cases and further disease in 12 to 14%, as listed in Table 1.5. 
Whilst a variety of lasers have been used to treat oral mucosal lesions, 
including higher potency and deeper penetrating neodymium:yttrium-
aluminium garnet (Nd:YAG) and potassium-titanyl-phosphate (KTP) lasers, 
the CO2 laser has become the preferred modality, primarily due to its ease of 
intra-operative use and its efficacy of oral soft tissue interaction (Thomson 
2012c, Jerjes et al 2012b, Kumar et al 2013, Matsumoto et al 2015, 
Mogedas-Vegara et al 2015). Lim et al (2010) reported reduction in rates of 
oral leukoplakia recurrence when KTP was used instead of CO2, but this was 
a small, retrospective ablative surgery study and did not examine the efficacy 
of laser excision. 
We have previously reported upon common complications following intra-oral 
laser surgery in 82 treated PMD patients, including pain, bleeding, 
submandibular salivary gland swelling following floor of mouth interventions, 
and lingual nerve dysaethesia as a consequence of lateral tongue surgery, 
but most of these proved minor and transitory in nature resolving within the 
first few post-operative months (Goodson et al 2012). 
Laser surgery is probably, therefore, the preferred treatment intervention for 
PMD because of its reliability and reproducibility, its ability to create relatively 
bloodless surgical fields, improved intra-operative accuracy and visualisation, 
reduced post-operative pain, limited scarring and reduction in damage to 
adjacent tissues, together with very low long-term complication rates (Lim et 





(b) Laser Excision versus Ablation. The fundamental distinction between 
laser excision and ablation techniques is the advantage of excision biopsy to 
facilitate histopathological analysis of mucosal lesions in their entirety, thus 
providing definitive diagnoses (van der Waal 2009) and reducing the risk of 
‘under-diagnosis’ inherent in incision biopsy sampling; we have previously 
reported ‘under-diagnosis’ of dysplasia in 28%, and masking of invasive 
cancer in 9%, of treated PMD lesions (Goodson et al 2012).  
Whilst a number of authors have reviewed the use of intra-oral CO2 laser 
ablative surgery (Chandu & Smith 2005, van der Hem et al 2005, Deppe et al 
2012, Brouns et al 2013) or excision surgery (Yang et al 2011, Matsumoto et 
al 2015) they have actually treated relatively small numbers of leukoplakia 
patients and have not carried out any comparative analyses of technique 
efficacy. 
Brouns et al (2014) recently described the treatment of 144 patients with oral 
leukoplakia using surgical excision, laser ablation or via clinical observation 
alone but did not feel able to compare treatment modalities due to the 
differing treatment indications. In a direct, retrospective comparison of laser 
excision and ablation treatment techniques for 77 oral leukoplakic lesions, 
Del Corso et al (2015) found no significant difference in clinical outcome, 
although recommended excision of lesions exhibiting dysplasia to prevent 
recurrence; this study was slightly flawed, however, because although CO2 
laser was used for excision, Nd:YAG was employed for all ablation 
procedures rendering meaningful comparison difficult.  
In Newcastle, we usually only recommend ablation of lesions arising on 
tightly-bound mucoperiosteal surfaces such as gingiva (previously illustrated 
in Figure 1.5), alveolar mucosa and hard palate to avoid bony dehiscence, or 
in soft palate sites to avoid the post-excision risk of oro-nasal fistula 
formation, and all such lesions must have undergone pre-laser incision 
biopsy (Thomson 2012c, Thomson & Goodson 2015). Ishi et al (2004) also 
advised laser excision of PMD lesions on non-keratinised tongue and buccal 
mucosa, but believed ablation suitable for gingival cases. On occasion, 





less than 1cm2 size arising on non-keratinised epithelium) are to be treated, 
because the resultant thermal artefacts seen in small excision specimens 
render accurate dysplasia grading unreliable and impractical; this technique, 
as applied to a suitable floor of mouth lesion is illustrated in Figure 4.7.    
 
(c) Type of Anaesthesia. Figure 4.6 clearly shows an increasing number of 
LA procedures carried out over time, and interestingly this parallels the 
similar rise seen in the use of ablative surgery (Figure 4.5). This most likely 
reflects the increasing personal experience of the operator and more 
discretionary application of varying laser techniques to different clinical 
scenarios. Laser ablation is usually a shorter and less technically demanding 
procedure, which is well tolerated by conscious patients (Thomson 2012c). 
Not all local anaesthetic procedures are undertaken to facilitate ablation, 
however, as some patients’ general medical status and/or cardio-respiratory 
co-morbidities inevitably contra-indicate the elective use of general 
anaesthesia for oral surgery; only 2 patients in the study required 
intravenous sedation to supplement local anaesthesia.  
Laser excision of large dysplastic lesions arising on floor of mouth and 
ventro-lateral tongue sites can, of course, be technically demanding and may 
be poorly tolerated by conscious patients. The additional requirements of 
adjacent soft tissue retraction, haemostasis, accuracy in visualisation of the 
operative field and lack of patient movement usually necessitate the use of 
GA techniques, which have been described in detail by the author previously 
(Thomson 2012c). An example of such a GA laser procedure, a partial 











Figure 4.7:  Interventional Laser Surgery Ablation (Floor of Mouth) showing (A) 
localised, small patch of non-homogeneous, mildly dysplastic leukoplakia arising in the left 
floor of mouth and (B) post-CO2 laser ablation appearance following superficial mucosal 













(d) Limitations of the Study. Although a large number of CO2 laser 
interventions over a 19-year period have been listed and reviewed in this 
study, the significance of these results are limited by the one-centre basis of 
the work and particularly by the inevitable clinician bias inherent in treatment 
selection for these patients. Similarly, this study primarily lists and describes 
the numbers and types of CO2 surgical procedures carried out, with little 
context to explain either the clinical or the histopathological background of 
treated disease. However, a further contemporaneous examination of the 
use of laser surgery will be reported in Clinical Study 3, whilst a detailed 
analysis of clinico-pathological data and patient outcomes following 




4.3 Clinical Study 3 – A Prospective Study Documenting 
Interventional CO2 Laser Surgery Use in Newcastle During 2015 
 
4.3.1. Aims. Directly following on from the previous study, the aim of this 
further investigation was to prospectively document in greater and additional 
detail the use of CO2 laser surgery by the author in the management of oral 
potentially malignant disease in Newcastle during the 12 months of the 
calendar year 2015, and to confirm both the pattern of disease presentation 
and mode of treatment. 
4.3.2. Method. In a prospective manner, the author recorded anonymised 
details of all PMD laser operations carried out during the 12 month period 
detailing the age and sex of treated patients, their presenting clinical lesions, 
histopathological diagnoses, length of time between treatment decision and 
subsequent attendance for laser surgery, the mode of surgical intervention 
(excision or ablation), and the use of general anaesthesia (GA) or local 





4.3.3. Results. Full anonymised details of patients operated on by the author 
and undergoing interventional laser surgery during 2015 are listed in 
Appendix IV. In total, 67 laser operations were carried out during the 12 
months and these are summarized in Figure 4.8 which illustrates the 
numbers of procedures carried out each month; numbers ranged from 0 to 
13 dependent upon both operating theatre timetabling and patient and 
surgeon availability. 
 
Figure 4.8:  Number of Interventional Laser Surgery Procedures Performed Each 
Month During 2015 (total number of procedures = 67).  
 
 
(a) Clinico-Pathological Features. 39 male patients (age range 38-84yrs; 
mean age 59.8yrs) and 28 female patients (age range 37-81yrs; mean age 
58.5yrs) were treated during this period. 51 patients were new PMD referrals 
undergoing laser surgery for the first time, whilst 16 cases attended for 
repeat laser surgery; none of the 67 patients underwent more than 1 laser 
surgery procedure during the 12 month study period. The majority of treated 
PMD lesions appeared clinically as oral leukoplakias (56 or 83.5%), with 
erythroleukoplakia and erythroplakia much less common, as shown in Table 


























mouth and ventrolateral tongue sites (34 or 50.7%). In terms of 
histopathological diagnoses, Table 4.3 reveals that 41 lesions (61%) 
exhibited features of either epithelial dysplasia or carcinoma-in-situ, 13 
(19.4%) were diagnosed as proliferative verrucous leukoplakia (PVL), whilst 
a further 10 (14.9%) showed features of PVL in combination with dysplasia.      
 
TABLE 4.2: CLINICAL APPEARANCE OF TREATED PMD LESIONS 
____________________________________________________________ 
Clinical Appearance                  No. of Patients                                 %   
 ____________________________________________________________ 
                Leukoplakia                                            56                                         83.5 
                Erythroleukoplakia                                  10                                         15.0 
                Erythroplakia                                           1                                             1.5 
___________________________________________________________ 
Total                                                    67                                         100                         
____________________________________________________________ 
 
Figure 4.9:  Number of Interventional Laser Surgery Procedures Performed Plotted 
against Anatomical Site (total number of procedures = 67) where FOM: Floor of Mouth,  


























TABLE 4.3: HISTOPATHOLOGY DIAGNOSES FOR TREATED PMD LESIONS 
_________________________________________________________________________ 
Histopathology Diagnosis                                    No. of Patients                     % 
_________________________________________________________________________ 
Hyperkeratosis                                                                         1                                1.5 
Chronic Hyperplastic Candidosis (CHC)                                  2                                3.0 
Proliferative Verrucous Leukoplakia (PVL)                            13                               19.4 
Mild Dysplasia                                                                        24                               35.8 
Mild Dysplasia + PVL                                                               9                               13.4                
Moderate Dysplasia                                                                 7                               10.4 
Moderate Dysplasia + PVL                                                      1                                 1.5         
Severe Dysplasia                                                                     8                               12.0 
Carcinoma-in-Situ                                                                     2                                3.0           
_________________________________________________________________________ 
Total                                                                                        67                           100.0 
_________________________________________________________________________ 
 
(b) Use of Interventional Laser Surgery.  Review of the data in Appendix IV 
reveals that the time to laser treatment, defined as the interval between initial 
diagnosis and treatment decision to the date when laser surgery was carried 
out, varied from 2 to 15 weeks, with an overall mean of 8 weeks. In relation 
to the specific use of CO2 laser in the 67 cases, most procedures (46) were 
performed as surgical excision biopsies, with the majority (42) carried out 
under GA. Table 4.4 confirms that, whilst most laser excision procedures 
(31) were carried out using GA, ablative surgery was performed in similar 
numbers under GA and LA; 11 and 10 operations, respectively.  
TABLE 4.4: USE OF GENERAL ANAESTHESIA (GA) AND LOCAL 
ANAESTHESIA (LA) FOR LASER EXCISION AND ABLATION PROCEDURES 
 GA LA Totals 
Laser Excision 31 15 46 
Laser Ablation 11 10 21 





Figure 4.10 illustrates the use of GA and LA techniques applied to the 
varying anatomical sites of treated PMD lesions confirming that, whilst most 
PMD sites were operated on using either anaesthetic technique, ventrolateral 
tongue surgery was more often performed under GA (18) compared with LA 
(5). 
 
Figure 4.10:  Number of GA and LA Laser Surgery Procedures Plotted against 
Anatomical Site (total number of procedures = 67) where FOM: Floor of Mouth, Dors 






Figure 4.11 similarly plots the number of laser excision or ablation 
techniques performed at each anatomical site, showing a clear 
predominance for excision surgery to occur at floor of mouth and 
ventrolateral tongue sites (31), whilst laser ablation was primarily used for 

































Figure 4.11:  Number of Laser Excision and Ablation Procedures Plotted against 
Anatomical Site (total number of procedures = 67) where FOM: Floor of Mouth, Dors 





(a) Patient Numbers and Demographics. By carrying out a prospective data 
collection of CO2 laser operations, this study has allowed additional 
characterisation of patients and PMD disease in North-East England over a 
12 month period in 2015. Whilst concentrating on patients undergoing 
intervention, the age and sex profile of these 67 laser patients is very similar 
to the demographic profile observed in the cross-sectional patient study 
reported in Chapter 3 with, in addition, the confirmation that the predominant 
clinical presentation of oral leukoplakia arising at floor of mouth and ventro-
lateral tongue sites remains highly consistent between studies. 
(b) Clinico-Pathological Features. Unsurprisingly, as a study group 
undergoing interventional management, the vast majority of PMD lesions 
were shown to be dysplastic or characterised as exhibiting features of PVL 
on histopathological examination. It was not, of course, the remit of this study 






























important part of the investigation in Chapter 5) but nonetheless such 
observation supports the profiling of PMD patients and histopathology data 
presented in Chapter 3.   
(c) Interventional Laser Surgery. Whilst the previous study reviewed the 
evolution and overall utilization of CO2 laser surgery as a treatment modality 
over a 19-year period, this study was designed to analyse contemporaneous 
interventional management over a more specific 12 month period. 
Interestingly, both the numbers of treated patients and the mode of laser 
treatment remained highly consistent between studies.  
It was interesting to note the varying numbers of cases operated upon each 
month (0 to 13, with a mean of 5.6); these figures were influenced not only 
by the number of patients presenting for treatment but also the myriad of 
administrative influences regarding clinic and theatre timetabling and both 
patient and surgeon availability.   
A useful, additional observation in this investigation was the determination of 
treatment times for patients: 64 patients (95%) were operated on within 12 
weeks of diagnosis, whilst 2 patients waiting 14 and 15 weeks for treatment 
(study numbers L58 and L7, respectively, in Appendix IV) specifically 
requested a later date for their surgery. Dost et al (2014) reported that a 6 
month period may be considered as a pragmatic ‘cut-off’ to account for 
biopsy sampling error or the co-existence of unexpected malignancy during 
PMD assessment. Whilst no specific time frame or guidelines have ever 
been proposed regarding PMD treatment intervention, a 12 week period 
seems reasonable to rule out significant disease progression between initial 
incision biopsy diagnosis and intervention; this is the time frame we have 
tried to adhere to in our treatment protocols (Thomson & Wylie 2002, 
Thomson 2012c & 2014).  
Diajil et al (2104) previously reviewed 100 Newcastle PMD patients and 
undertook a comprehensive analysis of clinical management times, 
confirming that 91% of patients were diagnosed and 49% definitively treated 
within 12 weeks of initial referral. Any delayed management, however, which 





to adversely influence clinical outcome. Issues related to outcome following 
PMD treatment will be reviewed in detail in the next chapter of this thesis. 
(d) Laser Excision versus Ablation. As previously discussed in Section 4.2.4, 
CO2 laser surgery usefully offers both excision and ablative modes of 
treatment, although laser excision biopsy remains the preferred treatment 
option for oral PMD lesions, confirmed in this study by its use in 46 patients 
(69%). The role of laser ablation in the superficial destruction of palatal, 
gingival and alveolar lesions is supported by Figure 4.11 which confirms that 
16 out of 18 lesions at these sites were treated by ablation rather than 
excision. Many of these issues have already been covered in the previous 
section of this chapter.  
(e) Type of Anaesthesia. Although the majority of laser surgery was carried 
out under GA (42 cases or 63%), Figure 4.10 shows that both GA and LA 
techniques were utilised at most oral sites during the study except for lateral 
and ventral tongue lesions which were primarily operated on under GA (18 
out of 23 cases). Decisions regarding treatment choice and the use of GA or 
LA for individual procedures requires careful assimilation of background 
medical issues, the specific technical requirements of the operative 
procedure and consideration of overall patient management issues, as 
previously discussed in Section 4.2.4.   
(f) Limitations of the Study. This is a review of 12 months laser surgery 
performed by one clinician treating PMD lesions in Newcastle upon Tyne. 
Similar to the comments in Section 4.2.4, the study is clearly limited by its 
one-site location, a vulnerability to treatment bias and its descriptive nature, 
although background clinico-pathological data for the treated patients and 










Contemporaneous opinion in the PMD literature now emphasizes the role of 
interventional management so that definitive surgical excision, rather than 
clinical monitoring or medical therapy, is most often recommended to treat 
potentially malignant oral lesions (Gomes & Gomez 2013, Dost et al 2014). It 
has, of course, been this author’s opinion for many years that interventional 
laser surgery offers a pragmatic and effective therapeutic intervention during 
oral carcinogenesis, and the unique and substantial data documenting 840 
laser surgery operations carried out over a 20-year period, presented and 
analysed in this chapter, is a clear testimony to this clinical management 
strategy. In the next chapter of this thesis, however, the efficacy of this 
treatment intervention will be tested by a detailed review of long-term clinical 























CLINICAL STUDY 4 
 
 Clinical, Histopathological & Clinical 
Outcome Analyses for Newcastle 
















The protocol for interventional laser surgery adopted by the author in 
Newcastle (Thomson & Wylie 2002), whereby PMD lesions are provisionally 
characterised by incision biopsy and subsequently treated by formal laser 
excision or ablation of ‘high risk’ dysplastic lesions, has undoubtedly helped 
rationalize modern management techniques for patients presenting with oral 
potentially malignant lesions offering both definitive diagnosis through whole 
lesion analysis and efficacious, low morbidity treatment (Thomson 2012c, 
Goodson et al 2012, Thomson 2014). It is encouraging that most 
contemporaneous authors now support such a management strategy 
(Mehanna et al 2009, van der Waal 2009a, Dost et al 2014). 
The specific hypothesis that such intervention prevents or reduces the 
ultimate risk of malignant transformation remains to be proven, however. 
Edwards (2014) commented that surgical excision of dysplastic oral lesions 
might reduce the risk of malignancy by 50%, but this is only an estimate and 
not readily applicable as a statistic during the active treatment of individual 
patients or lesions. 
The absence of relevant randomised clinical trials, especially comparing the 
benefits of surgical intervention with clinical observation or lesion 
surveillance, weakens the evidence base. It remains difficult, however, to 
envisage a comprehensive trial design which has both scientific validity and 
acceptability to clinicians and patients; a ‘non-intervention’ arm to manage 
lesions exhibiting significant dysplastic change, for example, being especially 
problematic. 
As documented in Chapter 1, we have undertaken and published a number 
of Newcastle patient cohort studies but these have been based upon 
relatively small patient numbers and varying follow-up periods. In the 
absence of meaningful clinical trial data, further detailed analysis of a large 
patient cohort with well-defined potentially malignant disease undergoing a 






5.2 Aim of the Study  
The aim of this retrospective, cohort study was thus to collate and then 
review in detail all available patient demographic, clinico-pathological, 
diagnostic, treatment and clinical outcome data for patients that attended the 
Newcastle Oral and Maxillofacial Surgery service for CO2 laser treatment of 
new-onset oral potentially malignant disease between 1st August 1996, when 
the author commenced consultant practice and established dedicated 
potentially malignant disorder services, and a clinical outcome census date 
of 31 December 2014.  
 
5.3 Method 
5.3.1. Caldicott Approval. As previously documented in Chapter 2, Caldicott 
approval was obtained from the Joint Newcastle University / Newcastle upon 
Tyne Hospitals NHS Foundation Trust to facilitate anonymized data 
collection from medical records, operating logs and pathology reports from 
potentially malignant disorder patients treated by the author and attending 
specialist Oral and Maxillofacial services at Newcastle Dental and Royal 
Victoria Infirmary hospitals (Appendix I). Ethical advice was sought and 
confirmed that individual patient consent was not required for anonymized, 
retrospective clinico-pathological and treatment data collection and analysis. 
5.3.2. Patient and Treatment Details. Utilising theatre log books as the 
starting point for data collection, supplemented when available by patients’ 
clinical records and pathology reports, anonymized demographic and clinico-
pathological details were recorded for individual patients undergoing CO2 
laser surgery treatment for oral potentially malignant disorders between 
August 1996 and December 2014 (inclusive). As the author held personal 
clinical responsibility for these patients, it was felt data collection would be 






The following data was documented for each study case: date of initial 
treatment by CO2 laser surgery (facilitating individual patient study numbers), 
patient age and sex, clinical appearance (leukoplakia, erythroleukoplakia or 
erythroplakia) and anatomical site of treated oral mucosal lesions, original 
histopathology diagnoses for both incision and where appropriate  post-laser 
excision biopsies, together with details of follow-up and the need for further 
laser treatment (distinguishing single from multiple procedure cases). Whilst 
the total number of follow-up appointments was not recorded for each 
individual, additional interventional treatment episodes were all re-
documented as above, and a formal clinical outcome status (described in 
detail in Section 5.3.4) was determined for each individual at the time of the 
study census date of 31 December 2014.  
Inclusion criteria for the study required that all clinical presentations of PMD 
disease had been new, with untreated oral mucosal lesions confirmed on 
provisional, incision biopsy diagnosis to be classifiable as an oral potentially 
malignant disorder (as listed in Table 1.2), and with follow-up and clinical 
outcome data fully documented up to 31 December 2014. Specifically 
excluded were patients with a previous history of oral cancer or pre-cancer, 
those presenting with widespread multi-focal potentially malignant disease, 
and patients who had previously undergone radiotherapy treatment for a 
head and neck malignancy.    
5.3.3. Histopathology Diagnoses. All incision biopsy procedures were carried 
out in Oral and Maxillofacial Surgery clinics under the personal direction of 
the author and laser excision specimens were obtained following 
interventional laser treatment as documented in previous Chapters; all laser 
surgery was carried out by the author, or by clinical colleagues working 
under direct supervision of the author, within 6 to 12 weeks following incision 
biopsy to avoid diagnostic confusion through potential disease progression. 
Formalin-fixed tissue specimens were assessed via standardized 
histopathology examination by experienced oral pathologists at the Royal 
Victoria Infirmary working to agreed diagnostic criteria with appropriate peer 
review and consensus grading (Sloan 2012). Using the World Health 





moderate or severe dysplasia categories, carcinoma-in-situ (CiS) or 
squamous cell carcinoma (SCC); Gale et al (2005). In addition, the presence 
of hyperkeratosis, lichenoid inflammation (LI), or the diagnoses of 
proliferative verrucous leukoplakia (PVL) or chronic hyperplastic candidosis 
(CHC) were recorded. All histopathology diagnoses were based on the 
original reports produced by the pathologists at the time of tissue analysis, 
and no formal review or re-interpretation of specimens was attempted.  
5.3.4. Clinical Outcome Categories. Review of all available patient clinical 
records was carried out by the author and each study patient was assigned 
to one of the following, specific clinical outcome categories, modified from 
the outcome categories reported in Table 1.5, and defined as of 31 
December 2014 as: Disease Free (DF), the absence of clinical signs of 
potentially malignant disease, Further Disease which ultimately progressed 
to Disease Free status following further intervention (Further/Disease Free), 
Further Disease which persisted despite intervention (Further/Persistent 
Disease) and Malignant Transformation (MT), in which the presence of 
invasive oral squamous cell carcinoma was confirmed by histopathological 
examination.  
5.3.5. Statistical Analyses. A variety of statistical techniques were employed 
to analyse the study results: 
(a) Descriptive Statistics were used throughout to both order and summarise 
details of patient demography, clinical features and pathological diagnoses 
from the study population, together with documentation of treatment 
interventions and overall clinical outcome and follow-up data.  
(b) Histopathology diagnoses were primarily treated as categorical variables, 
and specific testing of agreement between initial incision biopsy diagnoses 
and post-laser excision biopsy diagnoses carried out using 4 defined 
histopathology categories: Epithelial Dysplasia, Squamous Cell Carcinoma 
(SCC), together with the identifiable presence of Lichenoid inflammation (LI) 
or Proliferative Verrucous Leukoplakia (PVL) in biopsy specimens. 
Diagnoses of carcinoma-in-situ (CiS) were combined with Severe Dysplasia 





The percentage overall agreement was determined for each histopathology 
category as well as overall agreement when considering all 4 categories 
together. Kappa and weighted kappa statistics were used to measure the 
degree of agreement between incision biopsy and post-laser excision biopsy 
within each of the histopathology categories. A kappa coefficient of 1 was 
taken to represent perfect agreement, whilst less than 1 was considered less 
than perfect agreement.  
For histopathology categories assessable as either positive or negative, such 
as the identification of squamous cell carcinoma, the presence of lichenoid 
inflammation or features of proliferative verrucous leukoplakia, the sensitivity 
and specificity of initial, incision biopsies was determined. Sensitivity 
demonstrated how often the incision biopsy was positive when confirmed by 
a positive result on post-laser excision biopsy. Specificity showed how often 
the incision biopsy was negative when the condition proved negative on 
post-laser biopsy. Patients with incision and excision biopsies from more 
than one treatment episode were treated independently in the analysis, 
under the assumption that biopsy agreement was no more or less likely 
within individual patients (for samples taken at different time points) 
compared with those between different patients. 
(c) Clinical Outcome data were first stratified for statistical analysis as either 
a Successful Outcome (Disease Free) or Failure (Further PMD disease or 
Malignant Transformation); success rates and 95% Confidence Intervals (CI) 
were calculated. Multivariate logistic regression was used to analyse factors 
potentially prognostic of a Disease Free outcome (including age at first 
treatment, sex of patient, clinical lesion appearance, anatomical site of first 
presentation and initial, incision biopsy histopathology). Relationships 
between the potential factors were explored using chi-square tests, 
correlation coefficients or logistic regression to check for collinearity. The 
factors were first explored univariately and then a multivariate model was 
built using a stepwise procedure until all variables were significant at the 
10% level. Candidate variables for the initial model were those significant at 
the 20% level univariately. If collinearity was suspected only the most 





(d) Further comparative analyses between the defined Clinical Outcome 
categories of Disease Free, Further/Disease Free, Further/Persistent 
Disease and Malignant Transformation were carried out using, as 
appropriate, chi-square testing, Fisher’s exact test, t-test and Wilcoxon Rank 
Sum testing, dependent upon the parametric nature of the data and sample 
size. 
(e) Malignant Transformation, essentially the recognition of PMD lesions 
which progressed to cancer development despite treatment intervention, was 
further analysed using a univariate Cox regression model to investigate the 
clinico-pathological variables that might influence time to malignant 
transformation. Kaplan-Meier survival analyses were also carried out, as 
appropriate, for these variables.   
All statistical analyses were done using SAS/STAT® 9.3 software (SAS 
Institute Inc, Cary, USA). 
 
5.4 Results 
5.4.1. Patient Demography. A total of 590 PMD patients meeting the study 
criteria were treated during the 19-year period, and their full demographic, 
clinico-pathological, treatment and outcome data are listed in database 
format in Appendix V. All interventional treatment details were recorded as 
appropriate for each patient up until the census date of 31 December 2014, 
unless malignant transformation supervened in which case this was regarded 
as the individual’s exit-point from the study.  
Review of the database shows that patients requiring single treatment 
interventions were summarized as one-line entries, whilst patients 
undergoing multiple treatments had each intervention and corresponding 







The clinical outcome categories may be exampled by the following study 
patients: 
(a) Disease Free status (DF) is illustrated by Study Number 1998/2 which 
summarizes a patient successfully treated by laser excision of a severely 
dysplastic ventral tongue lesion in January 1998 with no subsequent 
episodes of PMD disease or malignant transformation, 
(b) Further/Disease Free outcome is shown in Study Number 1998/12 in 
which the patient underwent 2 treatment interventions, in November 1998 
and June 2005 for dysplastic buccal lesions, ultimately determined as 
disease free by the time of study census date, 
(c) Further/Persistent Disease is exampled by the history summarised in 
Study Number 2000/12 in which, despite laser ablation of a moderately 
dysplastic alveolar lesion in March 2000, the patient was noted to exhibit 
persistent PMD disease at the census date, 
(d) Malignant Transformation (MT) is illustrated firstly by Study Number 
1996/1, in which 8 treatment interventions at multiple oral sites were carried 
out over a 17-year period until malignancy was diagnosed in July 2013, and 
secondly by Study Number 1998/1 in which an unexpected micro-invasive 
squamous carcinoma was identified upon histopathological examination of a 
lateral tongue laser excision specimen in January 1998.   
 
In relation to patient age, the mean age at presentation was 59.7 years 
(Standard Deviation 12.6), with a median of 60 years (age range 23 to 94 
years). 347 patients (59%) were male and 243 (41%) female. In relation to 
reported risk factor behaviours, 513 patients (87%) were current or ex-








Overall patient distribution throughout the study period, recorded against 
their year of first presentation, is illustrated in Figure 5.1. 
 
 
Figure 5.1: PMD Patient Presentation showing the numbers of new patients who 




5.4.2. Clinical Features. Table 5.1 summarises the clinical appearance for all 
590 PMD lesions and shows that the vast majority (468 or 79%) presented 
as leukoplakias, with erythroleukoplakia and, especially, erythroplakia much 
less common; 17% and 4%, respectively. Table 5.2 lists the anatomical site 
distribution for these lesions, confirming that floor of mouth and ventrolateral 
tongue sites were most frequently affected (in 358 cases or 61%), with 







































TABLE 5.1: CLINICAL APPEARANCE OF ALL PMD LESIONS 
____________________________________________________________ 
Clinical Appearance                  No. of Patients                                 %                         
____________________________________________________________ 
                Leukoplakia                                          468                                           79 
                Erythroleukoplakia                                  99                                           17 
                Erythroplakia                                           23                                            4   
___________________________________________________________ 





TABLE 5.2: ANATOMICAL SITE DISTRIBUTION OF ALL PMD LESIONS 
_______________________________________________________________ 
Anatomical Site                              No. of Patients                             %                                                                                       
______________________________________________________________ 
           Floor of Mouth                                             172                                         29.2                                 
           Lateral Tongue                                            130                                         22.0                                 
           Buccal Mucosa                                              59                                        10.0                                  
           Palate                                                            57                                          9.7                                         
           Ventral Tongue                                             56                                          9.5                             
           Labial Commissure                                        29                                          4.9               
           Gingiva                                                          21                                           3.6                     
           Fauces                                                           20                                          3.4                                                        
           Alveolus                                                         18                                          3.1                        
           Labial Mucosa                                                11                                          1.9                                                
           Dorsum of Tongue                                         11                                         1.9                                                   
           Fauces/Retromolar                                  3                                         0.5 
           Retromolar                                                        3                                         0.5   
         __________________________________________________________________                                                                           







5.4.3. Histopathology Features.  
(a) Descriptive Analysis. An overall histopathological grading for each of the 
590 cases was obtained for initial profiling, based upon the most significant 
or severe diagnosis recorded from either incision and/or laser excision 
biopsy specimen data; these are listed in Table 5.3. 522 cases (88.5%) were 
shown to exhibit dysplastic change or the presence of carcinoma-in-situ. 
Features of lichenoid inflammation (LI) were seen in 88 cases, with the 
majority 60 (68.2%) also showing dysplasia. Proliferative Verrucous 
Leukoplakia (PVL) was reported in 74 cases, with the majority 59 (79.7%) 
again associated with dysplasia of varying grade.  
TABLE 5.3: HISTOPATHOLOGY DIAGNOSES FOR ALL PMD LESIONS 
_________________________________________________________________________ 
Histopathology Diagnosis                                    No. of Patients                     % 
_________________________________________________________________________ 
Hyperkeratosis                                                                         8                                1.4 
Hyperkeratosis + Lichenoid Inflammation (LI)                        28                                4.8 
Chronic Hyperplastic Candidosis (CHC)                                17                                2.9 
Proliferative Verrucous Leukoplakia (PVL)                            15                                2.5 
Mild Dysplasia                                                                      118                              20.0 
Mild Dysplasia + LI                                                                 28                                4.7 
Mild Dysplasia + PVL                                                             40                                6.8                
Moderate Dysplasia                                                              105                              17.8 
Moderate Dysplasia + LI                                                        24                                4.0                                                              
Moderate Dysplasia + PVL                                                    15                                2.5         
Severe Dysplasia                                                                   99                              16.8 
Severe Dysplasia + LI                                                              8                               1.4 
Severe Dysplasia + PVL                                                          4                               0.7                      
Carcinoma-in-Situ                                                                   81                             13.7           
_________________________________________________________________________ 






Whilst all the diagnostic categories were seen fairly consistently throughout 
the 19 year study period (as fully listed in Appendix V), Figure 5.2 illustrates 
that a specific, increasing trend was seen for lichenoid inflammation (LI) and 
especially proliferative verrucous leukoplakia (PVL) to be identified more 
frequently upon histopathological examination of biopsy specimens from 
2010 onwards. 
 
Figure 5.2: Change in Incidence of Histopathological Diagnoses of Lichenoid 
Inflammation (LI) and Proliferative Verrucous Leukoplakia (PVL) over Time (No. of 
Diagnoses between 1996 and 2014).  
 
 
There were relatively few cases exhibiting only simple hyperkeratosis on 
biopsy (1.4%) which presented as leukoplakias at a variety of intra-oral sites. 
In relation to chronic hyperplastic candidosis (diagnosed in 2.9% of cases), 
the majority were leukoplakic lesions arising on the labial commissures; all 








(b) Agreement Between Incision and Excision Biopsy Diagnoses. Both initial, 
incision biopsy histopathology diagnoses and post-laser excision specimen 
histopathology diagnoses were available for direct comparison in 609 
treatment interventions. These results are graphically represented in Figure 
5.3 which confirms that in 307 cases (50%) biopsy diagnoses were seen to 
agree, whereas in 220 (36%) excision specimens had to be effectively ‘up-
graded’ as they showed more severe dysplastic change or even invasive 
carcinoma, compared with their incision biopsy counterparts. Only in 82 
cases (14%) did the laser excision specimen exhibit less severe 
histopathological changes than those seen on incision biopsy. 
Figure 5.3: Direct Comparison of Laser Excision Histopathology Diagnoses with Initial 
Incision Biopsy Data stratifying results into Less Severe, Same, and More Severe 
Dysplasia categories or Identification of Carcinoma (number of cases = 609). 
 
 
Statistical analysis of agreement between incision and excision biopsy 
diagnoses was first carried out using the histopathological categories of ‘no 
dysplasia’ or the presence of ‘mild, moderate and severe dysplasia’, as 
summarised in Table 5.4.  Overall agreement occurred in 362 out of 609 
samples (59.4%). Weighted kappa was 0.45 (95% confidence interval 0.40 to 


















TABLE 5.4: AGREEMENT ON DYSPLASIA DIAGNOSES BETWEEN INCISION 
AND EXCISION BIOPSIES  
(MEASURED AS NO DYSPLASIA or MILD, MODERATE and SEVERE) 
 
 
Table of Dysplasia by Post-Laser Excision Dysplasia 

































































































Although formal histopathological re-grading by oral pathologists to establish 
a binary assessment (such as proposed by Kujan et al 2006) was not carried 
out in this study, a further agreement analysis between incision and excision 
diagnoses was performed by arbitrarily combining mild and moderate 
categories together as ‘low grade’ dysplasia whilst severe was considered 
‘high grade’ dysplasia; these data are shown in Table 5.5. Overall agreement 
was seen in 412 out of 609 samples (67.7%). Weighted kappa was 0.43 







TABLE 5.5: AGREEMENT ON DYSPLASIA DIAGNOSES BETWEEN INCISION 
AND EXCISION BIOPSIES  
(MEASURED AS NO DYSPLASIA or ‘LOW GRADE’ and ‘HIGH GRADE’) 
 
 
Table of Dysplasia by Post-Laser Excision Dysplasia 




Column Percent No 


































































In addition, the presence or absence of lichenoid inflammation (LI) observed 
in incision and excision biopsies was compared, and summarised in Table 
5.6. Overall agreement occurred in 531 out of 609 samples (87.2%). The 
sensitivity of the initial, incision biopsy was 55.7% and the specificity 91.3%. 
Kappa was 0.43 (95% confidence interval 0.32 to 0.53) indicating moderate 
agreement. Similarly, in Table 5.7, the histopathological identification of 
proliferative verrucous leukoplakia (PVL) was compared between incision 
and post-laser excision specimens. Overall agreement was seen in 567 out 
of 609 samples (93.1%). The sensitivity of the incision biopsy was 57.4% and 
the specificity 96.6%. Kappa was 0.56 (95% confidence interval 0.44 to 0.68) 






TABLE 5.6: AGREEMENT ON THE PRESENCE OR ABSENCE OF LICHENOID 
INFLAMMATION (LI) BETWEEN INCISION AND EXCISION BIOPSIES 
 
Table of LI by Post-Laser Excision LI 







































TABLE 5.7: AGREEMENT ON THE PRESENCE OR ABSENCE OF 
PROLIFERATIVE VERRUCOUS LEUKOPLAKIA (PVL) BETWEEN 
INCISION AND EXCISION BIOPSIES 
 
Table of PVL by Post-Laser Excision PVL 










































Review of the agreement between incision and excision tissue specimens for 
the 98 cases in which squamous cell carcinoma (SCC) was identified 
following laser excision is summarized in Table 5.8. Overall agreement 
between diagnoses occurred in 527 out of 609 samples (86.5%). The 
sensitivity of the incision biopsy was 16.3% and the specificity 100%. Kappa 
was determined as 0.25 (95% confidence interval 0.15 to 0.35) indicating 
only fair agreement between the two diagnostic samples in this analysis.  
 
TABLE 5.8: AGREEMENT ON THE PRESENCE OR ABSENCE OF SQUAMOUS 
CELL CARCINOMA (SCC) BETWEEN INCISION AND EXCISION 
BIOPSIES 
 
Table of SCC by Post-Laser Excision SCC 






































In Table 5.9, overall agreement for all histopathological diagnoses between 
incision and excision specimens is demonstrated, in (A) using the categories: 
‘no dysplasia’, or mild, moderate and severe, and in (B) arbitrarily combining 
mild and moderate as ‘low grade’ and severe as ‘high grade’. There appears 
slightly more agreement between incision and excision biopsies when the 







TABLE 5.9:  AGREEMENT IN ALL HISTOPATHOLOGY DIAGNOSES BETWEEN 
INCISION AND EXCISION BIOPSIES INCLUDING:  
(A) DYSPLASIA GRADED AS NONE, MILD, MODERATE OR SEVERE  
   





No 336 55.17 336 55.17 
Yes 273 44.83 609 100.00 
 
(B) DYSPLASIA GRADED AS NONE or ‘LOW GRADE’ and ‘HIGH GRADE’) 
 





No 296 48.60 296 48.60 




5.4.4. Patient Management. The initial treatment modality was laser excision 
in 526 patients (89%), and laser ablation in 64 (11%). In total, 773 treatment 
episodes were carried out on this 590 patient group during the study period, 
with 609 laser excision specimens obtained for histopathological 
examination. The mean number of treatments per patient was 1.2 (Standard 
Deviation 0.6), with a median of 1 (range 1 to 8).  
 
5.4.5. Overall Clinical Outcome. The mean duration of patient follow-up 
during this study was 7.3 years (Standard Deviation 5.1 years), with a 
median of 6 years (range 0 to 19 years). Figure 5.4 plots clinical outcome, 
defined in terms of disease free, further PMD disease or malignant 





Figure 5.4: Clinical Outcome Data illustrating numbers of patients PMD Disease Free, 
those exhibiting Further PMD Disease and those undergoing Malignant Transformation each 
year during the study period.  
 
 
In terms of overall clinical outcome, Table 5.10 shows that 438 patients 
(74.2%, with a 95% confidence interval of 70.7 to 77.8%) had a successful 
outcome and were free from PMD disease at the time of study census date; 
404 patients achieved this status immediately following initial laser surgery, 
whilst an additional 34 became disease free after further laser intervention. 
These outcomes provided an important distinction and sub-classification, 
therefore, between ‘immediately’ disease free cases and those with further 
disease who only became disease free following additional treatment. Out of 
the initial 87 patients who required repeat treatment intervention, 53 
ultimately showed persistent potentially malignant disease at the time of 




































































TABLE 5.10: OVERALL CLINICAL OUTCOME AT CENSUS DATE (31.12.14) 
____________________________________________________________ 
Clinical Outcome                         No. of Patients                                 %                         
____________________________________________________________ 
                PMD Disease Free                                438                                       74.2 
                Further PMD Disease                              53                                         9.0 
                Malignant Transformation                        99                                       16.8   
___________________________________________________________ 




Malignant transformation, the development of invasive squamous cell 
carcinoma and therefore the most significant clinical outcome, was seen in 
99 cases, with 80 patients developing a carcinoma at the same oral site as 
their PMD precursor lesion and 19 at new, distinct oral sites. In 71 cases, the 
diagnosis of malignancy was made unexpectedly following histopathological 
examination of initial laser excision specimens, whilst a further 28 patients 
developed malignancy during clinical follow-up although the time to 
malignancy varied substantially between 3 months to 17 years post 
intervention.  
In the next sections of this thesis, the specific clinical outcome categories of 
Disease Free (DF), Further/Disease Free, Further/Persistent Disease and 
Malignant Transformation will be reviewed and their clinico-pathological 









5.4.6 Disease Free Patients. In the study, 404 patients (68%) were rendered 
free from disease following first interventional laser treatment. The clinical 
appearance of the initial presenting PMD lesions in this patient group is 
shown in Table 5.11. Although the distribution is similar to that seen in Table 
5.1 (which lists the appearance for all 590 lesions), there is a tendency for a 
higher percentage of leukoplakias and a slightly lower percentage of 
erythroleukoplakias to be seen in the disease free patient group.  Anatomical 
site distribution for the Disease Free cases mirrored that seen for all 590 
PMD lesions summarized in Table 5.2 with no major differences; the most 
common sites were again the floor of mouth and ventrolateral tongue in 261 
cases (64.6%) and buccal mucosa in 32 (8%); original data for this patient 
group are all listed in Appendix V. 
Histopathological diagnoses for these 404 Disease Free cases are shown in 
Table 5.12, and may be directly compared with data for the 590 lesions in 
Table 5.3; there would appear to be little difference in the percentage 
distribution for individual pathology categories, with the majority (359 or 
88.9%) again showing features of either dysplasia or carcinoma-in-situ on 
biopsy.  
Associations between clinico-pathological features were checked using chi-
square tests for categorical variables or logistic regression for continuous 
variables (Table 5.13a). Univariate logistic regression analyses of clinico-
pathological features potentially influencing disease free status were carried 
out using initial, incision biopsy diagnoses and these results are shown in 
Table 5.13b. Multivariate analysis was then performed after excluding lesion 
site from the model, due to the large number of site categories and their high 
correlation with other variables, and also excluding PVL identification in 
incision biopsy specimens as this did not relate univariately. All other 
variables were included as they reached the 0.2 level of significance on 
univariate analysis. Sex was subsequently found to be non-significant in the 
model (p=0.42) and was eliminated. All other variables remained significant 
at the 10% level (although age was considered borderline) and were retained 





TABLE 5.11: CLINICAL APPEARANCE OF PMD LESIONS IN DISEASE FREE 
PATIENTS 
____________________________________________________________ 
Clinical Appearance                  No. of Patients                                 %                         
____________________________________________________________ 
                Leukoplakia                                          341                                            85 
                Erythroleukoplakia                                 50                                             12 
                Erythroplakia                                          13                                              3   
___________________________________________________________ 
Total                                                      404                                           100                         
____________________________________________________________ 
 
TABLE 5.12: HISTOPATHOLOGY DIAGNOSES OF PMD LESIONS IN DISEASE FREE 
PATIENTS 
_________________________________________________________________________ 
Histopathology Diagnosis                                    No. of Patients                     % 
_________________________________________________________________________ 
Hyperkeratosis                                                                         5                                1.2 
Hyperkeratosis + Lichenoid Inflammation (LI)                        20                                5.0 
Chronic Hyperplastic Candidosis (CHC)                                14                                3.5 
Proliferative Verrucous Leukoplakia (PVL)                              6                                1.5 
Mild Dysplasia                                                                        94                              23.3 
Mild Dysplasia + LI                                                                 23                                5.7 
Mild Dysplasia + PVL                                                             29                                7.2                
Moderate Dysplasia                                                               81                              20.0 
Moderate Dysplasia + LI                                                        17                                4.2                                                              
Moderate Dysplasia + PVL                                                    11                                2.7         
Severe Dysplasia                                                                   51                             12.6 
Severe Dysplasia + LI                                                              6                               1.5 
Severe Dysplasia + PVL                                                          4                               1.0                      
Carcinoma-in-Situ                                                                   43                             10.6           
_________________________________________________________________________ 






TABLE 5.13:  ANALYSIS OF CLINICO-PATHOLOGICAL FACTORS INFLUENCING 
DISEASE FREE STATUS SHOWING (A) RELATIONSHIP BETWEEN FACTORS AND (B) 
UNIVARIATE ANALYSIS (BASED UPON FIRST PRESENTATION & INCISION BIOPSY 
DATA) 
A 
 Site Age     Sex   Lesion Dysplasia      LI      PVL 
Site - <0.0001 <0.0001 <0.0001 <0.0001 0.0007 <0.0001 
Age  - 0.0654 0.1802 0.0085 0.0064 0.1154 
Sex   - 0.0219 0.0219 0.007 0.0903 
Lesion    - <0.0001 0.2756 0.0002 
Dysplasia     - 0.0003 0.0004 
LI      - 0.0011 
PVL       - 
p-values from chi-square tests for categorical variables or logistic regression for 
continuous variables 
B 
Factor               Univariate Logistic p-value 
Site                               0.0009 




(None, Mild, Moderate vs Severe) 




TABLE 5.14:  FINAL MULTIVARIATE MODEL OF CLINICO-PATHOLOGICAL 
INFLUENCE ON DISEASE FREE STATUS SHOWING ODDS RATIO ESTIMATES AND  







Age  0.987 0.971 1.003 0.11 
Lesion                       EK  vs LK 0.652 0.266 1.595 0.030 
Lesion                      ELK vs LK 0.525 0.323 0.854* 
Dysplasia            Mild  vs  Severe 3.010 1.658 5.464* 0.0003 
Dysplasia    Moderate vs Severe 2.593 1.391 4.834* 
Dysplasia          None  vs  Severe 1.333 0.774 2.296 
LI                              No vs Yes 0.545 0.290 1.028 0.061 
 






Overall, review of the final multivariate model (Table 5.14) shows that clinical 
lesion appearance was significantly related to Disease Free status (p=0.03) 
with a decreased odds of disease free status for erythroleukoplakic lesions at 
the time of first treatment compared with leukoplakia (OR 0.53, 95% CI 0.32 
to 0.85). The extent of dysplasia determined by histopathology examination 
was also significantly related to Disease Free status (p=0.003) with the odds 
of Disease Free status being increased for mild dysplasia (OR 3.01, CI 1.66 
to 5.46) and moderate dysplasia (OR 2.59, CI 1.39 to 4.83) versus severe 
dysplasia. To a lesser extent, Disease Free status was also less likely with 
increasing patient age and with lichenoid inflammation identified on initial, 
incision biopsy specimens.  
The analyses were then repeated this time using the ‘most significant’ 
dysplasia diagnoses obtained from either incision or excision biopsy 
samples; univariate analyses are summarised in Tables 5.15a & 5.15b. 
Multivariate analysis was then performed, although PVL was again excluded 
as it was not significant in the univariate analysis (p=0.2887). Site was not 
included due to the large number of categories and its high correlation to 
other variables. All other variables were included as they reached the 0.2 
level of significance univariately. Sex was removed in the first step (p=0.32), 
and age removed in the second step (p=0.15). All other factors were retained 














TABLE 5.15:  ANALYSIS OF CLINICO-PATHOLOGICAL FACTORS INFLUENCING 
DISEASE FREE STATUS SHOWING (A) RELATIONSHIP BETWEEN FACTORS AND (B) 
UNIVARIATE ANALYSIS (BASED UPON ‘MOST SIGNIFICANT’ DYSPLASIA 
DIAGNOSIS) 
A 
 Site     Age     Sex   Lesion Most 
Significant 
Dysplasia 
LI  PVL  
Site - <0.0001 <0.0001 <0.0001 <0.0001 0.0007 <0.0001 
Age  - 0.0654 0.1802 0.0021 0.0064 0.1154 
Sex   - 0.0219 0.0679 0.007 0.0903 




    - 0.0005 0.0002 
LI       - 0.0011 
PVL        - 
p-values from chi-square tests for categorical variables or logistic regression for 
continuous variables 
                                                                      B 





Most Significant Dysplasia 
(None, Mild, Moderate vs Severe) 




TABLE 5.16:  FINAL MULTIVARIATE MODEL OF CLINICO-PATHOLOGICAL 
INFLUENCE ON DISEASE FREE STATUS SHOWING ODDS RATIO ESTIMATES AND   







Lesion                       EK  vs LK 0.659 0.269 1.619 0.022 
Lesion                      ELK vs LK 0.510 0.314 0.828* 
Dysplasia            Mild  vs  Severe 2.247 1.270 3.976* <0.0001 
Dysplasia    Moderate vs Severe 1.693 0.954 3.006 
Dysplasia          None  vs  Severe 0.628 0.369 1.068 
LI                              No vs Yes 0.489 0.258 0.926 0.028 
 





Table 5.16 shows that this final multivariate model confirms that the 
categories of clinical lesion appearance (p=0.022), dysplasia (p<0.0001) and 
lichenoid inflammation (p=0.028) were all significant predictors of Disease 
Free status. Thus, erythroleukoplakic lesions at the time of first treatment 
had significantly lower odds of achieving Disease Free status compared with 
leukoplakias (OR 0.51, 95% CI 0.31 to 0.83), whilst the odds of Disease Free 
status were significantly increased for lesions exhibiting mild versus severe 
dysplasia (OR 2.247, 95% CI 1.27 to 3.98). The likelihood of achieving 
Disease Free status was reduced for lesions exhibiting features of lichenoid 





















5.4.7. Further / Disease Free Patients. 34 patients who developed further 
clinically recognisable oral potentially malignant lesions ultimately 
progressed to Disease Free status following subsequent laser intervention. 
Lesion clinical appearance is summarized in Table 5.17, and histopathology 
diagnoses listed in Table 5.18, although there are few clinical or 
histopathological differences in these features to distinguish or characterise 
this group from the other reported clinical outcome categories. In terms of 
anatomical site, the floor of mouth and ventrolateral tongue were most 
commonly affected in 16 cases (47%), with buccal mucosa next frequently 
involved in 9 (26%). All original patient data for this group can be accessed in 
Appendix V. 
Table 5.19 collates all clinico-pathological, treatment and clinical outcome 
data for these 34 patients; 77 treatment episodes were identified in total for 
this cohort, carried out between August 1997 and December 2014. In Table 
5.20, it can been seen that the mean number of treatments required to 
establish Disease Free status was 2.26 (with a range of 2 to 4) and a mean 
time period to become disease free of 32.88 months (but with a wide range 















TABLE 5.17: CLINICAL APPEARANCE OF PMD LESIONS IN  
FURTHER / DISEASE FREE PATIENTS 
____________________________________________________________ 
Clinical Appearance                  No. of Patients                                 %                         
____________________________________________________________ 
                 Leukoplakia                                             25                                         74 
                 Erythroleukoplakia                                     8                                         23 
                 Erythroplakia                                             1                                            3   
___________________________________________________________ 
  Total                                                       34                                        100                         
____________________________________________________________ 
 
TABLE 5.18: HISTOPATHOLOGY DIAGNOSES OF PMD LESIONS IN 
FURTHER / DISEASE FREE PATIENTS 
_________________________________________________________________________ 
Histopathology Diagnosis                                    No. of Patients                     % 
_________________________________________________________________________ 
Hyperkeratosis                                                                         0                                0.0 
Hyperkeratosis + Lichenoid Inflammation (LI)                          3                                8.8 
Chronic Hyperplastic Candidosis (CHC)                                  2                                5.9 
Proliferative Verrucous Leukoplakia (PVL)                              1                                2.9 
Mild Dysplasia                                                                          6                              17.6 
Mild Dysplasia + LI                                                                   2                                5.9 
Mild Dysplasia + PVL                                                               2                                5.9                
Moderate Dysplasia                                                                 1                                2.9 
Moderate Dysplasia + LI                                                          4                              11.8                                                              
Moderate Dysplasia + PVL                                                      0                                0.0       
Severe Dysplasia                                                                     8                              23.6 
Severe Dysplasia + LI                                                              1                                2.9 
Severe Dysplasia + PVL                                                          0                                0.0                      
Carcinoma-in-Situ                                                                    4                              11.8         
_________________________________________________________________________ 






TABLE 5.19: CLINICO-PATHOLOGICAL, TREATMENT AND CLINICAL OUTCOME 
DETAILS FOR THE 34 FURTHER / DISEASE FREE PATIENTS 







NO DATE SEX AGE LESION SITE IN. BIOPSY LASER EX. STATUS TRT Outcome 
1 1997/6 2 6 AUG1997 M 47 LK FOM CiS CiS Further M  
2 1997/6 2 6 MAY2000 M 49 LK FOM Sev Dysp Sev Dysp DF M DF 
3 1998/12 2 12 NOV1998 M 60 ELK Buccal Sev Dysp Sev Dysp+LI Further M  
4 1998/12 2 12 JUN2005 M 66 LK Buccal Mild Dysp HK+LI DF M DF 
5 1999/9 3 9 MAY1999 M 53 LK FOM Mod Dysp CiS Further M  
6 1999/9 3 9 JUN2000 M 54 LK FOM Mod Dysp+LI Sev Dysp Further M  
7 1999/9 3 9 SEP2001 M 56 LK Lat 
Tongue 
Mod Dysp+LI Sev Dysp DF M DF 
8 2001/12 3 12 JUN2001 M 60 LK FOM Mod Dysp+LI Sev Dysp Further M  
9 2001/12 3 12 JUL2003 M 62 LK Vent 
Tongue 
Mod Dysp Mod Dysp Further M  
10 2001/12 3 12 DEC2004 M 64 LK Lat 
Tongue 
Mod Dysp Mod Dysp DF M DF 
11 2001/5 2 5 FEB2001 F 58 LK Buccal Mod Dysp Mod Dysp Further M  
12 2001/5 2 5 JUL2002 F 59 LK Alveolus Mod Dysp+LI ABLATE DF M DF 
13 2002/16 2 16 DEC2002 M 45 LK Gingiva Mild Dysp ABLATE Further M  
14 2002/16 2 16 SEP2013 M 58 LK Labial Mild Dysp ABLATE DF M DF 
15 2002/9 2 9 OCT2002 F 64 ELK FOM CiS CiS Further M  
16 2002/9 2 9 JUL2004 F 66 LK Fauces Sev Dysp Sev Dysp DF M DF 
17 2004/18 2 18 JUL2004 F 55 LK Palate Sev Dysp ABLATE Further M  
18 2004/18 2 18 FEB2005 F 56 LK Fauces Sev Dysp CiS DF M DF 
19 2004/23 3 23 OCT2004 M 49 LK Lat 
Tongue 
CiS CiS Further M  
20 2004/23 3 23 FEB2005 M 50 LK Lat 
Tongue 
CiS CiS Further M  
21 2004/23 3 23 AUG2012 M 57 ELK Lat 
Tongue 
Mild Dysp Mild Dysp DF M DF 
22 2006/6 2 6 MAR2006 M 83 LK Lat 
Tongue 
Sev Dysp Sev Dysp Further M  
23 2006/6 2 6 JUN2007 M 84 LK Vent 
Tongue 
Mild Dysp+LI Mod Dysp DF M DF 
24 2006/7 2 7 JUN2006 F 67 LK Lat 
Tongue 
Mild Dysp Mod Dysp Further M  
25 2006/7 2 7 SEP2007 F 68 LK Lat 
Tongue 
Mild Dysp Mild Dysp DF M DF 
26 2007/26 3 26 NOV2007 F 61 LK Buccal Sev Dysp Sev Dysp Further M  
27 2007/26 3 26 MAR2011 F 64 ELK Alveolus HK+LI ABLATE Further M  










NO DATE SEX AGE LESION SITE IN. BIOPSY LASER EX. STATUS TRT Outcome 
29 2008/3 2 3 FEB2008 M 43 ELK FOM HK+LI Mild Dysp Further M  
30 2008/3 2 3 JUN2014 M 50 LK FOM Mild Dysp ABLATE DF M DF 
31 2009/14 2 14 MAR2009 M 48 LK Vent 
Tongue 
Sev Dysp Sev Dysp Further M  
32 2009/14 2 14 APR2010 M 49 LK FOM Sev Dysp Sev Dysp+LI DF M DF 
33 2009/23 2 23 JUL2009 F 44 ELK Dors 
Tongue 
CHC CHC Further M  
34 2009/23 2 23 JUN2014 F 49 LK Dors 
Tongue 
CHC CHC DF M DF 
35 2009/33 3 33 OCT2009 F 63 ELK Lat 
Tongue 
Sev Dysp Sev Dysp Further M  
36 2009/33 3 33 OCT2011 F 65 ELK Lat 
Tongue 
Sev Dysp ABLATE Further M  
37 2009/33 3 33 JUL2012 F 66 LK Vent 
Tongue 
Mild Dysp ABLATE DF M DF 
38 2009/40 4 40 NOV2009 M 68 ELK FOM Sev Dysp CiS Further M  
39 2009/40 4 40 JUL2011 M 70 LK FOM CiS ABLATE Further M  
40 2009/40 4 40 MAY2013 M 72 LK FOM Sev Dysp Sev Dysp Further M  
41 2009/40 4 40 SEP2014 M 74 LK Vent 
Tongue 
Sev Dysp Sev Dysp DF M DF 
42 2010/10 2 10 MAR2010 M 58 LK Buccal PVL HK+LI Further M  
43 2010/10 2 10 OCT2010 M 58 LK Labial 
Comm 
HK+LI PVL DF M DF 
44 2011/17 2 17 MAR2011 F 72 LK FOM PVL Mild Dysp+LI Further M  
45 2011/17 2 17 JUN2013 F 74 LK Buccal Mild Dysp+LI HK+LI DF M DF 
46 2011/24 3 24 MAY2011 M 65 LK Palate Sev Dysp Mod Dysp Further M  
47 2011/24 3 24 NOV2012 M 66 LK Lat 
Tongue 
Mod Dysp Mild Dysp Further M  
48 2011/24 3 24 NOV2014 M 68 ELK RM Sev Dysp Sev Dysp DF M DF 
49 2011/27 2 27 MAY2011 F 45 LK Palate Mild Dysp Mild Dysp Further M  
50 2011/27 2 27 MAR2014 F 48 LK Palate Mild Dysp ABLATE DF M DF 
51 2011/3 2 3 JAN2011 M 57 LK Palate Mod Dysp+LI Mod Dysp Further M  
52 2011/3 2 3 MAY2012 M 59 LK Palate Mod Dysp Mod Dysp DF M DF 
53 2011/34 2 34 JUN2011 M 47 LK Labial 
Comm 
CHC CHC Further M  
54 2011/34 2 34 JUN2013 F 49 LK Labial 
Comm 
CHC ABLATE DF M DF 
55 2011/50 2 50 SEP2011 M 74 LK Lat 
Tongue 
MildDyspPVL Mild Dysp Further M  
56 2011/50 2 50 JUL2012 M 75 LK Buccal Mild Dysp Mild Dysp DF M DF 
57 2011/51 3 51 SEP2011 M 46 ELK Labial 
Comm 
CHC MildDyspPVL Further M  
58 2011/51 3 51 DEC2013 M 47 LK Vent 
Tongue 










NO DATE SEX AGE LESION SITE IN. BIOPSY LASER EX. STATUS TRT Outcome 
59 2011/51 3 51 DEC2014 M 48 LK Labial 
Comm 
MildDyspPVL ABLATE DF M DF 
60 2011/62 2 62 DEC2011 F 57 LK Gingiva HK+LI ABLATE Further M  
61 2011/62 2 62 JUN2014 F 60 LK Gingiva HK+LI ABLATE DF M DF 
62 2011/9 2 9 FEB2011 F 77 LK Buccal PVL Mild Dysp Further M  
63 2011/9 2 9 JUN2013 F 79 LK Buccal Mild Dysp+LI HK+LI DF M DF 
64 2012/24 2 24 JUN2012 F 51 LK Buccal PVL PVL Further M  
65 2012/24 2 24 MAY2013 F 52 LK Buccal Mild Dysp MildDyspPVL DF M DF 
66 2013/1 2 1 JAN2013 M 70 ELK Buccal HK+LI Mild Dysp+LI Further M  
67 2013/1 2 1 MAY2013 M 71 ELK Buccal HK+LI HK+LI DF M DF 
68 2013/30 2 30 MAY2013 F 60 LK Alveolus HK+LI ABLATE Further M  
69 2013/30 2 30 JUN2014 F 61 LK FOM Mild Dysp Mild Dysp DF M DF 
70 2013/34 2 34 MAY2013 M 47 LK FOM Mild Dysp Mild Dysp Further M  
71 2013/34 2 34 MAY2014 M 48 LK FOM Mild Dysp Mild Dysp DF M DF 
72 2013/42 2 42 JUN2013 F 52 LK Lat 
Tongue 
Mod Dysp Sev Dysp Further M  
73 2013/42 2 42 MAY2014 F 53 LK Lat 
Tongue 
Mod Dysp+LI Sev Dysp DF M DF 
74 2013/5 2 5 JAN2013 M 54 EK Fauces Mod Dysp Sev Dysp Further M  
75 2013/5 2 5 FEB2014 M 55 LK Fauces Mod Dysp Sev Dysp DF M DF 
76 2013/54 2 54 AUG2013 F 63 LK FOM Mild Dysp Mild Dysp Further M  




TABLE 5.20: NUMBER OF TREATMENTS REQUIRED AND TIME (IN MONTHS) TO 
ESTABLISH DISEASE FREE STATUS 
(No of Patients = 34) 
 
 Mean Median     SD     SE    Max    Min     No 
No of 
Treatments 
  2.26   2.00   0.51   0.09    4.00   2.00     34 
No of 
Months 





5.4.8. Further / Persistent Disease Patients. During the study period, 53 
patients exhibited Further/Persistent PMD disease despite interventional 
treatment and their clinical features and histopathological diagnoses, which 
are relatively consistent with previous outcome categories, are presented in 
Tables 5.21 and 5.22. Floor of mouth and ventrolateral sites were again most 
commonly affected by disease (17 or 32%), but buccal (14 or 26%) and 
especially gingiva / alveolus sites (11 or 21%) were also involved more 
frequently (although non-significantly) in this persistent disease group. Full 
details on these patients can be found in Appendix V.  
Table 5.23 collates clinico-pathological, treatment and clinical outcome data 
for these 53 patients and shows that 38 patients (72%) underwent only 1 
treatment intervention, whilst the remaining 15 (28%) experienced 2 to 4 
treatment episodes.  
Table 5.24 directly compares clinico-pathological features, treatment and 
clinical outcome data from the 34 Further/Disease Free patient group with 
this 53 patient Further/Persistent Disease group to assess the influence of 
age, sex, clinical appearance, anatomical site, histopathological diagnosis, 
treatment and follow-up on outcome status. The only statistically significant 
difference seen was in the number of treatment interventions, which were 
exclusively administered as multiple interventions in the Further / Disease 
Free study group; p<0.0001. 
Although not of statistical significance by chi-square testing (p=0.47), review 
of the percentage of patients exhibiting characteristics of proliferative 
verrucous leukoplakia (PVL) on histopathology examination revealed a much 
higher occurrence in the Further/Persistent Disease group (37.6%) 
compared with much lower levels seen in all other clinical outcome 
categories: a figure of 12.5% overall for the 590 PMD lesions, 12.4% in the 
Disease Free cases and 8.8% in Further/Disease Free patients. These data 







TABLE 5.21: CLINICAL APPEARANCE OF PMD LESIONS IN  
FURTHER / PERSISTENT DISEASE PATIENTS 
____________________________________________________________ 
Clinical Appearance                  No. of Patients                                 %                         
____________________________________________________________ 
                 Leukoplakia                                             45                                         85 
                 Erythroleukoplakia                                    6                                          11 
                 Erythroplakia                                             2                                           4   
___________________________________________________________ 
Total                                                        53                                         100                         
____________________________________________________________ 
 
TABLE 5.22: HISTOPATHOLOGY DIAGNOSES OF PMD LESIONS IN  
FURTHER / PERSISTENT DISEASE PATIENTS 
_________________________________________________________________________ 
Histopathology Diagnosis                                    No. of Patients                     % 
_________________________________________________________________________ 
Hyperkeratosis                                                                         1                                1.9 
Hyperkeratosis + Lichenoid Inflammation (LI)                          2                                3.8 
Chronic Hyperplastic Candidosis (CHC)                                  0                                0.0 
Proliferative Verrucous Leukoplakia (PVL)                              7                               13.2 
Mild Dysplasia                                                                          7                               13.2 
Mild Dysplasia + LI                                                                   3                                5.7 
Mild Dysplasia + PVL                                                               9                               16.9                
Moderate Dysplasia                                                                 6                               11.3 
Moderate Dysplasia + LI                                                          3                                 5.7                                                             
Moderate Dysplasia + PVL                                                      4                                 7.5       
Severe Dysplasia                                                                     8                               15.1 
Severe Dysplasia + LI                                                              1                                1.9 
Severe Dysplasia + PVL                                                          0                                0.0                      
Carcinoma-in-Situ                                                                    2                                3.8         
_________________________________________________________________________ 






TABLE 5.23: CLINICO-PATHOLOGICAL, TREATMENT AND CLINICAL OUTCOME 




No SEX AGE LESION SITE 
HISTOPATHOLOGY 







1 2000/12 F 54 LK Alveolus Mod Dysp+LI Ablation Same   1 
2 2000/33 M 59 LK Ventral 
Tongue 
Mod Dysp Excision New   2 
3 2001/13 M 55 ELK Fauces CiS Excision Same   1 
4 2001/16 F 65 LK Gingiva Mild Dysp Ablate Same   1 
5 2002/8 M 41 LK FOM CiS Excision New   4 
6 2002/10 M 27 LK FOM Mod Dysp+LI Excision Same   1 
7 2003/6 F 67 EK Buccal Sev Dysp Excision New   2 
8 2005/2 M 69 LK FOM Mod Dysp Excision Same   1 
9 2005/4 M 55 LK Lateral 
Tongue 
CiS Excision Same   1 
10 2006/11 M 56 LK FOM Sev Dysp Excision Same   1 
11 2006/17 F 93 EK Buccal Sev Dysp Excision Same   1 
12 2007/7 F 58 LK FOM Mild Dysp Ablate New   3 
13 2008/11 M 56 LK Lateral 
Tongue 
Sev Dysp Excision Same   2 
14 2008/28 F 67 LK Palate Mild Dysp Excision New   3 
15 2009/10 M 52 LK Labial 
Comm 
Mild Dysp Excision Same   1 
16 2010/6 M 69 LK FOM Mild Dysp+LI Excision New   1 
17 2010/8 M 67 ELK Lateral 
Tongue 
Mild Dysp+LI Excision Same   1 
18 2010/19 M 72 LK Alveolus PVL Excision New   1 
19 2010/28 F 56 ELK Labial 
Comm 
Mod Dysp Excision New   1 
20 2010/30 M 70 LK Buccal ModDyspPVL Excision New   2 
21 2010/34 F 59 LK Palate HK Ablate Same   1 
22 2010/39 M 79 LK Alveolus MildDyspPVL Excision Same   3 
23 2011/1 M 63 LK Labial Sev Dysp+LI Ablate Same   1 
24 2011/11 F 61 LK Fauces ModDyspPVL Excision New   1 
25 2011/12 F 70 LK Buccal ModDyspPVL Excision New   1 
26 2011/22 M 42 LK Labial Mild Dysp Ablate Same   2 
27 2011/38 M 38 LK Buccal MildDyspPVL Excision Same   1 
28 2011/48 F 56 ELK Lateral 
Tongue 
Mod Dysp Excision New   3 







No SEX AGE LESION SITE 
HISTOPATHOLOGY 







30 2011/58 F 58 LK Gingiva MildDyspPVL Ablate Same   1 
31 2011/60 M 49 ELK Labial 
Comm 
MildDyspPVL Excision New   3 
32 2011/61 M 68 LK Alveolus Mild Dysp Ablate New   1 
33 2012/2 F 62 LK FOM ModDyspPVL Excision Same   3 
34 2012/3 M 51 LK Buccal HK+LI Excision Same   1 
35 2012/5 M 80 LK Buccal Mod Dysp Ablate New   1 
36 2012/15 F 24 LK FOM Mild Dysp+LI Excision   Same   1 
37 2012/18 F 57 LK Dorsum 
Tongue 
MildDyspPVL Excision Same   1 
38 2012/20 F 56 ELK Lateral 
Tongue 
Sev Dysp Excision Same   1 
39 2012/39 M 64 LK Gingiva PVL Excision New   1 
40 2012/40 M 58 LK Ventral 
Tongue 
Mod Dysp Excision Same   1 
41 2012/41 F 71 LK Buccal MildDyspPVL Excision New   1 
42 2012/48 M 59 LK Ventral 
Tongue 
Sev Dysp Excision Same   1 
43 2013/3 F 83 LK Buccal HK+LI Excision Same   1 
44 2013/6 M 56 LK Labial PVL Ablate Same   1 
45 2013/15 M 75 LK Gingiva PVL Ablate New   2 
46 2013/19 F 63 LK Alveolus HK+LI Ablate Same   1 
47 2013/47 M 68 LK Alveolus PVL Excision Same   1 
48 2013/69 M 82 LK Palate PVL Ablate Same   2 
49 2013/71 M 59 LK Lateral 
Tongue 
Mod Dysp+LI Excision Same   1 
50 2013/72 F 73 LK Labial Sev Dysp Excision Same   1 
51 2014/14 F 53 LK FOM MildDyspPVL Excision New   2 
52 2014/19 F 65 LK Gingiva PVL Ablate Same   1 













TABLE 5.24:  COMPARISON OF CLINICO-PATHOLOGICAL FEATURES BETWEEN 
FURTHER / DISEASE FREE AND FURTHER / PERSISTENT DISEASE PATIENT 
GROUPS 
 
  Further / 
DF            
(n = 34) 
 Further / 
Persistent 
 (n = 53) 
 
  Value       (%) Value     (%) 
Age (Years) Mean 57.7  61.0  
 Median 57.5  61.0  
 SD 10.3  12.6  
 SE 1.8  1.7  
 Max 83.0  93.0  
 Min 43.0  24.0  
      
Sex Female 16 (47) 22 (42) 
 Male 18 (53) 31 (58) 
      
Follow-Up 
(Months) 
Mean 80.7  61.0  
 Median 60.9  42.6  
 SD 57.8  48.3  
 SE 9.9  6.6  
 Max 212.3  180.6  
 Min 17.2  4.0  
      
Clinical 
Lesion 
Leukoplakia 25 (74) 45 (85) 
 Erythroleukoplakia 8 (23) 6 (11) 
 Erythroplakia 1 (3) 2 (4) 
      
Site Floor of Mouth 9 (26) 8 (15) 
 Ventro-Lateral 
Tongue 
7 (21) 9 (17) 
 Dorsum Tongue 1 (3) 1 (2) 
 Buccal 9 (26) 14 (26) 
 Fauces / Retromolar 1 (3) 2 (4) 
 Gingiva / Alveolus 3 (9) 11 (21) 
 Labial 0 (0) 5 (9) 






  Further / 
DF            
(n = 34) 
 Further / 
Persistent 
 (n = 53) 
 
  Value       (%) Value     (%) 
      
Dysplasia None 9 (26) 14 (26) 
 Mild 9 (26) 16 (30) 
 Moderate 3 (9) 13 (25) 
 Severe 13 (39) 10 (19) 
      
PVL No 29 (85) 35 (66) 
 Yes 5 (15) 18 (34) 
      
Lichenoid  
Inflammation 
No 28 (82) 43 (81) 
 Yes 6 (18) 10 (19) 
      
Treatment 
Intervention 
Multiple 34 (100) 15 (28) 
 Single 0 (0) 38 (72) 
      
 
               Test                p-value 
Age t-test p=0.21 
Sex Chi-square p=0.61 
Follow-Up Wilcoxon rank sum p=0.08 
Clinical Lesion Fisher’s exact p=0.27 
Site Fisher’s exact p=0.55 
Dysplasia Chi-square p=0.12 
PVL Chi-square p=0.47 
Lichenoid Inflammation Chi-square p=0.89 










The numbers of patients who developed Further/Disease Free and 
Further/Persistent Disease status are listed against their year of first clinical 
presentation in Table 5.25, and the corresponding percentage figures 
illustrated in Figure 5.5. There appears to be a trend for an increasing 
percentage of patients to exhibit Further/Persistent Disease from around 
2010 onwards, although the actual number of patients affected (3 to 10 per 
year) remains small.   
 
 
TABLE 5.25:  NUMBERS (AND PERCENTAGES) OF FURTHER / DISEASE FREE AND 
FURTHER / PERSISTENT DISEASE PATIENTS PRESENTING EACH STUDY YEAR  
 
 





     % No. of 
Further/Persistent 
Disease 
       % 
1996 2 0 0 0 0 
1997 7 1 14.3 0 0 
1998 28 1 3.6 0 0 
1999 29 1 3.4 0 0 
2000 45 0 0 2 4.4 
2001 30 2 6.7 2 6.7 
2002 22 2 9.1 1 4.5 
2003 34 0 0 1 2.9 
2004 45 2 4.4 0 0 
2005 24 0 0 2 8.3 
2006 33 2 6.1 2 6.1 
2007 37 1 2.7 1 2.7 
2008 47 1 2.1 2 4.3 
2009 54 4 7.4 1 1.8 
2010 56 1 1.8 7 12.5 
2011 73 9 1.4 10 13.7 
2012 65 1 1.5 10 15.4 
2013 89 6 6.74 8 9.0 













Figure 5.5:  Percentage of Further/Disease Free (DF) and Further/Persistent Disease 


































































5.4.9. Malignant Transformation Patients. 99 out of 590 treated PMD patients 
(16.8%) developed an oral squamous cell carcinoma during the study period. 
Importantly, 71 (12%) were identified upon histopathological assessment of 
initial laser excision specimens, with only 28 patients (4.8%) progressing to 
malignancy during subsequent follow-up. Original patient data for this group 
can be reviewed in Appendix V. Figure 5.6 illustrates the overall pattern of 
malignant disease presentation during the study period. 
 
Figure 5.6: Percentage of PMD Cases undergoing Malignant Transformation (both 
unexpected at initial presentation and during follow-up) plotted against Year of Initial PMD 
Precursor Lesion Presentation.  
 
 
The anatomical site distribution of the 99 precursor lesions is illustrated in 
Figure 5.7; the floor of mouth and ventro-lateral tongue sites accounted for 
the majority of cases (60). Overall, 80 carcinomas developed at the same 







Figure 5.7: Anatomical Site Distribution of Presenting PMD Lesions in Patients 




The clinical appearance of the 99 presenting PMD lesions are recorded in 
Table 5.26, showing a much higher percentage of erythroleukoplakia lesions 
(48%) and a corresponding reduction in leukoplakia (48%) compared to other 
specific outcome categories (documented in Tables 5.11, 5.17 and 5.21). 
The histopathological profiles of the lesions are listed in Table 5.27 and are 
presented graphically in Figure 5.8 to demonstrate the much higher 
percentage of severe dysplasia and carcinoma-in-situ diagnoses seen in the 
malignant transformation group (64.6% in total) compared with Disease Free 
(25.7%), Further / Disease Free (38.3%), and Further / Persistent Disease 




























TABLE 5.26: CLINICAL APPEARANCE OF PMD LESIONS IN MALIGNANT 
TRANSFORMATION PATIENTS 
____________________________________________________________ 
Clinical Appearance                  No. of Patients                                 %                         
____________________________________________________________ 
                 Leukoplakia                                            48                                          48 
                 Erythroleukoplakia                                  47                                          48 
                 Erythroplakia                                             4                                            4   
___________________________________________________________ 
 Total                                                      99                                         100                         
____________________________________________________________ 
 
TABLE 5.27: HISTOPATHOLOGY DIAGNOSES OF PMD LESIONS IN MALIGNANT 
TRANSFORMATION PATIENTS 
_________________________________________________________________________ 
Histopathology Diagnosis                                    No. of Patients                     % 
_________________________________________________________________________ 
Hyperkeratosis                                                                         2                                2.0 
Hyperkeratosis + Lichenoid Inflammation (LI)                          3                                3.0 
Chronic Hyperplastic Candidosis (CHC)                                  1                                1.0 
Proliferative Verrucous Leukoplakia (PVL)                              1                                1.0 
Mild Dysplasia                                                                        11                              11.1 
Mild Dysplasia + LI                                                                   1                                1.0 
Mild Dysplasia + PVL                                                               0                                0.0                
Moderate Dysplasia                                                                16                              16.3    
Moderate Dysplasia + LI                                                          0                                 0.0                                                             
Moderate Dysplasia + PVL                                                      0                                 0.0       
Severe Dysplasia                                                                   32                               32.3 
Severe Dysplasia + LI                                                              0                                 0.0 
Severe Dysplasia + PVL                                                          0                                 0.0                      
Carcinoma-in-Situ                                                                   32                              32.3    
    
_________________________________________________________________________ 





Figure 5.8: Histopathology of Presenting PMD Lesions in Patients Undergoing 
Malignant Transformation (total number of lesions = 99; HK Hyperkeratosis, LI Lichenoid 





Table 5.28 summarizes overall clinico-pathological data for the 71 presenting 
PMD lesions cases in which ‘unexpected’ SCC was diagnosed following 


































TABLE 5.28: CLINICO-PATHOLOGICAL FEATURES OF PRECURSOR PMD LESIONS 
WHERE LASER EXCISION REVEALED UNEXPECTED SCC (Number = 71) 
Patient No. PMD Lesion Lesion Site Incision Biopsy 
Histopathology 
1997/4 ELK Buccal Sev Dysp 
1997/5 LK Lateral Tongue Mod Dysp 
1997/7 LK Buccal HK 
1998/1 ELK Lateral Tongue CiS 
1998/3 ELK Lateral Tongue Sev Dysp 
1998/4 LK FOM CiS 
1998/6 ELK Fauces Sev Dysp 
1998/8 ELK Lateral Tongue Sev Dysp 
1998/9 EK RM CiS 
1998/13 LK Lateral Tongue CiS 
1998/15 ELK Lateral Tongue Sev Dysp 
1998/16 ELK Buccal CHC 
1999/2 LK Lateral Tongue Sev Dysp 
1999/3 LK Lateral Tongue Sev Dysp 
1999/4 LK FOM Mod Dysp 
1999/5 ELK Lateral Tongue Sev Dysp 
1999/6 ELK FOM Mod Dysp 
1999/8 ELK FOM CiS 
1999/15 ELK Palate CiS 
1999/16 ELK FOM CiS 
1999/19 ELK Lateral Tongue Sev Dysp 
1999/21 LK Buccal Sev Dysp 
2000/17 LK Ventral Tongue CiS 
2000/19 LK Palate CiS 
2000/20 LK Lateral Tongue CiS 
2000/29 LK FOM CiS 
2000/30 LK Palate CiS 
2001/8 EK Fauces / RM CiS 
2001/15 ELK Fauces CiS 
2001/24 LK Buccal CiS 
2002/1 LK Ventral Tongue HK 
2002/4 ELK FOM Sev Dysp 
2003/11 LK Alveolus Sev Dysp 
2003/19 LK Lateral Tongue Sev Dysp 
2003/20 LK Ventral Tongue CiS 
2003/25 LK Lateral Tongue CiS 
2004/4 LK Lateral Tongue HK + LI 
2004/9 LK FOM CiS 
2004/10 ELK Lateral Tongue CiS 
2004/15 LK FOM Sev Dysp 
2004/16 ELK Lateral Tongue CiS 
2004/25 LK Lateral Tongue CiS 
2004/27 LK Ventral Tongue Mild Dysp 





2005/11 ELK FOM Sev Dysp 
2005/12 ELK FOM CiS 
2005/13 ELK Lateral Tongue Sev Dysp 
2006/9 LK Dorsum Tongue Mild Dysp 
2006/18 ELK RM Sev Dysp 
2007/1 LK Lateral Tongue CiS 
2007/2 ELK Lateral Tongue Mod Dysp 
2007/6 EK Fauces CiS 
2007/9 LK Lateral Tongue Mod Dysp 
2007/10 ELK Buccal Mod Dysp 
2007/11 LK Dorsum Tongue PVL 
2007/12 ELK Ventral Tongue Sev Dysp 
2007/14 EK Palate Sev Dysp 
2007/18 LK Buccal Mild Dysp 
2008/26 LK Lateral Tongue Mild Dysp + LI 
2008/38 LK FOM Sev Dysp 
2009/11 LK Ventral Tongue Mod Dysp 
2010/11 ELK FOM Sev Dysp 
2010/33 LK Lateral Tongue Mild Dysp 
2011/32 LK FOM Sev Dysp 
2012/37 ELK Alveolus Mild Dysp 
2012/52 LK Fauces Sev Dysp 
2013/14 ELK Lateral Tongue CiS 
2013/16 LK FOM Sev Dysp 
2013/24 ELK Lateral Tongue Sev Dysp 
2013/56 LK Lateral Tongue Mild Dysp 
2013/66 ELK Fauces CiS 
 
 
Clinico-pathological details of the 28 cases that progressed to malignancy 
during follow-up are listed in Table 5.29. Same site transformation occurred 
in 9 cases between 3 and 48 months (mean 28 months) post-laser, whilst 
new site transformation in 19 cases generally took longer, varying between 9 
to 204 months (mean 61.3 months). Figure 5.9 illustrates the Kaplan-Meier 
survival curve of time to malignant transformation; patients whose carcinoma 
diagnosis was made at the time of first interventional treatment were 
excluded leaving 519 patients in the analysis. Patients who did not undergo 
malignant transformation by the study census date were censored in the 
Kaplan-Meier plot at the time of most recent follow-up. Overall, the median 
time to malignancy in the 28 transforming cases was 87.3 months (95% CI 





TABLE 5.29: CLINICO-PATHOLOGICAL FEATURES OF PRECURSOR PMD LESIONS 


















1996/1 LK Mod Dysp Buccal LK Alveolus 204 New  
1996/2 LK HK + LI Alveolus LK Palate 30 New  
1997/3 LK CiS Fauces/RM ELK RM 48 Same 
1998/5 EK CiS Fauces/RM LK L Tongue 8 New 
1998/7 EK CiS Buccal ELK Alveolus 86 New 
1999/17 LK Mod Dysp V Tongue LK L Tongue 15 New 
1999/22 LK Mod Dysp L Tongue LK Buccal 12 New 
2000/3 LK Mod Dysp Palate ELK Alveolus 124 New 
2000/31 LK CiS L Tongue ELK FOM 133 New 
2000/37 LK CiS Lab Com ELK D Tongue 147 New 
2001/10 ELK CiS Fauces ELK Palate 158 New 
2002/7 LK Mod Dysp Lab Com LK Labial 9 New 
2003/1 LK Sev Dysp L Tongue ELK L Tongue 35 Same 
2003/7 LK CiS L Tongue LK FOM 12 New 
2003/9 LK Mod Dysp Alveolus ELK Buccal 69 New 
2003/12 ELK Sev Dysp L Tongue ELK L Tongue 59 Same 
2006/1 LK Mild Dysp L Tongue ELK Palate 18 New 
2007/4 ELK Sev Dysp L Tongue ELK Palate 70 New 
2007/5 LK CiS Fauces ELK FOM 17 New 
2008/17 LK Mild Dysp Palate ELK Palate 3 Same 
2008/20 LK Sev Dysp FOM ELK FOM 4 Same 
2008/23 LK Mild Dysp Buccal LK Labial 28 New 
2008/30 EK CiS FOM LK FOM 16 Same 
2009/36 ELK Sev Dysp L Tongue ELK L Tongue 24 Same 
2010/5 LK Mild Dysp V Tongue ELK V Tongue 42 Same 
2010/9 ELK Sev Dysp L Tongue ELK Fauces 9 New 
2010/22 ELK  Sev Dysp FOM ELK Labial 16 New 













Figure 5.9: Kaplan-Meier Analysis plotting Time to Malignant Transformation (months) 




In terms of clinical appearance, Table 5.30 and Figure 5.10 directly compare 
precursor PMD lesions with their SCC transformed appearance, 
demonstrating that lesions presenting as erythroleukoplakia were 
significantly more likely to exhibit malignancy (p=0.0019; Fisher’s exact test).  
 
TABLE 5.30: CLINICAL APPEARANCE OF PRECURSOR PMD LESIONS AND 
TRANSFORMED SCC LESIONS  
 
 Leukoplakia Erythroleukoplakia Erythroplakia Totals 
Precursor 
Lesion 
   19 (68%)        6  (21%)        3  (11%) 28 (100%) 
SCC    10 (36%)      18  (64%)        0   (0%) 28 (100%) 
 






Figure 5.10: Change in Clinical Appearance between Precursor PMD Lesions and 





Univariate Cox regression analyses of clinico-pathological variables which 
might influence the time to malignant transformation, including patient sex, 
age, anatomical site, clinical appearance, dysplasia grading (most significant 
from combined incision and excision biopsies), identification of PVL features 
and lichenoid inflammation on histopathology, were carried out but none 
showed a significant influence at the 5% level. This, however, is likely to 
have been influenced by the small sample size of this population (28). P-
values for these data are summarised in Table 5.31, except for the 
categories of lesion site and PVL identification in which insufficient data was 
available in each category for estimation, and additionally graphically 



























TABLE 5.31: CLINICO-PATHOLOGICAL VARIABLES INFLUENCING MALIGNANT 
TRANSFORMATION (p-Values)  
Clinico-Pathological Variable            p-Value 
Sex             0.58 
Age             0.46* 
Site of Initial Presentation**                - 
Clinical Appearance             0.55 
Dysplasia Grading  (WHO)             0.96 
Dysplasia Grading (Binary)             0.86 
Proliferative Verrucous Leukoplakia**                - 
Presence of Lichenoid Inflammation             0.70 
 





Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
Age 1 0.01176 0.01592 0.5463 0.4598 1.012 
 
**Insufficient data available in category for analysis 
 
Figure 5.11: Kaplan-Meier Analysis plotting Time to Malignant Transformation 







Figure 5.12: Kaplan-Meier Analysis plotting Time to Malignant Transformation 




Figure 5.13: Kaplan-Meier Analysis plotting Time to Malignant Transformation 
(months) against Clinical Appearance of Initial PMD lesion: Erythroleukoplakia (ELK) 
71.0, 95%CI 59.9-160.3; Erythroplakia (EK) 87.3, 95%CI 8.1-87.3; Leukoplakia (LK) 124.8, 






Figure 5.14: Kaplan-Meier Analysis plotting Time to Malignant Transformation 
(months) against WHO Dysplasia Grading (most significant from combined 
incision/excision data): Mild 42.6, 95%CI 28.4-NA; Moderate 70.0, 95%CI 15.2-205.9; 
Severe 71.0, 95%CI 35.5-149.2; None 87.3, 95%CI 48.7-160.3; p=0.96. 
 
Figure 5.15: Kaplan-Meier Analysis plotting Time to Malignant Transformation 
(months) against Binary Dysplasia Grading (most significant from combined 
incision/excision data): Low Grade (Mild/Mod) 70.0, 95%CI 28.4-205.9; High Grade 






Figure 5.16: Kaplan-Meier Analysis plotting Time to Malignant Transformation 
(months) against the histopathological identification of Proliferative Verrucous 
Leukoplakia (PVL).  
 
 
Figure 5.17: Kaplan-Meier Analysis plotting Time to Malignant Transformation 
(months) against the histopathological identification of Lichenoid Inflammation (LI):  






5.4.10. Comparative Analyses of Clinical Outcome Categories. A number of 
comparative analyses were carried out utilising the defined clinical outcome 
categories of: Disease Free, Further Disease which progressed to Disease 
Free status following further intervention (Further/DF), Further PMD Disease 
which persisted despite intervention (Further/Persistent) and Malignant 
Transformation (MT). 
 
Table 5.32 lists the clinical appearance of PMD lesions seen in each clinical 
outcome category whilst Figure 5.18 illustrates, to facilitate a direct 
comparison, the percentage of lesions within each category plotted against 
their presenting clinical appearance. A significant difference in clinical 
outcome was seen between lesions with varying clinical appearance, most 
notably the high percentage of erythroleukoplakic lesions undergoing 
malignant transformation (p<0.0001; Fisher’s exact test).  
 
 
TABLE 5.32: CLINICAL APPEARANCE OF PMD LESIONS IN EACH CLINICAL 
OUTCOME CATEGORY 




Leukoplakia 341 (85%) 25 (74%) 45 (85%) 48 (48%) 
Erythroleukoplakia 50 (12%) 8 (23%) 6 (11%) 47 (48%) 
Erythroplakia 13 (3%) 1 (3%) 2 (4%) 4 (4%) 
Totals 404 (100%) 34 (100%) 53 (100%) 99 (100%) 
 









Figure 5.18: Clinical Appearance of PMD Lesions versus Outcome, plotting the 
percentage of leukoplakia, erythroleukoplakia and erythroplakia lesions against clinical 
outcome categories, comprising DF disease free, Further/DF whereby further PMD disease 
resolved to disease free status, Further / Persistent when PMD lesions persisted, and MT 
malignant transformation. 





In Table 5.33, and subsequently illustrated in Figure 5.19, the change in 
PMD appearance between initial presenting lesion and further PMD disease 
is shown for each clinical outcome category (excepting disease free cases). 
The same clinical appearance was most commonly seen in the 









TABLE 5.33: CLINICAL APPEARANCE OF PMD LESIONS IN EACH CLINICAL 
OUTCOME CATEGORY FOLLOWING INTERVENTIONAL LASER SURGERY 
 Further / DF Further / Persistent Malignant  
Transformation 
Same Appearance 23 (68%) 49 (92%) 14 (50%) 
Change in Appearance 11 (32%) 4 (8%) 14 (50%) 
Totals 34 (100%) 53 (100%) 28* (100%) 
*Only Transforming SCC Cases Included 
Chi-squared test p<0.0001 
 
 
Figure 5.19: Change in Appearance of PMD Lesions following Interventional Laser 
Surgery versus Outcome, plotting the percentage of same or changed appearance against 
clinical outcome for the categories of Further/DF whereby further PMD disease resolved to 
disease free status, Further / Persistent when PMD lesions persisted, and MT malignant 
transformation.  
   
 
 
In Figure 5.20, the percentage of PMD lesions exhibiting each clinical 
outcome is plotted against their most significant initial histopathological 
diagnosis; malignant transformation is most frequently seen in lesions that 
exhibited severe dysplasia or carcinoma-in-situ, as originally illustrated in 

























Figure 5.20: Histopathology Diagnoses for PMD Lesions versus Outcome, plotting the 
percentage of each diagnosis against clinical outcome categories, comprising DF disease 
free, Further/DF whereby further PMD disease resolved to disease free status, Further / 





In Table 5.34 and in Figure 5.21, the change in severity of histopathological 
grading between initial and subsequent PMD lesion biopsy is analysed 
against clinical outcome, suggesting that PMD lesions which persist were 
more likely to retain their original histopathological character, whilst the 
pathological appearance of subsequent lesions was likely to be less severe 




































TABLE 5.34: CHANGE IN SEVERITY OF HISTOPATHOLOGY DIAGNOSES BETWEEN 
PRESENTING AND FURTHER PMD LESIONS FOLLOWING INTERVENTIONAL LASER 
SURGERY 
 Further / DF Further / Persistent 
Less Severe 12 (56%) 6 (11%) 
Same 19 (35%) 44 (83%) 
More Severe 3 (9%) 3 (6%) 
Totals 34 (100%) 53 (100%) 
 
Fisher’s exact test p=0.013 
 
 
Figure 5.21: Change in Histopathology Diagnoses between Presenting PMD Lesion 
and Further Lesions versus Outcome, plotting the percentage of less severe, same and 
more severe histopathological diagnosis against the clinical outcome categories of 
Further/DF whereby further PMD disease resolved to disease free status, and Further / 




By plotting anatomical location against outcome, Figure 5.22 confirms that 
malignant transformation is more commonly seen in PMD lesions arising at 
lateral tongue and floor of mouth sites, confirming data initially presented in 

























Figure 5.22: Anatomical Location of PMD Lesions versus Outcome, plotting the 
percentage of lesions seen at each oral site against clinical outcome categories, comprising 
DF disease free, Further/DF whereby further PMD disease resolved to disease free status, 





In terms of change in anatomical site location, Table 5.35 and Figure 5.23 
show that Further/Persistent Disease and Malignant Transformation occurred 
more frequently at the same site as the initial presenting lesions (p=0.0003; 
Chi-squared test), whereas this relationship was less clear for 










TABLE 5.35: ANATOMICAL LOCATION OF PMD LESIONS IN EACH CLINICAL 
OUTCOME CATEGORY FOLLOWING INTERVENTIONAL LASER SURGERY 
 Further / DF Further / Persistent Malignant 
Transformation 
Same Site 17 (50%) 42 (79%) 80 (81%) 
New Site 17 (50%) 11 (21%) 19 (19%) 
Totals 34 (100%) 53 (100%) 99 (100%) 
 
Chi-squared test p=0.0003 
 
 
Figure 5.23: Change in Anatomical Location between Presenting PMD Lesion and 
Further Lesions versus Outcome, plotting the percentage of same site and new site PMD 
disease against the clinical outcome categories of Further/DF whereby further PMD disease 
resolved to disease free status, Further / Persistent when PMD lesions persisted, and MT 
































Regarding the method of interventional laser management, Table 5.36 and 
Figure 5.24 demonstrate clinical outcomes seen following either laser 
excision or ablation techniques, confirming significant difference with ablation 
associated with a higher number of Further/Persistent PMD disease cases 
(p<0.0001; Chi-squared test).  
 
TABLE 5.36: CLINICAL OUTCOME RESULTS IN RELATION TO INTERVENTIONAL 
LASER SURGERY TECHNIQUE (EXCISION vs ABLATION)  




Excision 363 (90%) 30 (88%) 38 (72%) 95 (96%) 
Ablation 41 (10%) 4 (12%) 15 (28%) 4 (4%) 
Totals 404 (100%) 34 (100%) 53 (100%) 99 (100%) 
 
Chi-squared test p<0.0001 
 
Figure 5.24: Interventional Laser Surgery Technique (Excision or Ablation) versus 
Outcome, plotting the percentage of each clinical outcome category against surgical 
technique, comprising DF disease free, Further/DF whereby further PMD disease resolved 
to disease free status, Further / Persistent when PMD lesions persisted, and MT malignant 
































5.5.1. Introduction. This data set of 590 PMD patients, undergoing a 
standardised and coordinated treatment intervention by a single surgeon, is 
the largest cohort of its kind ever studied and as such offers unparalleled 
insight into the natural history of oral potentially malignant disease in the 
North-East of England. The study also provides detailed clinical outcome 
data recorded over one of the longest ever follow-up periods, 19 years, with 
a mean patient follow-up of 7.3 years.    
 
5.5.2. Patient Demographics. The age and sex demographics of the study 
population appear consistent with previous Newcastle patient cohort studies, 
confirming a median patient age of 60 years and, with 59% of cases male 
and 41% female, a 1.4:1 male to female ratio; these data are consistent with 
several recent PMD population studies (Cowan et al 2001, Jaber et al 2003, 
Jerjes et al 2012a, Dost et al 2013 & 2014, Watabe et al 2015). No 
significant relationships between patient age or sex and potentially malignant 
disease presentation or clinical outcome were characterised in this study 
which is similar to our observations from all previous analyses (Thomson & 
Wylie 2002, Hamadah & Thomson 2009, Diajil et al 2013); patient numbers, 
although large in terms of PMD studies, are probably too limited to be able to 
determine significant demographic differences. As in previously documented 
reports, the vast majority of PMD patients in this study regularly smoked 
tobacco (87%) and drank alcohol (84%), confirming these as the most 
significant aetiological factors in this Northern England population. 
 
5.5.3. Clinico-Pathological Features. Consistent with previously published 
Newcastle data, the vast majority of oral lesions in this study (79%) 
presented as leukoplakia, with the floor of mouth and ventro-lateral tongue 
sites most commonly affected (61%); these observations are highly 
consistent with many other previously published studies (Schepman et al 





Graveland et al 2013, Dost et al 2014). We have previously characterised 
increased epithelial cell proliferative activity within floor of mouth and ventral 
tongue sites, and it may well be that these oral regions actually exhibit an 
underlying predisposition to carcinogenic influence, particularly as increasing 
cell dysregulation appears to be a key factor driving oral carcinogenesis (Liu 
et al 1998, Thomson et al 1999a & 1999b, 2001, 2002, Cruz et al 2002, 
Thomson et al 2006 & 2008).  
Histopathological diagnoses for all 590 patients in this study were provided 
by 4 specialist oral pathologists, based in the Pathology Department at the 
Royal Victoria Infirmary in Newcastle, who worked throughout the study 
period using agreed WHO diagnostic standards with appropriate peer review 
and consensus grading. The majority of oral lesions in the study exhibited 
significant histopathological abnormality, with 88.5% showing dysplasia or 
carcinoma-in-situ; this is also similar to our previous studies and 
distinguishes this patient data set from many others in the literature in which 
disparate types of lesions, many non-dysplastic in nature, are included in 
retrospective analyses (Thomson 2012d). Re-examination of tissue 
specimens in a formal, research-orientated approach was not undertaken in 
this MD study as it was felt such re-calibrated data would not accurately 
reflect the ‘real-world’ nature of the PMD diagnosis and management 
protocol that the 590 cases had undergone. Whilst Dost et al (2014) have 
also commented on this issue in relation to oral epithelial dysplasia research, 
Speight et al (2015) have more recently reported upon a multi-stage 
histopathology review and adjudication process which they hope may form 
the basis of a ‘gold standard’ for future oral potentially malignant disorder 
research. 
The extensive PMD data set in this study not only benefits from coordinated 
clinical recording and consistent ‘real-world’ histopathological diagnoses by 
experienced oral pathologists, but is also one of the largest and best defined 
series of oral dysplastic lesions in the current literature. Table 5.37 
summarises and compares patient demography and salient clinico-
pathological features from this current study with 4 previous Newcastle 





there does appear to be a slight increase in the number of female patients 
affected by PMD disease in the present study. This latter observation is 
consistent with many recent reports suggesting an increase in oral 
carcinogenesis in female patients, possibly due to a rise in tobacco and 
alcohol consumption in younger females (Warnakulasuriya 2009, 2010). 
 
TABLE 5.37: COMPARATIVE PATIENT DEMOGRAPHIC AND CLINICO-
PATHOLOGICAL DATA FOR NEWCASTLE PMD PATIENT COHORT STUDIES        
(2002-2016)  

















 57 40 78 100 590 
M:F 
Ratio 
 1.85:1 2.3:1 1.9:1 2.1:1 1.4:1 
Mean 
Age (Yrs) 




Leukoplakia 69 65 68 78 79 
 Erythroleukoplakia 28 23 27 16 17 























An interesting observation, illustrated in Figure 5.2, was the trend for 
increased recognition of lesions exhibiting lichenoid inflammation or 
proliferative verrucous features on histopathological examination during the 
later years of the study. It is likely that this is due to an increasing awareness 
amongst oral pathologists not only of the potential significance of lichenoid 





upon in Publication 2.4 of this thesis) but also greater recognition of the 
relevance of persistent, multi-focal mucosal disorders such as proliferative 
verrucous leukoplakia (PVL) which are increasingly believed to exhibit a high 
risk of malignant transformation (Bagan et al 2010a, 2011). Interestingly, 
comparison of Figure 5.2 with Figure 4.5 confirms a similar increase in laser 
ablation techniques over the same time period, which parallels the increase 
in PVL lesions seen primarily affecting keratinised gingiva and alveolar sites.  
 
The prognostic significance of oral lesions exhibiting lichenoid inflammatory 
features has, of course, been debated for many years and remains 
controversial, although in this study patients whose lesions showed lichenoid 
inflammation were less likely to achieve Disease Free status, and there is 
little doubt that in clinical practice identification of isolated erythroleukoplakic 
lesions showing lichenoid features and arising at sites such as the ventro-
lateral tongue are increasingly regarded as being at ‘high risk’ for malignant 
transformation (Thomson 2012e, Farah et al 2014). Dost et al (2013) 
observed lichenoid features in 25 out of 124 dysplastic oral lesions (20%); 
this is higher than the 11.5% (60 lichenoid inflammatory lesions out of 522 
dysplasias) seen in this study, however. Some authors have coined the term 
‘lichenoid dysplasia’ for such lesions, and emphasised their high risk of 
progression to carcinoma, although the term is not universally applied 
(Krutchkoff & Eisenberg 1985, Lovas et al 1989, Speight 2007, Dost et al 
2013, Patil et al 2014). Whilst oral lichenoid lesions have not been routinely 
followed up continuously, some authors have recommended this practice to 
specifically monitor for early cancerous change (Xue et al 2005, Al Hashimi 
et al 2007, Greaney et al 2014).  
 
Traditionally, diagnoses of proliferative verrucous leukoplakia (PVL) have 
generally been made late during the course of PMD presentation once 
progressive spread to different oral sites, high recurrence rates following 
treatment intervention and malignant transformation all become apparent. 
Increasingly, specialist oral pathologists have attempted earlier and more 





of the PVL spectrum which almost certainly accounts for the increased 
frequency of the diagnosis during the latter years of this study (Speight 2007, 
Cerero-Lapiedra et al 2010). Gouvea et al (2013) usefully emphasised 
salient criteria to support contemporary PVL diagnoses including: females 
older than 50 years with no active tobacco or alcohol misuse, multiple-site 
leukoplakic lesions, and progressive clinical and histopathological features 
confirmed during follow-up. Whilst these authors quoted an approximate UK 
PVL prevalence of 0.1% (1 PVL for every 1000 leukoplakias), 74 out of the 
590 PMD lesions in this MD study (12.5%) were shown to exhibit features of 
PVL (Table 5.3) suggesting a much higher disease presence.  
 
Histopathologically, PVL has classically been described as exhibiting a 
continuum of morphological change, passing through an initial phase of 
hyperkeratosis without dysplasia, followed by verrucous hyperplasia leading 
on to verrucous carcinoma and invasive squamous carcinoma (Cerero-
Lapiedra et al 2010). Complicating the early phase of lesion development 
further, however, is the recognition that significant lymphocytic infiltration 
may be identified in the immediate sub-epithelial region effectively mimicking 
the appearance of oral lichenoid lesions (Issrani et al 2013); these latter 
observations may have particular relevance for the study data reported in 
Publication 2.4.   
 
Whilst it remains to be seen exactly how far such histopathology diagnoses 
will equate with PMD lesion behaviour long-term, clinicians specialising in 
potentially malignant disease must for now remain highly vigilant for signs 
and symptoms of putative PVL disease, liaising closely with pathology 
colleagues in agreeing diagnostic criteria which must be appropriately 
tailored to individual, presenting cases (Gouvea et al 2013). 
 
Chronic hyperplastic candidosis (CHC), sometimes termed candidal 
leukoplakia, is a specific potentially malignant variant of oral candida 
infection that may present as leukoplakia on the labial commissures of 
tobacco smokers; it is unclear whether candida initiates dysplastic change or 





Samaranayake 2003).  Whilst there is no overall consensus on management, 
the 17 cases identified in this MD study were initially treated with systemic 
anti-fungal treatment and smoking cessation advice prior to CO2 laser 
treatment of their persisting lesions which successfully rendered 16 free from 
disease. Interestingly, 1 case arising on buccal mucosa exhibited 
unexpected squamous carcinoma which was diagnosed only following laser 
excision.  
 
Formal re-assessment of original histopathology specimens for research 
calibration did not form part of the methodology of this MD thesis, but there is 
little doubt that review of PMD cases with known unfavourable clinical 
outcome data, especially those exhibiting lichenoid inflammatory change and 
PVL features in archived biopsy specimens, could well contribute to useful, 
future clinico-pathological characterisation of PMD lesions and perhaps an 
improved understanding of their overall natural history. 
 
5.5.4. Laser Excision Histopathological Data. The structured treatment 
intervention applied throughout the study period facilitated a unique, direct 
comparison of 609 histopathological diagnoses from initial, incision biopsy 
samples with their ‘whole lesion’ laser excision counterparts. An important 
hypothesis influencing the Newcastle interventional treatment protocol was, 
of course, that incision biopsy data alone cannot accurately represent the 
true nature of oral potentially malignant lesions. Agreement between incision 
and excision diagnoses was seen in only 50% of samples in this study, with 
36% having to be subsequently ‘up-graded’ in severity once ‘whole lesion’ 
specimens were also examined microscopically; Figure 5.3.  
Kappa agreement between incision and excision biopsy data, both using 
traditional WHO dysplasia grading and an arbitrary ‘binary’ system was only 
deemed moderate, although overall histopathology agreement for all 
diagnostic samples appeared slightly improved when ‘high-grade’ and ‘low-
grade’ classifications were utilised. Formal testing of the effectiveness of 






Perhaps of most clinical significance, however, was the poor specificity 
(16.3%) of incision biopsy techniques to diagnose squamous carcinoma in 
oral potentially malignant lesions when directly compared with laser excision 
biopsy (kappa agreement only 0.25). As the majority of laser treatments in 
this study were all carried out within 6 to 12 weeks of initial biopsy, disease 
progression is not likely to be a major influence on any disparity between 
tissue samples (Lumerman et al 1995, Warnakulasuriya et al 2011, Diajil et 
al 2014). Rather, these differences most likely reflect a more specific 
inadequacy of undertaking limited, incision biopsy sampling of oral lesions, 
which is especially pertinent for potentially malignant disorder cases 
presenting with larger, more widespread and multi-focal mucosal disease; 
the latter clinical presentation is known to affect up to 25% of Newcastle 
PMD patients (Hamadah et al 2010).   
 
Table 5.38 compares the MD study data with 2 earlier Newcastle laser 
studies in which comparison of incision and excision biopsies were also 
carried out. Consistent diagnoses were seen in 50 to 55% of cases, but more 
severe dysplasia was seen in 11 to 29% of excision specimens and, perhaps 
of most significance, squamous cell carcinoma was identified in a further 9 to 
16%. In 7 to 25% of cases, excision biopsy specimens showed less severe 
dysplasia than initial biopsy, but this is of no real clinical significance as such 
lesions always retain their most significant histopathology diagnosis in 











TABLE 5.38: COMPARISON BETWEEN LASER EXCISION HISTOPATHOLOGY 
DIAGNOSES AND INITIAL INCISION BIOPSY DATA IN NEWCASTLE PMD PATIENT 
COHORT STUDIES (2002-2016)  
 
  Thomson 







  No.       % No.         % No.        % 
Direct 
Comparisons 
 55      100 169      100 609     100 
Dysplasia Less 
Severe 
14        25   11         7   82       14 
 Same 30        55   94       55 307       50 
 More 
Severe 
  6        11   49       29 122       20 
SCC     5          9   15         9   98       16 
 
 
van der Waal (2009a) emphasised the important distinction between incision 
biopsy diagnoses, which should only be considered provisional in nature, 
and the more definitive diagnoses achieved via whole lesion inspection; the 
results from the 609 specimens examined in this study strongly support this 
viewpoint, and concur with the arguments presented in sections 1.6.1 and 
1.6.2 of this thesis. Dost et al (2014) have recently recommended that all 
potentially malignant oral lesions exhibiting dysplasia should receive 
definitive treatment by whole lesion excision.  
As discussed in section 1.6.3, thermal cytological artefacts following CO2 
laser excision biopsies have been suggested as a limitation of such 
treatment intervention (Seoane et al 2010), but their presence or absence did 
not detract from full and accurate histopathology assessment and diagnosis 
for the 609 excisions specimens analysed in this study by specialist oral 






5.5.5. Clinical Outcome.  Long-term cohort studies such as this one facilitate 
detailed analysis and stratification of clinical outcome data, and the outcome 
categories applied to patients in this study were refined to specifically reflect 
important, distinct clinical outcomes for treated PMD cases. In this study, 
nearly three-quarters of patients (74.2%) were recorded as PMD Disease 
Free at the end of study census date, confirming considerable efficacy of 
laser intervention as a treatment modality. This is especially pertinent 
because 88.5% of lesions were treated for significant dysplasia or 
carcinoma-in-situ, and these results compare favourably with previous 
outcome data from our studies originally summarised in Table 1.5. In terms 
of patient profiling, Disease Free patients tended to be of a younger age and 
on histopathological examination exhibited mild or moderate dysplasia 
without the presence of lichenoid inflammatory features in their biopsy 
specimens; section 5.4.6. 
 
It is difficult to meaningfully compare treatment outcomes from this MD study 
group with other published data due to substantive differences in diagnostic 
and clinical decision making processes, varying types of lesions treated, 
inconsistent surgical techniques and lack of agreed clinical outcome 
definitions in most papers in the current literature (Shiu & Chen 2003, 
Thomson 2012d). Yang et al (2015) recently commented, not entirely 
helpfully, that making any comparison between PMD treatment studies is 
probably impossible. Nonetheless, data from 6 recent, comparable CO2 laser 
treatment studies is tabulated and an attempted comparison with this MD 










TABLE 5.39: COMPARATIVE CLINICAL OUTCOME DATA FOR CO2 LASER 
























   282    114   77     30        38       65    590 
Follow-Up 
(Mean Years)  
    4.3     3.4   6.4       5        0.5      1.25     7.3 
Disease Free      89%    71.1% 70.1%   86.7%     81.6%     50.8%   74.2% 
Further 
Disease  
    9.9%    17.5% 29.9%   13.3%     18.4%     33.8%   15.4% 
Development 
of SCC  
   1.1%    11.4% 10.4%     0%       0%     15.4%   16.8% 
 
 
Whilst the data from this MD study cohort comprises by far the largest 
number of treated patients (590) and the longest mean follow-up period (7.3 
years), the overall pattern for clinical outcome listed in Table 5.39 appears 
quite similar between studies. Disease Free outcomes are seen in 50.8 to 
89% of cases (mean calculated as 74.8%), whilst further PMD disease 
affected between 9.9 and 33.8% (with a mean of 19.7%).  
The specific follow-up data collected during the MD study allowed an 
additional distinction to be made between patients ultimately rendered 
Disease Free following further potentially malignant disease presentation and 
subsequent repeat treatment (34 or 5.8%), and those whose disease 
persisted despite repeated intervention (53 or 9%). The characteristics of 
these distinct further disease outcome categories have been analysed in 
sections 5.4.7 and 5.4.8, and summarised in Table 5.24. Although primarily 
statistically non-significant, probably due to the low sample size, patients 
who exhibited Further/Persistent PMD disease (that is, disease arising at the 
same anatomical site, and with consistent clinical and histopathological 





on the gingiva, alveolus and labial mucosa, often exhibiting clinico-
pathological features consistent with PVL and were more likely to have been 
treated by ablation techniques rather than surgical excision (as summarised 
in Table 5.36 and Figure 5.24). Other workers have also noted high disease 
recurrence following PVL treatment; Bagan et al (2011), for example, 
reported an 85% rate of PVL recurrence following both laser and surgical 
intervention. In contradistinction, patients in the Further/Disease Free 
category were younger, presented with new lesions at different oral sites, 
usually with less severe dysplastic features and responded well to multiple 
laser excision treatments; the latter observation, interestingly, being the only 
statistically significant one (p<0.0001; Chi-squared test). 
Jerjes et al (2012a) followed 77 PMD patients after CO2 laser surgery and 
distinguished clinical outcomes that included complete response, partial 
response, stable disease, progressive disease, recurrence and malignant 
transformation but as these categories were used differently between initial 
treatment and subsequent 3, 5-year and final outcome assessments it is 
difficult to make a direct comparison with the data analysed in this thesis. 
Jerjes et al (2012a) did observe, however, a significantly increased risk for 
recurrent PMD disease and malignant transformation to affect erythroplakic 
and non-homogeneous leukoplakic lesions, and to arise more often in heavy 
smokers and heavy alcohol drinkers. 
Chiesa et al (1993) reported that following successful primary treatment 
intervention, 18.5% of oral leukoplakia patients exhibited local disease 
recurrence, 16.2% developed new-site leukoplakia and 6.6% developed 
carcinoma. Primarily resulting from field change carcinogenesis, 
environmental factors may still influence dysplastic and neoplastic change in 
such patients. Wan et al (2014) reviewed 6 papers in which persistent or 
further PMD disease was identified following treatment and reported a 
frequency for new lesions (principally leukoplakia) to affect between 6.3% 
and 83.3% of cases.  
Malignant transformation rates for PMDs vary worldwide, of course, with 





effectively counsel individual patients. Such data are probably the most 
difficult to interpret in the literature and in Table 5.39 alone, rates are seen to 
vary from 0 to 16.8% (mean 7.45%). However, close inspection of the zero 
transformation results reported by Del Corso et al (2015) and Matsumoto et 
al (2015) is warranted because only small numbers of PMD lesions were 
actually treated in these studies, 40 to 60% of lesions were non-dysplastic 
and, in the Matsumoto et al (2015) study, only a limited follow-up of 6 months 
post-treatment was carried out. In contrast, 88.5% of lesions in this much 
larger MD study exhibited significant dysplasia, most carcinomas (71 or 12%) 
were diagnosed fortuitously upon initial laser excision and, as we have 
previously demonstrated, the incidence of further PMD disease and 
malignant transformation are both known to increase with length of follow-up, 
which was longest in this study at 7.3 years (Diajil et al 2013, Wan et al 
2014).  
The median transformation time for the 28 cases that developed cancer in 
this MD study was 87.3 months, which emphasises the importance of long-
term clinic follow-up for these cases. The difficulty remains, however, how to 
identify or predict those patients at particular risk of such transformation. 
Review of the malignant transformation data from this study suggests that a 
clear and important distinction should be made between the identification of 
pre-existing but unknown foci of squamous cell carcinoma in oral mucosal 
lesions and the development of carcinoma in a patient who has previously 
been diagnosed and treated for a potentially malignant lesion. In our 590 
patient study the former clearly predominated (71 cases) with only 28 
developing carcinoma post-treatment. Clinico-pathological features that were 
associated with malignant transformation included erythroleukoplakic lesions, 
the presence of severe dysplasia or carcinoma-in-situ in initial biopsies and 
floor of mouth and lateral tongue sites of origin; these observations are 
consistent with previously reported data (Napier & Speight 2008), although 
other authors have not found clinical or pathological observations to reliably 
or consistently correlate with malignant transformation risk (Arduino et al 
2009, Watabe et al 2015). We have shown in a number of patient cohort 





transformation in treated cases, there remains the risk of field change 
cancerization and new site disease (Thomson & Wylie 2002, Hamadah & 
Thomson 2009, Thomson 2012e, Diajil et al 2013, Thomson 2014).   
Clearly, the emphasis during PMD treatment must be to identify those cases 
in which the risk of dysplastic disease progression and malignant 
transformation are at their highest level, and then to intervene definitively in 
the shortest period of time possible, as reviewed by Diajil et al (2014). The 
comparative analyses carried out between the different clinical outcome 
categories in Section 5.4.10 has provided insight into the varying clinical 
presentation of PMD and the importance of monitoring for change during 
patient follow-up. Ultimately, however, despite the ability of clinicians to 
identify potentially malignant oral lesions, there are very few clinico-
pathological features that consistently characterise distinct PMD lesion 
behaviours, and accurate prediction of all clinical outcome data still remains 
frustratingly elusive in contemporary clinical practice (Lee et al 2000, Speight 
2007, Thomson 2012d).  
 
5.5.6. Limitations of the Study.  The study reported in this chapter is 
inevitably limited by the realization it is not a prospective, randomised 
controlled trial, nor is it multi-centre in its organisation. Similarly, it is 
important to recognise the inherent allocation bias affecting both patient 
recruitment and treatment intervention, which are firmly based on the 
author’s preferred management protocol. The latter, of course, may weaken 
the establishment of a causal relationship between clinical outcome and 
treatment, and the outcome data are probably additionally compromised by 
the varying durations of patient follow-up. However, as a longitudinal patient 
cohort study following a large, well-defined group of patients from a 
recognisable geographic location presenting with a specific oral disorder and 
undergoing a consistent treatment intervention coordinated by one clinician 
throughout nearly 20 years, it provides one of the most important oral 
potentially malignant disorder data sets yet studied in contemporary 





In relation to patient profiling, no specific attempts were made in this study to 
detail patients’ general medical status or individual use of long-term 
pharmacotherapy. Whilst this might have provided an additional stratification 
of patient risk, previous work has not found these data to be especially useful 
in profiling PMD patients or in predicting the risk of oral carcinogenesis 
(Hamadah & Thomson 2009, Macfarlane et al 2012, Diajil et al 2013). 
Whilst a patient cohort study of this nature is particularly suited to the 
analysis of a relatively rare condition such as oral potentially malignancy, 
reliance on pre-existing clinical records can also become a significant 
limitation, as detail and accuracy inevitably vary over time.  It was especially 
disappointing, for example, to find incomplete data recorded in case notes for 
long-term tobacco and alcohol use during the patient follow-up period as 
these may be significant confounding factors influencing clinical outcome. It 
has, however, previously been noted that significant change or longer-term 
improvement in tobacco and alcohol use in Newcastle PMD patients is 
disappointingly poor (Hamadah et al 2007, Goodson et al 2010a). 
It is probably not surprising that retrospective data should prove vulnerable to 
loss and contamination during 19 years of clinical study; Warnakulasuriya et 
al (2011) noted similar omissions in data recording when reviewing patients 
attending Oral Medicine clinics at Guy’s Hospital in London. Fortunately, 
detailed tobacco and alcohol habits have been recorded in a number of 
previous Newcastle potentially malignant disorder studies which confirm, 
unsurprisingly, an important aetiological role in the local population. 
Thomson & Wylie (2002) first noted that, in a 57 PMD patient cohort, 79% of 
patients were smokers and 82% regularly consumed alcohol. In a study of a 
further 78 cases, Hamadah & Thomson (2009) observed that 90% were 
either current or ex-smokers and 78% regularly consumed greater than 30 
units of alcohol per week, whilst Goodson et al (2010a) analysed another 54 
patient population all of whom smoked and drank alcohol. In a further study 
of 96 Newcastle patients, Hamadah et al (2010) confirmed that 75% both 
smoked and drank alcohol regularly. Diajil et al (2013), in a 100 Newcastle 
PMD patient cohort study confirmed that 86% were current or ex-smokers 





Whilst initial clinical records in this study usually contained accurate details of 
patients’ smoking and alcohol use, these data were not always up-dated 
during follow-up visits. It would not have been appropriate, therefore, to 
include such incomplete data in a clinical outcome analysis. It is interesting 
to note, however, that Hamadah & Thomson (2009) observed a trend for 
male patients to smoke most heavily and for smokers to be at increased risk 
of PMD lesion recurrence. Similarly, Goodson et al (2010a) noted an 
increased risk for PMD same-site recurrence in patients consuming more 
than 28 units per week. 
In a study following PMD patients post-laser for a mean period of around 5 
years, Diajil et al (2013) observed that the incidence of further PMD disease 
was statistically higher in patients continually exposed to tobacco, although 
no significant relationships between either the numbers of cigarettes smoked 
or the units of alcohol consumed and documented clinical outcome data 
were seen. 
The significance of tobacco use in an oral potentially malignant disease 
population was, however, specifically emphasised by the findings of the 
Hamadah et al (2007) study, which reported upon 5-year follow-up data for 
27 smokers who underwent laser excision of oral PMD lesions, and revealed 
that 75% still continued to smoke, despite the percentage of smokers 
temporarily falling to 62% at around 3-years follow-up, probably due to the 
temporary benefit of structured intensive, smoking cessation interventions 
provided during their clinic follow-up (Hamadah et al 2007). 
Although patients’ views and experiences regarding their PMD diagnosis and 
management were discussed in chapter 2, patient satisfaction and quality of 
life issues were not formally assessed in this clinico-pathological review. 
These specific areas of clinical research, however, are of particular 
importance in modern healthcare provision, and should certainly form an 








Upon deciding upon an optimal management strategy for a patient with an 
oral potentially malignant disorder, the responsible clinician must attempt to 
determine the risk of cancer development in that individual, the most suitable 
treatment intervention and an appropriate follow-up regime to mitigate such 
risk (Field et al 2015). As previously discussed in this thesis, none of these 
aims are easily achievable, nor are they at all predictable during individual 
patient care.    
The 590 patients reported upon and analysed in this study, however, have 
provided a unique insight into the natural history of PMD disease in North-
East England over a 19 year period, albeit in a defined hospital population, 
and have also facilitated analysis of detailed clinical outcome data following a 
structured treatment intervention using CO2 laser surgery. This treatment 
modality has proved particularly effective as a diagnostic tool, not only to 
provide definitive assessment of excision biopsy specimens but also to 
identify early cancer change. The latter finding, which occurred in 12% of this 
study cohort, is probably enough to justify this treatment intervention by itself. 
Overall, laser surgery as a treatment modality has also proved effective in 
removing dysplastic mucosal lesions and rendering patients free from PMD 
disease in nearly three quarters of the study cases. 
It remains to be seen, of course, just how far these results can be 
extrapolated to either national or, perhaps even more pertinently, 
international studies, although there would appear to be consistency in the 
results of this MD study cohort when compared with both previous Newcastle 

































6.1 The Potentially Malignant State 
There is little doubt, as discussed in Publication 2.5b of this thesis, that a 
clinically detectable disease process that is neither entirely benign nor frankly 
malignant remains a particularly difficult concept both for clinicians and 
patients alike. The specific relevance of this to overall patient management 
was examined in Publications 2.3a, 2.3b and 2.3c.  
Potentially malignant disease presents clinically as localized ‘precancerous’ 
lesions which are non-invasive at initial diagnosis but which, through time, 
may transform into cancer or alternatively can regress and disappear.  Any 
individual potentially malignant lesion may, of course, contain a range of cells 
with varying malignant potential (Scully & Petti 2010). Epithelial tissue 
throughout the upper aero-digestive tract, as well as skin, gastro-intestinal 
mucosa and uterine cervix, have all been identified as commonly affected 
sites. Uncertainty pervades all aspects of diagnosis, individual patient 
prognoses and interventional management techniques.  
Oral potentially malignant disorders have been recognised for many years of 
course and a substantive literature exists, although much of it is confusing 
and contradictory in nature and terminology (Thomson 2012a). Rationalizing 
the diagnosis and management of potentially malignant disease not only 
offers relief from uncertainty and unpredictability but may also improve 
patient morbidity and reduce mortality rates from invasive cancer. 
Recent attempts have been made to establish guidelines for ‘pre-cancer’ 
management, but these remain highly anecdotal and are still often based 
upon individual clinicians’ experience and belief (Cosway & Paleri 2015, Diz 
et al 2015, Field et al 2015). In general, whilst treatment has been 
recommended to relieve symptoms and prevent malignant transformation, in 
Newcastle we have consistently found that interventional laser surgery also 
offers clarity in histopathological diagnoses alongside, perhaps most 
significantly, treatment efficacy and reliability (Thomson 2014). It has been 
the specific purpose of this thesis to examine evidence accrued from clinical 





challenge the, oft perceived but rarely tested, null hypothesis that treatment 
intervention fails to influence the progress of potentially malignant disease.  
 
6.2 Incidence and Prevalence of Oral Potentially Malignant Disease 
Reliable incidence and prevalence data for potentially malignant oral lesions 
remain sparse, although Napier & Speight (2008) reported a worldwide 
prevalence of 1 to 5% whilst Carnelio et al (2011) noted occurrence in 
approximately 2.5% of the general population. Diz et al (2015) quoted rates 
of 1 to 2% for leukoplakia, but only 0.02 to 0.83% for erythroplakia. The 
reality is, of course, that such figures vary by geographic region, the nature 
of the patient population studied and the varying disease definitions 
employed (Tadakamadla et al 2015). Villa & Gohel (2014) screened 3,142 
patients in an USA dental hospital setting and identified 27 cases (0.9%) with 
an oral potentially malignant lesion, although only 3 actually exhibited 
dysplasia on histopathological examination. The data presented in Chapters 
3, 4 and 5 in this thesis provide a unique and consistent profile of oral 
potentially malignant disorder patients in North-East England. Neither study, 
unfortunately, allows accurate incidence or prevalence calculations. 
Whilst oral cancer incidence is known to be high in North-East England, it 
remains unclear how many invasive cancers develop from previously 
identifiable precursor lesions although it is not unreasonable to speculate 
that the majority probably do. In Publication 2.4, we discussed the difficulties 
inherent in trying to characterise transformation of oral precursor lesions 
within a specified population. A wider and particularly difficult patient 
management issue remains, however, which is how to identify and then 
target more patients with potentially malignant disease before transformation 
occurs to invasive cancer.    
The reality is that most potentially malignant oral lesions are asymptomatic 
and are usually identified by dental practitioners during routine oral 
examinations. Unfortunately, many patients at risk of oral cancer are not 





with suspicious oral symptoms may also delay seeking healthcare advice for 
3 months or more (Scott et al 2009).  
General population screening for oral cancer is not currently supported in the 
UK, due to a poor evidence base, lack of specific and reliable screening tests 
and, perhaps of most significance, a failure to demonstrate significant 
improvement in overall cancer survival rates following early detection of 
disease (Brocklehurst et al 2013, Solutions for Public Health 2015, 
Warnakulasuriya et al 2015).  
We have previously emphasized the pragmatic value of case finding and 
opportunistic testing of ‘high-risk’ groups to aid oral potentially malignant 
disorder diagnosis and facilitate interventional treatment, but these remain 
primarily secondary and tertiary preventive techniques which rely almost 
entirely upon individual patient recognition and presentation for appropriate 
specialist care and advice (Thomson 2012a).  
In relation to PMD diagnosis, it is probably true that a thorough and 
methodical visual examination of the oral mucosa by an experienced 
clinician, supplemented by targeted incisional biopsy for provisional 
histopathological examination, remains the ‘gold standard’ assessment. 
Despite intensive investigation, few of the proposed adjunctive diagnostic 
techniques including light-based or optical inspection systems, vital tissue 
staining, or brush biopsy and exfoliative cytology have shown any significant 
benefit in contemporary clinical practice (Lingen et al 2008, Awan et al 
2011a, 2011b & 2012, Thomson & Goodson 2012b, Messadi 2013, Goodson 
et al 2014a & 2014b, Macey et al 2015). 
 
6.3 Early Detection of Oral Malignancy 
Despite limited evidence regarding improved cancer survival rates, early 
diagnosis of oral malignancy must, intuitively at least, be a priority public 
health objective and is probably the most important single factor that 
improves individual patient prognosis, with cure rates approaching 90% for 





remains, however, that most oral cancer cases are in an advanced stage at 
the time of clinical detection due to diagnostic delays (Gomez et al 2010, 
Warnakulasuriya 2010). Although targeted screening of ‘high-risk’ patients 
may be an effective strategy, Ford & Farah (2013) comprehensively 
reviewed a number of factors that adversely influence the early diagnosis of 
oral cancer and potentially malignant disease. Of particular interest was their 
emphasis on potential delays during the initial recognition and subsequent 
diagnosis of potentially malignant disease, both by patients themselves and 
by their primary health care practitioners. Scott et al (2009) examined 
perceived ‘barriers’ preventing patients from seeking advice on potentially 
malignant oral symptoms, which were often related to pre-existing health 
beliefs, behaviours and personal circumstances, whilst effective ‘triggers’ to 
seek help included the severity of individual patients’ symptoms and the ease 
of access to appropriate health care services. Some of these issues were 
introduced in this thesis in Publication 2.3a.  
Both Ford & Farah (2013) and Brocklehurst et al (2009a & 2009b) have 
commented upon the fundamentally important role that primary care dental 
practitioners may have in PMD diagnosis, but emphasized the difficulties 
inherent in recognising salient but subtle mucosal changes, the wide range of 
potentially malignant lesion presentation, problems created by a lack of 
systematic and rigorous oral examination techniques and underlying 
diagnostic uncertainties. They both recommended improvements in training 
and enhanced oral mucosal examination competency for general dental 
practitioners together with wider efforts to raise public awareness of oral 
malignant disease; these observations were supported by Epstein et al 
(2007). 
Interestingly, Ford & Farah (2013) also highlighted a requirement to explore 
the varying needs and experiences of PMD patients during all aspects of 
their diagnosis, risk behaviour modification, treatment and clinic review; 
these observations strongly support the concepts introduced in this thesis in 





Recognising the limitations of oral cancer screening programmes, 
Amarasinghe et al (2010) proposed a risk-factor model, based upon 
questionnaire analysis of age, socioeconomic status, and tobacco, betel-quid 
and alcohol habits, to improve detection of oral potentially malignant 
disorders in a high prevalence Sri Lankan population. Whether such an 
approach would be applicable to a Western population remains unproven, 
but appropriate weighting of smoking, alcohol and other population-specific 
risk factors have been discussed in Publications 2.5a and 2.5b and may well 
prove useful tools in future clinical practice and demographic studies.  
 
6.4 Diagnosis and Histopathological Grading 
In the absence of accurate predictive biomarkers, assessment and grading of 
epithelial dysplasia in tissue biopsy specimens remains fundamental to both 
diagnosis and decision making for treatment intervention during oral 
potentially malignant disorder management, and yet it is an area of practice 
known to be fraught with subjectivity and is lacking in both intra- and inter-
observer reproducibility (Bosman 2001, Sloan 2012). It has also been noted 
that dysplasia grading appears most reliable for ‘high-grade’ lesions 
exhibiting the most severe dysplasia changes, whereas ‘low-grade’ lesions 
appear to be at particular risk of poor objectivity (Speight et al 2015). Whilst 
the association between worsening grades of dysplasia identified in oral 
biopsies and an increasing risk of malignant transformation has long been 
recognised, Edwards (2014) raised genuine concerns about the validity of 
basing treatment decisions wholly upon dysplasia diagnoses obtained from 
localised, incision biopsies harvested at single time points during the lifetime 
and evolution of unstable mucosal lesions. Total reliance on incision biopsy 
results for definitive diagnoses of oral potentially malignant lesions has been 
criticised on a number of occasions previously (Holmstrup et al 2007, Scully 
& Petti 2010). 
Indeed, the problems and unreliability inherent in attempting to categorize an 
essentially dynamic and continuous spectrum of epithelial tissue changes 





Publication 2.5b. Nonetheless, dysplasia grading still offers the best 
opportunity for pathologists to convey to clinicians the nature of individual 
mucosal lesions and ultimately to assess the overall risk of malignancy 
(Edwards 2014). It was encouraging to see such consistently high levels of 
agreement between Newcastle oral pathologists’ histopathological diagnoses 
in the studies reviewed in this thesis. Overall, it is quite clear that accurate 
diagnosis of oral potentially malignant disease relies fundamentally on the 
clarity of two-way communication between clinician and pathologist (Farah et 
al 2014).  
An accurate pathological diagnosis is, of course, also dependent upon 
appropriate clinical sampling of oral lesions and, whilst incision biopsies 
harvested from the most suspicious or most representative parts of individual 
lesions may provide sufficient detail, multiple or ‘field mapping’ biopsies and 
laser excision samples are likely to provide more detailed information and 
overall provide better representation of the true nature of oral mucosal 
lesions (Thomson & Wylie 2002, Thomson & Hamadah 2007, Sloan 2012). 
These specific issues were examined in the patient cohort reviewed in 
Chapter 5.   
Edwards (2014) also highlighted the important observation that not all 
neoplastic precursor lesions will exhibit the classic morphological features of 
epithelial dysplasia, especially those disorders exhibiting lichenoid features 
and verrucous hyperplasia; these issues have been reviewed in Publication 
2.4 and discussed at length in Chapters 2 and 5.   
This thesis was not prepared as a treatise on the histopathological diagnosis 
of epithelial dysplasia but, nonetheless, the recognition of dysplasia within 
oral mucosal biopsies plays a fundamental role in overall PMD management. 
As Bosman (2001) presciently observed, however, dysplasia classification is 
only likely to be improved upon by establishing a better understanding of the 
clinical progress and natural history of the potentially malignant state and by 







6.5 Interventional Treatment for Oral Potentially Malignant Disorders 
Management of oral potentially malignant disease has, for many years, been 
controversially polarised between surgical excision to remove identifiable 
mucosal lesions and more conservative medical or observational techniques 
(Carnelio et al 2011). As Mandal et al (2014) observed, whilst the definition 
of potential malignancy intuitively warrants some form of targeted 
management, rather than passive observation, the diverse range of 
treatment options quoted in the literature still confounds individual treatment 
decisions.   
Carnelio et al (2011) and Kumar et al (2013) have recently reviewed a 
number of non-surgical PMD treatments including the use of antioxidant 
supplements such as carotenoids and retinoids, or chemotherapy with 
bleomycin, but significantly noted the lack of any evidence of efficacy, the 
risk of side effects, the high rates of recurrence reported following treatment 
cessation, and perhaps most pertinently no evidence whatsoever regarding 
effective prevention of malignancy. Interestingly, Lee et al (2000) previously 
reported a 31.4% malignant transformation rate in oral leukoplakias treated 
with isoretinoin and/or β-carotene, emphasizing the limitation of medical 
treatment. Marley et al (1996) noted that only 3 to 4% of UK Oral and 
Maxillofacial Surgeons would utilise chemo-preventive agents in PMD 
treatment and Kanatas et al (2013) recently confirmed this observation, in a 
questionnaire-based study, finding that only 2% of surgeons would ever 
consider medical treatment, thus demonstrating the contemporary 
redundancy of such treatment.  
The confusion that still plagues the literature regarding oral potentially 
malignant disorder management was well summarised by van der Waal 
(2014) who, on the one hand opinions that local lesion recurrence is common 
following surgical treatment of leukoplakia and that neither intervention nor 
long term clinic follow-up is effective in reducing the risk of cancer 
development, whilst on the other hand makes the important observation that 





recommend surgical excision of localised, well-circumscribed oral mucosal 
lesions followed by long-term, specialist clinic follow-up.  
The evidence-base for treatment intervention is both scanty and confused. 
Shiu & Chen (2003) attempted a systematic literature review to determine 
the effectiveness of treatment interventions for oral leukoplakia, the 
commonest PMD, but found such wide variation in diagnostic criteria, an 
extensive heterogeneity of proposed treatment methodologies and such 
disorganised patient compliance and follow-up data that they felt it was quite 
impossible to quantify their analysis in any meaningful way. 
Lodi et al (2006) previously stated that, whilst many quoted treatment 
interventions may be effective in initially resolving individual oral leukoplakic 
lesions, clinical relapse, adverse effects and limited evidence regarding the 
effective prevention of malignant transformation limited the usefulness of 
currently available techniques. Wan et al (2014) observed that following 
successful primary therapy, local recurrence of leukoplakia and the 
development of new-site (or second primary) leukoplakias accounted for the 
majority of unfavourable events experienced by patients.  
Despite these negative observations and the limitations in evidence-based 
guidelines, a number of recommendations have recently been made for oral 
potentially malignant disorder treatment. In 2011, for example, ENT-UK 
(British Association of Otorhinolaryngology-Head & Neck Surgery) published 
multidisciplinary management guidelines for head and neck cancer which 
included advice upon targeted biopsy and histopathological assessment of 
potentially malignant lesions, advice to patients to reduce tobacco and 
alcohol use, surgical excision when lesion size and post-operative function 
allow, together with long term clinic surveillance. Most authors now actively 
encourage intervention, and mucosal lesion excision rather than observation 
is recommended, together with long term follow-up by specialist clinicians 






Although some workers have suggested that minimally invasive approaches 
to treat less severely dysplastic lesions may be appropriate (Huff et al 2010), 
Arnaoutakis et al (2013) strongly recommended excision and/or ablation of 
all head and neck mucosal pre-malignancy, emphasizing the high risk of 
recurrence and disease progression consequent upon observing, rather than 
treating, even mildly dysplastic oral lesions. 
This has certainly been the treatment philosophy adopted in Newcastle since 
1996. Excision of potentially malignant oral mucosal lesions, if necessary 
followed by repeat surgery when recurrence or further disease occurs as 
clearly demonstrated by the patient cohort presented in Chapter 5 of this 
thesis, facilitates not only a coordinated follow-up regime but also renders 
identification and diagnosis of progressive PMD disease straightforward and 
probably has significant health economic benefits by ultimately proving less 
expensive than carrying out multiple, repeated incision biopsies over many 
years of subsequent, observational follow-up; this is a point endorsed by 
Farah et al (2014). 
In considering the wider aspects of health economics in relation to oral 
potentially malignant disorder management, details of treatment efficiency, 
cost and value for money all require attention, particularly in comparison to 
the extensive healthcare costs inevitably associated with oncology treatment. 
There are virtually no data in the literature to support or refute the concept 
that early, minimal intervention to attempt secondary or tertiary prevention of 
oral cancer in an ‘at risk’ population is cost-effective, but it is certainly not an 
unreasonable hypothesis.  
In recent years the UK Department of Health has introduced Patient-Level 
Information and Costing Systems (PLICS) to determine healthcare resources 
consumed by individual patients by measuring the costs incurred by NHS 
healthcare organizations in providing particular treatments 
(http://webarchive.nationalarchives.gov.uk). Whilst still relatively new in 
concept, PLICS can be applied to the diagnosis and management pathway 






PLICS data from the Newcastle upon Tyne Hospitals NHS Foundation Trust 
for a 6 month period (April-October 2015) are utilized in Table 6.1 to directly 
contrast averaged health economic calculations associated with the provision 
of diagnostic and surgical treatment services for interventional laser surgery 
of potentially malignant disease (averaged at around £997.90 per treated 
patient) and the multi-disciplinary care required for oral cancer (averaged at 
£5,471.58 per patient). Initial management of an established oral cancer thus 
costs more than 5 times the treatment of a pre-cancer lesion and, of course, 
there will be additional significant costs for head and neck cancer care 
including the requirement for adjuvant radiotherapy and/or chemotherapy 
treatments which are not included in these calculations.    
Although limited in evidence, Tadakamadla et al’s (2015) literature review 
also reported no significant adverse quality of life outcomes for oral 
potentially malignant disorder patients, when contrasted with the known 
sequelae of oral cancer treatment including pain, trismus, xerostomia, 
speech and swallowing disorders, along with loss of cognitive, social, 




















TABLE 6.1: COMPARISON OF HEALTHCARE COSTS - INTERVENTIONAL CO2 LASER 





*Data Source PLICS 2015 (April – October) 
Provided by Mr. Patrick Pearce, Directorate Finance Manager, Newcastle upon Tyne 




CO2 Laser Surgery for Oral Precancer Lesions Cost Income Margin
Oral Surgery Out-Patient Appointment:
WF01B-Non-Admitted Face To Face Attendance, First £816,889 £1,605,630 £788,741
Activity 7,899
Average cost and income per attendance £103.42 £203.27 £99.85
Out-Patient LA Biopsy Appointment (see Oral OPROC tab): £56,130 £137,659 £81,529
Activity 486
Average cost and income per case £115.49 £283.25 £167.76
Day Case Laser Surgery RVI Theatre (Claremont) - see Oral DC tab: £30,381 £23,577 -£6,803
Activity 39
Average cost and income per case £778.99 £604.55 -£174.44
Total Average Oral Surgery Cost & Income £997.90 £1,091.06 £93.17
Major Head & Neck Surgery (Freeman ENT) Cost Income Margin
Multi-Disciplinary Clinic Attendance:
WF02B-Multiprofessional Non-Admitted Face To Face Attendance, First £5,859 £6,621 £762
Activity 47 47 47
Average cost and income per attendance £124.67 £140.87 £16.20
Inpatient Surgery (see ENT EL detail tab):
In-Patient Stay (Ward 10 Freeman) for approx. 14 days £52,368
Major Theatre (All-Day List Freeman) £87,838
ITU / HDU Stay (approx. 1 day) £13,912
All other costs £33,024
Total Inpatient Cost £187,142 £105,251 -£81,890
Activity 35 35 35
Average cost and income per case £5,346.91 £3,007.18 -£2,339.73
Total Average ENT Cost & Income £5,471.58 £3,148.05 -£2,323.52
Total Length of stay for IP activity 204





It is also instructive to compare and contrast the potential efficacy of different 
PMD treatment modalities against the overall management goals initially 
listed in Chapter 1 of this thesis, and these are summarized in Table 6.2. 
This exercise again supports the assertion that surgical excision of identified 
oral potentially malignant lesions comes closest to being the optimal 
interventional management technique (Thomson 2012d). 
 
TABLE 6.2: EFFECTIVENESS OF PMD TREATMENT MODALITIES IN ACHIEVING 
MANAGEMENT GOALS 
  Treatment 
Modality 
 






Accurate Diagnosis No No Yes 
Early Recognition of Malignancy Possibly No Yes 
Removal of Dysplastic Mucosa No No Yes 
Prevention of Recurrent or Further 
PMD disease  
No No Possibly 
Prevention of Malignant 
Transformation 
No No Possibly 
Minimal Patient Morbidity Yes No Yes 
 
 
There appears, therefore, to be substantive evidence supporting diagnostic 
and treatment efficacy, acceptable quality of life outcomes and significant 
cost-effectiveness for the use of interventional laser surgery in the 










6.6 Clinical Outcome 
Uniform use of appropriate diagnostic criteria, and agreed terminology to 
accurately document clinical outcome data are recognised as essential for 
both patient management and conducting and communicating research 
findings (Napier & Speight 2008). It was only by undertaking long-term 
follow-up of a large number of PMD patients during the study reported in 
Chapter 5, that it was possible to recognise and then specifically define 4 
important clinical outcomes:  
1. Disease free patients who, following treatment intervention, no longer 
have identifiable oral mucosal lesions or exhibit clinical signs of PMD 
disease,  
2. Patients with further (new-site) or persistent (same-site) PMD disease, 
but who ultimately achieve disease free status following additional 
treatment intervention(s), 
3. Further (new-site) or persistent (same-site) PMD disease where 
clinical lesions persist following treatment, and  
4. Malignant transformation, including both same-site transformation 
following treatment of a precursor lesion and new-site cancer 
development. 
Each of these distinct patient groups possess important characteristics that 
define both their presentation and ultimate clinical course, and these have 
been described and analysed in detail in Chapter 5 of this thesis. In Table 
6.3, consistently identified clinico-pathological features in this thesis 
associated with, or in some cases significantly predictive of, the varying 
clinical outcome categories are summarised. Where no reliable association 
was found, no entry is recorded against that category. Undoubtedly, careful 
attention to these outcome categories will be of paramount importance in 







TABLE 6.3: CONSISTENT CLINICO-PATHOLOGICAL FEATURES ASSOCIATED WITH 









Patient Age Younger* Younger Older           - 
Clinical Lesion Leukoplakia* Leukoplakia Leukoplakia Erythroleukoplakia* 
Site   
       - 
 





Floor of Mouth 
Lateral Tongue 














        - New Site Same Site Same Site 
 
LI: Lichenoid Inflammation; PVL: Proliferative Verrucous Leukoplakia 
*Statistical Significance 
 
Whilst it is indeed encouraging for the treatment intervention adopted by this 
author in Newcastle that over 70% of treated patients fall in to the disease 
free category, it is almost certainly the further and persistent PMD disease 
categories and the malignant transformation patient groups that represent 
the most aggressive potentially malignant disorders. From the data analysed 
in Chapter 5 of this thesis, it is possible to define an erythroleukoplakic lesion 
appearance and the presence of severe dysplasia or carcinoma-in-situ and 
lichenoid inflammatory change on histopathology examination as significant 
predictors of progressive PMD disease and, perhaps most importantly, of 
malignant transformation risk. Further, detailed clinico-pathological analyses 
of these patients should ultimately provide vital data to learn more about the 
natural history of the potentially malignant state, and these studies are now 
on-going in Newcastle. 
Of particular importance in the future will be our ability to stratify individual 
patient risk (as discussed in detail in Publication 2.5b), and the differentiation 





fundamental requirement if we are to truly improve and rationalize potentially 
malignant disease management.     
 
6.7 Malignant Transformation 
Transformation of a pre-existing potentially malignant lesion into a frankly 
invasive tumour must rank as the ultimate treatment failure for PMD patients, 
and yet prediction of such ‘high-risk’ behaviour and cancer development 
remains elusive in clinical practice. Field et al (2015) recently quoted 
transformation rates for oral epithelial dysplastic lesions ranging from 6.6 to 
36.4%, and ‘average’ transformation times varying widely between 0.5 and 
17 years. 
Shiu et al (2000) reported that the likelihood of malignant transformation 
within previously identified oral leukoplakic lesions will increase with the 
duration of patient follow-up, quoting a 14% rate over 10 years in a 
Taiwanese population. This was similar to Cowan et al (2001) who observed 
a 15% transformation rate in 165 oral epithelial dysplasia cases in a 
population from Northern Ireland. In contrast, Schepman et al (1998), Hsue 
et al (2007), and Warnakulasuriya et al (2011) all noted similar 
transformation rates of 2.9%, 3%, and 2.6% respectively in the Netherlands, 
Taiwan, and South-East England, although it is unclear how many initial 
lesions in these studies were truly dysplastic. Saito et al (2001) reported a 
6.3% transformation rate in 142 patients treated by surgery for oral 
leukoplakia, although only 91 lesions exhibited dysplasia on initial biopsy. 
Speight (2007) emphasised the importance of dysplasia severity as an 
indicator of transformation risk, quoting rates of 16% for severe dysplasia, 
between 3 and 15% for moderate dysplasia and less than 5% for mild 
dysplasia, but with little evidence of consistency in different studies and 
overall transformation rates were quoted which varied from approximately 7 
to 50%. Warnakulasuriya et al (2011) also reported a significantly higher risk 
of cancer development with higher grades of dysplasia and a trend for that 





It is interesting that Ho et al (2013) reported quite a high, 25%, malignant 
transformation rate, with a median time to transformation of 40.3 months, in 
91 PMD patients formally monitored in a specialist clinic in North-West 
England, although no details were provided regarding PMD treatment 
intervention. Warnakulasuriya & Ariyawardana (2015) recently reviewed 24 
observational studies of oral leukoplakia and again confirmed a wide range 
of malignant transformation rates varying between 0.13% and 34.0% (with a 
mean of 3.5%); advanced age, female patients, lesions greater than 
200mm2, non-homogenous clinical appearance and higher grades of 
dysplasia all appeared to increase the risk of cancer development, which are 
findings consistent with previously published studies (Thomson 2012e).  
The patient data set presented in Chapter 5, which comprised lesions 
primarily exhibiting quite significant dysplasia and all treated by CO2 laser, 
showed a relatively low malignant transformation rate of 4.8% during the 
study follow-up period; this is similar to a rate of 4.7% recently quoted by 
Dost et al (2014) for an Australian study population, but this was a less well-
defined patient group. The much more common finding in this MD study 
(affecting 71 patients or 12%) was the identification and complete excision of 
unexpected foci of invasive carcinoma upon initial PMD lesion excision. This, 
of course, is actually an important diagnostic and treatment success for such 
an interventional treatment regime and in this context can hardly be 
considered as a ‘treatment failure’.  
Distinction should also probably be made between malignant transformation, 
which is the change of a previously identified oral precursor lesion into an 
invasive carcinoma at the same site, and cancer development which occurs 
when patients with pre-existing or previously treated pre-cancer lesions 
subsequently develop carcinoma at new, distinct intra-oral sites (Thomson 
2012e). Interventional treatment to excise potentially neoplastic cells may 
thus help prevent malignant transformation at the site of the excised lesion 
but, as a consequence of field change, cancer development at new sites 
remains a risk. However, by ensuring that active patient surveillance and 





early signs of cancer development can be recognised and further active 
surgical intervention is facilitated (Thomson 2012e). 
 
6.8 Patient Follow-Up 
It is undoubtedly true that, particularly in relation to head and neck cancer, 
patient follow-up clinics have limited efficacy in identifying recurrent 
malignant disease or second primary tumours with patients themselves often 
alerting clinicians to suspicious signs and symptoms on their re-attendance 
(Cooney & Poulsen 1999, Thomson 2012d). No consensus exists in the 
literature to determine the exact nature or duration of patient follow-up for 
oral potentially malignant disease (Marley et al 1996 & 1998, Nankivell & 
Mehanna 2011), although evidence does exist which highlights the 
occurrence of further PMD disease 10 to 15 years after initial patient 
presentation (Thomson 2012d). Some workers have reported clinic 
strategies ranging from immediate post-treatment discharge to life-time 
follow-up (Epstein et al 2007), whilst Mehanna et al (2009) have suggested 
keeping PMD patients under surveillance for at least 20 years. Life-long 
follow-up examinations at 3 to 6 month intervals have been advised by other 
workers (van der Waal 2010, Kanatas et al 2011, Diajil et al 2013, Lian et al 
2013, Wan et al 2014). Greaney et al (2014) also advised similar follow-up 
regimes for suspicious oral lichenoid lesions. 
In Newcastle, PMD patients are reviewed 1-month following surgery and 
then at 3 to 6 month intervals dependent upon their individual clinical course 
and overall risk assessment; disease free patients with reduced risk factor 
behaviour are seen less frequently. Coordinated and detailed follow-up, 
supplemented by careful visualisation and inspection of the oral mucosa, can 
identify recurrent or further PMD disease at the earliest possible stage, 
alongside important opportunities to elicit the presence of early malignant 
change (Epstein et al 2007, Thomson 2012d). The overall objectives of a 
structured patient follow-up regime following potentially malignant lesion 





TABLE 6.4: OBJECTIVES OF PMD PATIENT FOLLOW-UP AND SURVEILLANCE 
FOLLOWING TREATMENT INTERVENTION 
Assess efficacy of treatment intervention 
Recognise treatment complications 
Early identification of recurrent or further PMD disease 
Early identification of malignancy 
Timing and coordination of further treatment interventions 
Modify patient risk factor behaviour 
Assess long-term patient risk 
  
The precise clinical environment in which patients are followed-up is also 
important; carcinoma development is more likely to be diagnosed earlier with 
a reduction in morbidity and mortality when patients attend specialist oral 
oncology or potentially malignant disease clinics (Diajil et al 2013, Ho et al 
2013, Thomson 2014), although it was noted in Publication 2.2 that few UK 
clinicians actually provide such a service.  
We have previously emphasised that interventional management strategies 
should really be considered cyclical in nature, passing from active surgical 
excision through to surveillance but returning to surgical intervention upon 
diagnosis of further pre-cancer disease (Thomson 2012e). It is, therefore, 
both a consistent and a determined approach to patient management and 
applied rigorously has the ability to reduce the risk of invasive cancer 
development. 
 
6.9 Clinical Impact of MD Thesis Research 
The clinical impact of new knowledge, treatment innovation or improved 
management protocols can only truly be judged by the influence they 
ultimately have on the long-term outcome of a specified medical disorder. 
Despite the demonstration of new knowledge or an innovative clinical 
application, instigating change in established clinical practice is known to 
take time, often many years. It is of general importance, therefore, to improve 





findings, although delays in information dissemination, reluctance of 
clinicians to alter long-established practice, cultural influences which favour 
preservation of the status quo and resource implications remain the principal 
detractors of change (Glasziou et al 2014).  
The early diagnosis of oral cancer and the management of potentially 
malignant disorders are recognized as areas of contemporary clinical 
practice in which variability in decision making and a lack of high-quality 
evidence has confounded treatment initiatives. Perhaps of greater 
significance is the realization that, owing to the limited relevance of existing 
clinical trial data, systematic literature reviews and meta-analyses have 
repeatedly failed to answer the fundamental diagnostic and management 
dilemmas inherent in potentially malignant disease treatment and discussed 
in Chapter 1 of this thesis (Moles et al 2002, Downer et al 2004, Lodi et al 
2006, Smith et al 2009, Mehanna et al 2009, Walsh et al 2013).  
Lavelle & Scully (2007) usefully highlighted the formidable, multi-factorial 
influences and heterogeneous challenges that frustrate early identification of 
individuals at high risk of oral carcinogenesis. However, the clinical studies 
presented in this MD thesis, particularly the extensive patient cohort followed 
in Chapter 5 which combined a defined surgical intervention with detailed 
patient profiling and active clinic surveillance, strongly suggest that a 
properly coordinated and methodical clinical management protocol may have 
the potential to intervene to stall or even halt the inevitable process of oral 
carcinogenesis, although this remains unproven. Whilst efficacious for all 
patient groups, interventional treatment appears to be of especial relevance 
for those exhibiting progressive PMD disease or deemed to be at ‘high risk’ 
of malignant transformation.  
By establishing and thus defining the role of interventional laser surgery in 
our Newcastle clinical practice we have helped facilitate definitive oral 
diagnosis and efficacious low morbidity treatment (Thomson & Wylie 2002, 
Goodson et al 2012), reduced same-site malignant transformation rates 
(Thomson 2014), allowed early diagnosis and treatment of cancer (Goodson 





disease, and helped define specific, distinct clinical outcome categories 
(Diajil et al 2013). It is probably true to say that surgical excision of potentially 
malignant oral lesions is now regarded as the preferred treatment modality in 
contemporary practice (van der Waal 2009, Gomes & Gomez 2013). 
Active patient surveillance following interventional therapy has enhanced our 
understanding of the natural history of potentially malignant disease, helped 
identify and target high risk patients, encouraged recognition and 
modification of individual risk factor behaviours, highlighted the significance 
of multiple-lesion presentation and helped develop new techniques such as 
‘field mapping’ biopsies to identify and treat the most significant sites of 
mucosal disease (Thomson 2002, Thomson & Hamadah 2007, Bagan & 
Scully 2008, Thomson 2012c).  
Figure 6.1 summarizes the contemporaneous management pathway for oral 
potentially malignant disorders that has evolved following the pragmatic 

















Figure 6.1: Newcastle Management Protocol for Oral Potentially Malignant Disorders 
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There are 3 fundamental areas of clinical practice which are significantly 
influenced by the research studies presented in this thesis:                                                                           
 
1. Perhaps of greatest importance is the widespread acknowledgement that 
observational or medical treatments are ultimately unsatisfactory in 
potentially malignant disorder management (Dionne et al 2014), and that 
formal surgical excision of oral mucosal lesions is necessary for both 
definitive diagnosis of the presenting condition and an ultimately successful 
treatment intervention (Thomson & Wylie 2002, Mehanna et al 2009, van der 
Waal 2010, Balasundaram et al 2013, Thomson 2012c, Thomson 2014). 
2. There is now increased realization that field cancerization effects within 
the oral cavity may be much more significant than previously recognized and 
that multiple lesion disease may well represent a distinct disease entity with 
an increased risk of malignancy requiring proactive, targeted treatment 
intervention (Thomson 2002, Thomson & Hamadah 2007, Hamadah et al 
2010, Arduino et al 2013, Kumar et al 2013, Wan et al 2014).  
3. Recognition that patient profiling, risk factor stratification and active long-
term surveillance are all part of the fundamental management strategy for 
patients, which commences at the point of PMD diagnosis and continues 
during interventional treatment and throughout long-term follow-up. The 
specific role of dedicated specialist clinics has also evolved through 
recognition of the significant practical benefits they bring to both patients and 











6.10 Limitations of MD Research Work and Suggestions for the Future   
As a one-centre, UK-based, clinical academic unit, there are clearly 
limitations to the significance and applicability of Newcastle’s oral potentially 
malignant disease research work on a worldwide basis. However, the 
breadth of work reported in this MD thesis and, in particular, the unique long-
term nature of the clinical study reported in Chapter 5, its large sample size 
of 590 well-defined cases and the methodical and coordinated treatment 
intervention applied to the patient cohort, provides one of the most important 
and detailed PMD clinico-pathological databases yet reported in the 
literature, and it is clear that overall this programme of research has informed 
and helped influence contemporary clinical practice over recent years. 
Research priorities for the future were usefully summarised by Mehanna et al 
(2009) and included: developing effective prognostic or predictive markers in 
clinical practice, rationalising patient follow-up regimes, determining the 
efficacy of post-treatment surveillance in the early detection of PMD 
recurrence and malignant transformation, and refining less invasive but 
effective treatment interventions. Much of the work presented in this MD 
thesis concurs, and has attempted to contribute to the development of such a 
programme.  
Holmstrup (2009) and Smith et al (2009) both emphasized the importance of 
uncertainty which still pervades all aspects of pre-cancer treatment, and also 
stated that it was undoubtedly time to develop a definitive and relevant 
prospective, multi-centre trial with long term patient follow-up and appropriate 
bio-molecular analyses to enhance oral cancer diagnostic science and define 
the role of interventional management in PMD treatment in the 21st Century. 
A well-designed, randomized trial is thus now essential to provide the best 
evidence of effectiveness of surgical intervention in oral potentially malignant 
disease. To succeed and provide meaningful results, however, the trial must 
be based upon a firm understanding of the scientific basis of oral 
carcinogenesis, an enhanced knowledge of the natural history of the 
potentially malignant state and ensure that effective treatment modalities are 





exist in establishing surgeons’ equipoise and in challenging long-established 
practices and beliefs (McCulloch et al 2002, Potter et al 2014). Core clinical 
outcomes, such as disease activity, treatment efficacy, quality of life and 
health resource utilization, must be defined and relevant clinician and patient 
viewpoints incorporated into study protocols (Harman et al 2013). Feasibility 
and internal pilot studies are likely to be required to ensure trial validity. Much 
of this preliminary work has now begun, however, and is discussed in 
publications 2.3 and 2.5b, and by Ford & Farah (2013), Green (2013), 
Thomson (2014) and Tadakamadla et al (2015).  
PMD trials have ultimately proved unsuccessful in the past because of 
fundamental flaws in patient recruitment, ill-defined disease stratification, 
lack of clinician agreement and ineffective treatment intervention. Nankivell 
et al (2012), for example, recently documented insurmountable difficulties in 
attempting to run a UK-based oral dysplasia trial which resulted in early 
study closure due to patient recruitment failures. The clinician involvement 
project reported in Publication 2.2 should help address many of these 
potential problems in designing a relevant and pragmatic clinical trial for the 
future, although it is recognised there are many practical difficulties to 
overcome especially in attempting to randomize treatment interventions and 
develop ethically and clinically acceptable patient control groups.  
It is thus hoped that the academic work presented in this MD thesis has not 
only facilitated the implementation of a rational and pragmatic approach to 
the early diagnosis of oral malignancy, the stratification of cancer risk and the 
management of potentially malignant disease, but will also contribute to a 
demonstrable and pragmatic ‘launch-pad’ to facilitate the design, conduct 
and analysis of the long overdue definitive, randomized clinical trial for oral 









6.11 Treatment Recommendations 
In terms of contemporaneous PMD patient management, there seems little 
benefit in supporting a policy of observation or ‘watch and wait’; the 
consequences for an individual patient of developing an invasive oral 
squamous carcinoma within the oral cavity can be devastating and life-
threatening (Thomson 2014). Interventional laser surgery, on the other hand, 
is recommended as a definitive treatment modality for effective removal of 
mucosal PMD disease, definitive histopathological diagnosis and early 
interventional treatment for occult malignancy. There is, however, as 
discussed previously an urgent need to establish multi-centre, randomized 
controlled trials to confirm the overall efficacy of such treatment. 
 
6.12 Future Considerations Regarding Oral Potentially Malignant 
Disorder Diagnosis and Management  
It is probably accurate to state that attempts to establish the true 
carcinogenic risk for oral potentially malignant lesions will be the subject of 
epidemiological, diagnostic, histopathological, bio-molecular and translational 
clinical research for many years to come. The precise interplay of these 
factors is a complex process, however, and malignant transformation is most 
likely to result from a combination of intrinsic and extrinsic influences acting 
both synchronously and metachronously in any individual patient. Only by 
gaining better understanding of the mechanisms involved in oral 
carcinogenesis will we be able to improve prevention, early diagnosis, 
treatment and prognosis for both oral pre-cancer and ultimately invasive 
squamous cell carcinoma itself (Thomson & Goodson 2012c). 
In the future, with the rates of new oral cancer cases rising, it will become 
increasingly important to strengthen efforts to facilitate primary prevention of 
oral potentially malignant disease, particularly in raising wider public health 
awareness. There is clear evidence that cessation of smoking may result not 
only in the clinical resolution of established potentially malignant lesions but 
also help prevent further disease following treatment. Thus, greater and 





in modern clinical practice and this, together with recognition and attention to 
excessive alcohol consumption and improved diet, are probably most 
effective if provided directly to patients as part of specialist potentially 
malignant disorder services (Hamadah et al 2007, Goodson et al 2010). 
In publication 2.2, following widespread clinicians’ opinion canvassing, it is 
clear that there is poor coordination of potentially malignant disorder services 
in the UK and this author is convinced that centralisation of PMD patients in 
dedicated clinics with consistent, continually reinforced specialist advice and 
treatment together with multidisciplinary support particularly for identifying 
and modifying risk factor behaviours provides the optimum management 
strategy. In the future, it would be more sensible for dedicated PMD clinics to 
be established to concentrate clinical experience, facilitate rigorous audit, 
research and encourage new treatment trials rather than current 
arrangement whereby patients attend a variety of different surgical or 
medical clinics dependent primarily upon local or historical clinic 
arrangements (Thomson 2012c, 2014).  
The relevance of risk in relation to potentially malignant disease has been 
explored in Publications 2.5a and 2.5b. We have tried in our clinics to 
delineate PMD patients thought to be at ‘high-risk’ from those deemed ‘low-
risk’. Based upon a combination of their age, sex, medical background and 
risk factors, together with the anatomical site, size, clinical appearance and 
histopathology of their presenting oral lesions, this is designed to identify 
those cases requiring urgent or more systemic interventional treatment to try 
to prevent cancer development. Clinico-pathological features most 
associated with, or indeed predictive of, specific post-treatment clinical 
outcomes were listed in Table 6.3.  
We believe this is an appropriate and pragmatic approach to current patient 
management, but it remains a somewhat crude decision making tool. Recent 
research, after an inauspicious beginning, has again started to focus on 
alterations in DNA content (aneuploidy) within oral mucosal lesions as a 
potential marker of aggressive behaviour and increased cancer risk, although 





Rendon et al 2009, Gouvea et al 2013). Sperandio et al (2013), in a 
retrospective analysis of 273 oral dysplasia cases, observed a higher 
predictive value for malignant transformation by combining DNA ploidy 
analysis with dysplasia grading and also suggested that ploidy analysis might 
be able to detect additional ‘at risk’ lesions in the absence of dysplasia. 
In the future, PMD treatments should ideally become much more 
individualised and patient specific based upon molecular profiling and 
targeted therapeutic intervention. Molecular targeted therapy, for example, 
may inhibit tumour growth and metastasis by targeting the tumour 
microenvironment or vasculature, or specifically focussing on protein and 
signal transduction pathways in neoplastic tissue leaving normal cells 
unaffected (Thomson & Goodson 2012c).  
Central to future developments in oral oncology is the need to improve 
knowledge and understanding of molecular biology. As our ability to identify 
molecular alterations associated with various disease states increases, the 
requirement to analyse these for diagnostic and therapeutic purposes grows. 
Unfortunately, contemporary bio-molecular analyses do not provide practical 
or reliable diagnostic or predictive tools for the clinical management of oral 
oncology patients (The Cancer Genome Atlas Network 2015). Similarly, 
there are no markers that reliably predict malignant transformation in an 
individual patient with an oral potentially malignant lesion (Smith et al 2009, 
van der Waal 2010).  
The ultimate aim of genotype based predictive tests must be, of course, the 
ability to stratify risk, determine prognosis and thus personalise therapeutic 
intervention at an individual patient level (Ye et al 2008, Hingorani et al 
2010). 
Clinical outcomes following oral malignancy treatment will only improve by 
earlier detection of cancer and effective management of precursor lesions 
with malignant potential (Mishra 2012). daSilva et al (2011) believe that 
advances in oral cancer biology offer unprecedented opportunities for future 
translational research with clinical impact. It is important to remember, 





before clinical use and that, as Mishra (2012) observed, others will only be 
relevant to patients from specific geographical locations and will vary with 
race, lifestyle and both type and amount of carcinogen exposure.     
In the future we will need to definitively classify PMD patients into ‘high’ and 
‘low risk’ categories and delineate individually tailored treatment protocols 
based upon bio-molecular profiling to target the salient markers of dysplastic 
change, to facilitate genetic profiling of abnormal mucosa, and to quantify the 
risk of malignant transformation and predict outcome. 
A variety of treatment strategies, ideally marshalling systemic therapies, will 
be required for patients in differing risk categories. Better clinical outcomes 
will require improved response rates to interventional treatment and, 
perhaps, an enhanced immune response to fundamentally challenge the 










































Having reviewed contemporaneous and relevant literature regarding oral 
carcinogenesis and potentially malignant disorders in Chapter 1, and then 
having presented and discussed a number of recent, pertinent papers by this 
author relating to patient, clinician, and diagnostic PMD parameters in 
Chapter 2, the principal aim of this MD thesis was to undertake a 
comprehensive review of patient demographics and clinico-pathological data 
from patients presenting to a specialist, oral potentially malignant disorder 
service in a university teaching hospital in North-East England (Chapter 3), to 
determine both the appropriateness and the usefulness of treatment and the 
clinical outcomes following interventional laser surgery and thereby to 
attempt an objective assessment of the overall effectiveness of interventional 
PMD management (Chapters 4 and 5). 
It remains problematic to definitively characterise the demographic and 
clinico-pathological profile of oral potentially malignant disease in the UK but 
the data reviewed in Chapters 3 and 4 usefully ‘sets the scene’ for North-
East England and appears consistent over the last decade when compared 
with the un-published data presented in Appendix III. Unlike malignant 
neoplasms, however, there are no comprehensive classification systems for 
potentially malignant disease and, as an illustration of such difficulties 
globally, the 10th revision of the International Classification of Diseases and 
Related Health Problems (ICD-10) is particularly unhelpful as a diagnostic 
tool including only ‘leukoplakia and other disturbances of oral epithelium, 
including tongue’ (Chapter XI; K13.2) as the only relevant PMD entry (WHO 
2010). 
By attempting to characterise the presentation of oral potentially malignant 
disease within a defined, specialist clinical service in Newcastle upon Tyne 
and then reviewing the clinical outcomes following a specific and coordinated 
treatment intervention in a longitudinal patient cohort study it was the 
author’s intent to substantially add to the current knowledge base regarding 





7.2. Response to the Study Hypotheses 
In Chapter 1, a number of specific hypotheses pertinent to both the diagnosis 
and management of oral potentially malignant disease were highlighted for 
testing during the collation and analysis of the clinical and pathological study 
data presented in this thesis. Responses to these hypotheses will now be 
reviewed.   
 
7.2.1. Assessment of standard clinico-pathological features cannot predict 
disease progression or clinical outcome for oral potentially malignant 
disorders.  
Whilst this hypothesis is partially supported, clinical study results analysed in 
Chapter 5 have shown that certain, salient clinico-pathological features may 
provide pragmatic guidance regarding prognosis during the overall 
management of PMD patients. For example, as summarised in sections 
5.4.7 through 5.4.9, increased patient age, oral mucosal lesions presenting 
as erythroleukoplakias, identification of severe epithelial dysplasia on 
histopathological examination, together with the presence of lichenoid 
inflammation and proliferative verrucous leukoplakia, were all associated with 
either progressive PMD disease or malignant transformation.   
Although it is clear that further research is warranted to delineate the 
relevance and importance of individual clinico-pathological factors in the 
prediction of clinical behaviour of oral potentially malignant lesions, these 
specific observations are of considerable practical value during the ‘day-to-
day’ management of individual PMD patients.  
 
7.2.2. Incision biopsy techniques are insufficient for definitive 
histopathological diagnosis, which requires whole lesion excision for 
microscopic examination.  
This hypothesis is strongly supported by the work presented in this thesis, in 
particular the direct comparison carried out between 609 incision and 





Chapter 5, and analysed in detail in section 5.4.3. Perhaps of most clinical 
significance were the observations that histopathological agreement was 
seen in only 50% of cases (307), whilst 36% (220) required ‘up-grading’ to 
more significant epithelial dysplasia or even a diagnosis of cancer following 
laser excision (Figure 5.3), together with the poor sensitivity of incision 
biopsy as a diagnostic technique to identify invasive carcinoma in oral 
potentially malignant lesions.  
The important clinical relevance of this hypothesis is, therefore, that whole 
mucosal lesion excision should be considered mandatory for definitive 
histopathological diagnosis of oral potentially malignant lesions, and the 
practical realization is that such diagnosis is readily facilitated by the use of 
interventional CO2 laser surgery as a treatment modality. 
 
7.2.3. Interventional laser surgery is an effective tool for definitive diagnosis 
and effective treatment of potentially malignant lesions.  
This hypothesis is strongly supported. Firstly, by the evidence discussed in 
section 7.2.2 in relation to the improved reliability of histopathological 
diagnoses obtained from laser excision biopsy specimens. Secondly, by the 
body of evidence presented in section 5.4.5 in Chapter 5 that showed that 
interventional surgical treatment of 590 PMD patients rendered 438 (74.2%) 
disease free.       
The implication for clinical practice is clear. Based upon the study results of 
this thesis, intervention to excise identifiable potentially malignant oral 
lesions improves diagnostic accuracy and is effective in rendering the 
majority of cases disease free. Observation alone as a treatment modality, 









7.2.4. Active intervention during the progress of ‘pre-malignancy’ halts the 
progress of oral carcinogenesis and reduces the risk of cancer development.  
This hypothesis remains unproven. Despite a body of evidence presented in 
Chapter 5 that showed significant diagnostic and treatment benefits resulting 
from the interventional surgical treatment of the 590 study patients and the 
successful removal of oral potentially malignant lesions achieving disease 
free status for 438 (74.2%), 99 (16.8%) developed invasive squamous 
carcinoma diagnosed either following initial laser surgical excision or by 
further biopsy during subsequent post-operative follow-up. Whilst 71 patients 
(12%) benefitted, in a clinically highly significant and fortuitous manner, from 
the early diagnosis and effective treatment of an unexpected carcinoma 
following laser excision, this cannot be considered to equate with ‘halting’ the 
carcinogenic process. Similarly, 19 patients (3.2%) out of the 28 (4.8%) who 
developed carcinoma during follow-up did so at new, distinct oral sites 
distant from their presenting lesions so that ‘one-site laser surgery’ will 
clearly not ‘reduce the risk’ of new-site cancer development.  
Whilst a definitive clinical recommendation is difficult with this evidence base, 
it seems clear that a treatment intervention such as CO2 laser surgery which 
reliably facilitates the early diagnosis of occult malignancy offers significant 
practical value as a significant preventive technique. 
 
7.3. Additional Observations 
In addition to the formal responses to the tested hypotheses, a number of 
additional, general observations regarding oral potentially malignancy 
diagnosis and management may be made following review of the clinical 
work presented in this thesis. 
 
7.3.1. Potentially Malignant Disease Diagnosis. This is recognised as an on-
going difficulty in contemporary clinical practice, not only in terms of 





also in managing individual presenting patients and their oral lesions. Oral 
potentially malignant disorders demonstrate a considerable heterogeneity in 
clinical presentation with an unpredictable potential for change over time and 
it must, therefore, be recommended that oral clinicians remain alert for signs 
of potentially malignant lesions together with early cancer development in all 
patients when performing routine oral and dental examinations. Whilst this 
may be especially relevant for patients who use tobacco and regularly 
consume alcohol, it has been clearly shown by the work of this thesis that 
patient risk profiling remains a complex task and that individual clinicians’ 
experience and appropriate suspicion remain the most applicable and 
consistently reliable diagnostic tools. Provision of specialist PMD services, 
emphasizing consistency in clinical management and patient education 
together with coordinated post-operative follow-up regimes, offer the best 
opportunities for definitive diagnoses and treatment.   
     
7.3.2. Interventional Management. Surgical excision of oral potentially 
malignant lesions is probably the optimal management technique facilitating 
definitive histopathological diagnosis, early recognition and treatment of 
malignancy, effective removal of dysplastic tissue, minimal patient morbidity 
and the likelihood of reducing the risk of further PMD disease. Continued, 
active surveillance for all patients post-treatment remains essential, but the 
frequency and duration of that follow-up is probably best ‘tailored’ to 
individual patient risk. This, hopefully, will become a pragmatic clinical tool in 
the years ahead, based more firmly upon individual patient genetic profiling 
and bio-marker analysis. 
  
7.3.3. Clinical Outcome. The ability to predict clinical outcome for individual 
patients or potentially malignant lesions is still somewhat elusive in clinical 
practice, although a number of significant predictors of outcome have been 
identified in this thesis. Defining the parameters by which outcome are 
measured and the longitudinal study of patient cohorts offer the best 





potentially malignant disease, and ultimately to determine the efficacy of 
treatment intervention. 
 
7.3.4. Malignant Transformation. Oral potentially malignant disorders have a 
variable and unpredictable risk of squamous carcinoma development. 
Malignant disease can arise at the site of a precursor lesion as 
transformation or as new site disease at distant oral sites as a result of field 
cancerisation. Whilst interventional laser surgery may reduce the risk of 
same-site transformation, and also offers opportunities to diagnose and 
effectively treat occult invasive carcinomas, new-site cancer development 
remains an unquantifiable risk for all PMD patients. 
 
7.4. Conclusions 
In a North-East England population, we have characterised that PMD 
patients most commonly present in the 5th and 6th decades of their life, with a 
distinct male predominance and an overwhelming predilection for individual 
mucosal lesions to arise as leukoplakias on floor of mouth and ventrolateral 
tongue sites, usually exhibiting features of epithelial dysplasia and 
increasingly proliferative verrucous leukoplakia on histopathological 
examination.  
Overall, the recognisable clinical manifestations of potentially malignant 
disease present clinicians with a ‘therapeutic window’ of opportunity to 
intervene during the process of oral carcinogenesis, although in reality this 
window may be unpredictably opaque (Thomson 2012f). It is the author’s 
opinion that the interventional surgical management technique presented 
and discussed in this thesis provides a readily available, effective and low 
morbidity treatment which is successful in excising or ablating PMD mucosal 
lesions, facilitates early diagnosis of occult malignancy, and which may help 
reduce the overall risk of squamous carcinoma development in individual 





The risk of recurrent or further potentially malignant disease development 
and ultimately malignant transformation, however, has been shown to 
increase with the length of patient follow-up post-intervention. Continued, 
active surveillance of all PMD patients thus remains essential to ensure early 
recognition of such adverse outcomes which arise almost certainly as a 
consequence of field cancerization. Precise data governing the length of 
patient follow-up or the optimal time intervals between appointments are not 
known at present and require further research. Multi-centre, prospective, 
ideally randomized, controlled trials are now needed to confirm the efficacy 
of interventional laser surgery, to better delineate the nature of patients with 
progressive PMD disease, and to disseminate research findings more widely. 
It is hoped that the clinical work carried out over nearly 20 years by this 
author and presented and analysed in this MD thesis will help inform and 
encourage further relevant research into oral potentially malignant disease 
and thus ultimately lead to a reduction in the incidence of disease and an 
improvement in morbidity and mortality outcomes for invasive oral squamous 
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